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ABSTRACT 
Logistic regression models are often proposed to describe dose-response 
relationships in dose-escalation clinical trials to determine the maximum tolerated 
dose. In a Bayesian setting, the 1-parameter continual reassessment method and the 
2-parameter escalation with overdose control designs have been implemented 
assuming acceptable tolerability thresholds of between 20% and 35%. 
The literature is sparse on the operating characteristics of 2-parameter Bayesian 
logistic regression models (BLRM) when sample sizes are small (i.e. <50); response 
rates <20% or >35% are of interest; and expert beliefs are available for incorporating 
into prior distributions for model parameters.  
Motivated by a case study of a new infertility treatment, this thesis describes the 
operating characteristics of the 2-parameter BLRM in a dose-escalation setting, with 
small sample sizes, and applied to response rates consistent with both safety and 
efficacy endpoints i.e. 10% to 90%. When information external to the trial is available 
from expert beliefs, ways in which those beliefs may be elicited in a structured manner 
are evaluated. Simulation is used to assess the impact of these prior distributions on 
trial conclusions. 
I have demonstrated that elicitation can be performed in a structured manner in both 
academic and industry settings and I provide specific recommendations for the 
structured planning and execution of elicitation sessions. Simulations show that there 
is no single set of priors that always produce unbiased estimates with minimum 
variance across a range of target response rates, so simulations specific to the planned 
trial must be conducted. Furthermore, when only discrete doses are available, 
simulations show that choosing the available dose closest to that recommended by the 
model is more likely to lead to an unbiased estimate of the dose that attains a pre-
specified response rate.  
Recommendations are provided for how to improve the study design and analysis for 
the motivating case study. 
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1. Introduction 
1.1 Outline of This Chapter 
This chapter provides an introduction to the field of randomised controlled clinical 
trials including a short overview of their purpose and history with particular focus on 
drug development by research institutions and pharmaceutical companies. The chapter 
continues by describing the early phase clinical trial that motivated much of the 
research work in this thesis. The chapter concludes by describing the research aims 
and an outline of the remaining chapters. 
1.2 Overview of Clinical Trials 
There is a large literature on clinical trials, see for example the reviews by Day (2006), 
Bhatt (2010) and Julious et al. (2010). Hackshaw (2009) provides the newcomer to 
clinical trials a useful introduction to the subject by defining the two basic types of 
study designs employed in health research, namely observational and experimental. 
Observational studies do not intentionally involve intervening in the way 
individuals live their lives, or how they are treated. However, clinical trials 
are specifically designed to intervene, and then evaluate some health-
related outcome. 
From this definition, a clinical trial can be thought of as an extension to an 
observational study in which the researcher can plan how to intervene. In theory, the 
researcher can then plan the optimal way in which to evaluate that intervention; in 
practice there may be limitations to implementing that optimal evaluation plan, for 
example, taking measurements that are deemed invasive for the patient may 
necessitate a modified frequency of taking the measurements. The different types of 
- 17 - 
 
clinical trial are often referred to as occurring in a sequence using the terminology 
Phase 1 to 4 although such a sequential approach has been criticised (e.g. 
International Conference on Harmonisation, ICH Topic E8 (1997)) as too simplistic 
because trials may span multiple phases and/or contain multiple objectives. 
Notwithstanding these limitations, the definitions of Phases 1 to 4 adapted from ICH 
E8 provide a useful general guide: 
• Phase 1: initial administration in humans with an objective to evaluate safety, 
tolerability and pharmacokinetics 
• Phase 2: explore therapeutic efficacy in patients 
• Phase 3: demonstrate or confirm therapeutic efficacy 
• Phase 4: studies after initial approval to optimise the drug’s use 
Although the scope of this thesis is the development of a single (experimental) drug, it 
is acknowledged that in some trials, previously licensed drugs may be co-administered 
alongside the experimental drug, for example, because it is unethical to withhold 
standard-of-care. Development of new drugs is usually performed using a series of 
controlled studies in which a single experimental factor (i.e. treatment) is varied but 
recent guidance from the US Food and Drug Administration, FDA (2013a) outlines the 
considerations when sponsors wish to evaluate more than one experimental 
intervention. 
Distinction between practises employed by academic institutions and pharmaceutical 
companies will be highlighted where relevant, otherwise the reader may assume that 
the practices are broadly similar (Munos, 2009). For a specific disease under 
investigation, typically only one new molecule is chosen to progress from pre-clinical 
experiments to undergo human testing in clinical trials but a “back up” molecule may 
- 18 - 
 
be selected to follow, in case the “lead” molecule fails during (early stage) clinical trials 
(Ting, 2006). 
For the purposes of this introductory review of clinical trials, it is assumed that the 
traditional sequential approach of four different phases occurs, however, it is 
acknowledged that there may be significant blurring of the boundaries between the 
phases (or even skipping of a phase altogether). Due to the early phase scope of this 
thesis, the remaining overview concerns trials with dose-response objectives and no 
further description of Phase 3 and 4 trials will be covered. 
1.3 Dose-response Trials 
For the purpose of this thesis, the response of a patient to a treatment intervention 
may be a sign of a poor outcome (e.g. an adverse event is observed) or of a favourable 
outcome (e.g. an improvement in clinical signs and symptoms). In this introductory 
section, only a subset of clinical trial designs are considered in which changes to the 
dose or dose regimen are employed and the resulting impact on response is assessed. 
A more detailed description of the study designs employed to assess the Phase 1 and 
2 objectives appears in Chapter 2. 
1.3.1 Objectives for Phase 1 trials 
Phase 1 trials are those where the molecule is administered to humans for the first 
time and are predominantly concerned with assessing the initial safety, tolerability and 
pharmacokinetics of the molecule in a small number of healthy volunteers but may 
also be conducted in patients with the disease. The term subjects is frequently used as 
an umbrella term to refer to either healthy volunteers or patients, though it should be 
noted that patients are still participating on a voluntary basis and may withdraw from 
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the trial at any time (World Medical Association, 2013). A range of doses of the 
molecule may be tested, for example, administering six different doses to groups of 
subjects is common. Phase 1 trials typically recruit between 10 and 60 patients but 
sometimes more. 
1.3.2 Objectives for Phase 2 trials 
Phase 2 studies are those in a larger group of patients and are predominantly 
concerned with assessing preliminary efficacy of the molecule together with identifying 
the dosing regimens that are likely to lead to a favourable benefit-risk profile when 
evaluated in larger trials. This is elegantly summarised in a quote attributed to the 16th 
Century alchemist Paracelsus “All substances are poisonous, there is none which is not 
a poison; the right dose differentiates a poison from a remedy” (Huth & Murray, 2006). 
Phase 2 trials typically recruit between 50 and 120 patients but sometimes more and 
the safety and tolerability can now be assessed in the intended patients, though due to 
the small sample sizes, Phase 2 trials are unlikely to reveal rare adverse effects of the 
experimental drug. In the situation of oncology drug development where patients with 
the disease are frequently recruited into Phase 1 trials, those Phase 1 study designs 
often have elements of Phase 2, for example, by employing a dose-expansion cohort 
at the end of the Phase 1 part of the trial to assess efficacy using the dose(s) intended 
for later phase studies. 
Although I have so far referred to “dose” in the usual sense of the amount of drug 
administered to the patient (e.g. 100mg), when it comes to the statistical analysis, the 
value used may be some function of dose e.g. log(dose) so that a constant spacing 
amongst doses on some interval is being reflected; Wong and Lachenbruch (1996) 
termed this function the dose metameter. For trials with pharmacokinetic objectives 
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one may instead choose to use concentration of the drug in plasma rather than dose 
administered. 
To outline the context for the research presented in this thesis, details are provided of 
the case study that motivated the work into specific aspects of dose-response studies. 
1.4 Description of the Case Study Motivating the Research 
The response to an intervention will (amongst other aspects) depend on the dose or 
dose regimen administered to the patients and so choice of which doses to use in a 
clinical trial is an important consideration at the trial design stage. In January 2010, 
Professor Waljit Dhillo had already written a draft protocol for a Phase 2 study and 
sought statistical input on potential trial designs that would evaluate the effects of the 
naturally occurring hormone kisspeptin as a potential treatment intervention for In 
vitro fertilisation (IVF). Professor Dhillo’s previous work had described the role of 
kisspeptin and the initial trials in healthy individuals (Dhillo et al., 2005; Dhillo et al., 
2007; Dhillo, 2008) and further research was required to establish the dose(s) of 
kisspeptin likely to induce oocyte maturation in women undergoing IVF therapy. 
1.4.1 Study Objectives of Motivating Case Study 
The primary objective of the proposed study was stated as “Investigate whether 
kisspeptin could stimulate oocyte maturation in IVF therapy for infertility” although in 
practice other objectives and constraints would need to be incorporated in the final 
study design. For example: 
• only 6 specific (doubling-doses) were available 0.4, 0.8, 1.6, 3.2, 6.4 and 12.8 
nmol/kg 
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• the most common serious complication of IVF is ovarian hyperstimulation 
syndrome (OHSS) and this was to be avoided due to the increased risks (Expert 
Group on Multiple Births after IVF, 2006) 
• a further trial was to be conducted in which a subset of 2 or 3 promising doses 
from the current study would be used 
• rather than an absolute definition of “promising dose”, the totality of benefit 
and risk would be used to determine dose(s) that would be used in subsequent 
trials 
• funding was available for a trial to recruit approximately 90 patients 
Since hormones other than kisspeptin may have a role in inducing oocyte maturation 
(Hameed et al., 2010) it was hoped that regular blood samples could be taken to 
permit assessment of the relationship amongst the various hormones over time. 
1.4.2 Clinical Trial Design of Motivating Case Study 
The final study design and results have since been published (Jayasena et al., 2014), 
however, additional key aspects of the initial trial design (i.e. at the time of statistical 
consultation) and subsequent trial design variations are included here in order to 
motivate the research for the thesis. 
The original study design that had been proposed was a conventional parallel group, 
open-label trial in which patients would be randomised to one of the six available 
doses and the patients would receive their allocated dose followed by observation until 
assessment of the primary endpoint (oocyte maturation). The primary endpoint was 
assessed at the time of oocyte retrieval which was between 32 and 36 hours after 
administration of kisspeptin. 
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At the time of consultation over statistical aspects, a modification was being discussed 
to restrict the treatment allocation scheme to the lowest three doses for the initial 9 
patients (3 patients in each of 3 cohorts) so that the safety and tolerability of the 
lowest doses could be assessed. 
The sample size calculations in the trial protocol were based on the secondary 
endpoint, difference between group mean levels of luteinising hormone and indicated 
that 15 patients in each of the 6 cohorts would provide at least 90% power to detect a 
difference of 148IU/L of luteinising hormone amongst any 2 groups (2-sided 5% 
significance level without multiplicity correction and standard deviation 78 IU/L). 
The schedule of assessments for the final trial design appears in Figure 1 of Jayasena 
et al. (2014) and is reproduced in Figure 1. 
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Figure 1. Superovulation protocol using subcutaneous kisspeptin-54 as a trigger to induce egg maturation. The time line 
shows the day of menstrual cycle for a typical patient. On day two of the menstrual cycle, daily subcutaneous recombinant FSH 
(Gonal F, 150 IU) was commenced. Daily GnRH antagonist injections (Cetrotide, 0.25 mg) were commenced when the lead 
follicle was greater than 14 mm in diameter on an ultrasound scan. When at least three ovarian follicles of 18 mm or greater in 
diameter were visible on ultrasound, a subcutaneous bolus injection dose of kisspeptin-54 (1.6, 3.2, 6.4, or 12.8 nmol/kg) was 
administered to trigger egg maturation (between 8:30 pm and 9:30 pm). Injections of GnRH antagonist and FSH were stopped 24 
and 12 hours, respectively, prior to administration of kisspeptin-54. Transvaginal ultrasound–directed egg retrieval was carried out 
36 hours following kisspeptin-54 injection, and intracytoplasmic sperm injection was performed using sperm from the male 
partner. One or two embryos were transferred to the uterine cavity three to five days following egg collection. Progesterone (400 
mg twice daily suppository/pessary) and estradiol valerate (2 mg orally 3 times daily) for luteal phase support were started after 
egg collection and continued until 12 weeks gestation. Biochemical pregnancy (βHCG > 10 miU/ml) was assessed 12 days 
following embryo transfer, and clinical pregnancy was assessed at six weeks gestation. Reproductive hormone secretion during 
the 12 hours following kisspeptin injection is presented in red: a subgroup of women receiving the two highest doses of kisspeptin-
54 (6.4 or 12.8 nmol/kg, n = 10/dose) underwent overnight measurements of serum LH, FSH, estradiol and progesterone, and 
plasma kisspeptin IR just prior to and during the 12 hours following kisspeptin-54 injection. 
Footnote: From Jayesena et al (2014) Kisspeptin-54 triggers egg maturation in women 
undergoing in vitro fertilization. Journal of Clinical Investigation, 124 (8), pp.3667–3677. 
Copyright 2014 American Society for Clinical Investigation. Reproduced by permission. 
Figure 1 Schedule of Assessments from Case Study Motivating the Research 
Although the planned trial could have been run with 9 patients allocated to the lowest 
3 doses followed by the remaining 81 patients randomly allocated to the 3 higher 
doses in parallel (subject to satisfactory safety and tolerability on the lowest 3 doses), I 
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wanted to explore alternative trial designs that could either provide similar information 
with fewer patients and/or provide answers to a range of questions and not just tests 
of significant differences between dose groups. The potential additional study design 
issues and opportunities are discussed in Section 1.4.3. Although further meetings 
were arranged with Professor Deborah Ashby, Professor Dhillo and myself to discuss 
the actual design to be used in the trial, my research would occur in parallel so that 
the protocol could be finalised in a timely manner but still incorporate any useful 
findings from my initial work. 
As can be seen from Jayasena et al. (2014), only 4 of the doses were used (1.6, 3.2, 
6.4 and 12.8 nmol/kg) because both patients randomised to the first dose (i.e. 1.6 
nmol/kg) did not attain response (i.e. clinically difficult egg collection was reported 36 
hours following study treatment) and the investigators proceeded to randomise the 
next 9 patients on a 1:1:1 basis to 3.2, 6.4 and 12.8 nmol/kg. The remaining 42 
patients were then randomised 1:1 to either 6.4 or 12.8 nmol/kg. The total number of 
patients randomised to each group is shown in Table 1. 
Table 1 Final Allocation of Patients to Doses in Case Study Motivating the Research 
 
Dose (nmol/kg)  
0.4 0.8 1.6 3.2 6.4 12.8 Total 
Number of Patients 0 0 2 3 24 24 53 
 
My research aimed to provide recommendations of alternative study designs for future 
trials that could either provide similar information with fewer patients and/or provide 
answers to a range of additional questions that would improve the design of 
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subsequent Phase 2 and/or Phase 3 trials. These opportunities are discussed in the 
next section. 
1.4.3 Opportunities for Alternative Trial Designs 
• Although the selected doses (0.4 to 12.8 nmol/kg) were expected to span the 
most promising doses it could be possible to use intermediate dose(s) in 
subsequent trials. However, the results of t-tests to compare 6 dose groups 
would not provide efficient estimation of doses other than those studied in this 
trial. Alternatively, if a model could be imposed on the underlying dose-
response relationship then more efficient estimation of that underlying dose-
response relationship could be formed and then intermediate doses could be 
selected for the subsequent trial(s). 
• Since the primary endpoint was assessed shortly after treatment intervention, it 
could be possible to employ a response adaptive treatment allocation 
procedure, see, for example, comprehensive reviews by (Bornkamp et al., 2007; 
Rosenberg, 2010; Lee et al., 2010). 
• Furthermore, since ovarian hyperstimulation was to be avoided then a study 
design could be employed which penalised over-dosing more than under-
dosing and thus may lead to a more appealing study design for both patients 
and investigators. 
• Information from both published and unpublished research on the role of 
kisspeptin was available to the investigators but was not incorporated in a 
formal manner in the originally planned trial. Bayesian methods with informative 
priors could provide a formal way to incorporate external information (Berry, 
2006; Berry et al., 2010; Cuffe, 2011; Hobbs et al., 2012; Shen et al., 2008; 
Spiegelhalter et al., 2004; Viele et al., 2014; Whitehead et al., 2008) 
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The above list of opportunities was identified prior to the protocol finalisation but 
because the actual kisspeptin trial has now completed, then it is also possible to 
identify if the number of patients allocated to each dose group could have been 
reduced with alternative study designs. 
A candidate study design to address many of the above aspects is the design 
introduced by Babb et al. (1998) and later extended by Tighiouart et al. (2005) termed 
Escalation with Overdose Control (EWOC)  which is based on a 2-parameter Bayesian 
logistic dose-response model. However, the performance of the EWOC design has 
generally been confined to its use in oncology trials where toxicity (response) rates 
have been between 20% and 35%. In an efficacy setting, Thevenin et al. (2008), Dai et 
al. (2012), Ivanova and Xiao (2013) and Zohar et al. (2013) have all recently 
implemented a 1-parameter model under the framework of the Continual 
Reassessment Method (CRM) that was originally introduced by O’Quigley et al. (1990). 
Whitehead and Williamson (1998) suggested a decision theoretic approach for high 
response rates but did not provide evidence of their performance across a range of 
response rates. Haines et al. (2003) consider the problem from an optimal designs 
perspective and, through simulations, made comparisons with EWOC for the specific 
cases of toxicity rates 20% and 40%. 
Hence, my work to combine all of these aspects and provide increased clarity of the 
operating characteristics of 2-parameter Bayesian logistic dose-response models 
appears to be novel. The specific research aims and objectives are described below. 
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1.5 Research Aims and Objectives 
1.5.1 Purpose of Research 
To improve the design and analysis of clinical trials within a drug development 
programme with particular emphasis on the application of Bayesian methods in early 
phase clinical trials to enable better design of confirmatory (Phase 3) trials. 
1.5.2 Aims 
With reference to the issues and opportunities identified in Section 1.4.3, the specific 
aims of this research are: 
• Characterise the performance of 2-parameter Bayesian logistic dose-response 
models across a range of experimental design choices when sample sizes are 
small 
• Assess the impact of a range of prior distributions (weakly and more 
informative distributions) on posterior conclusions 
• Evaluate methods for extracting beliefs from experts (i.e. elicitation) 
• Evaluate methods for incorporating expert beliefs into informative priors for the 
2-parameter Bayesian logistic dose-response model 
The outcome of the research will be to propose recommendations for the 
incorporation of external information into the prior distributions for the 2-parameter 
Bayesian logistic dose-response model across a range of experimental design choices. 
The range of response rates considered could thus be applied to future studies with 
safety and tolerability objectives (e.g. Phase 1 oncology trials in patients) and/or to 
Phase 2 trials with efficacy objectives. 
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Through better understanding of the operating characteristics of the EWOC design 
with informative priors, it would also be possible to recommend the total number of 
patients to allocate to the most promising dose (e.g. to the expansion cohort of a 
Phase 1 oncology study in which a Recommended Phase 2 Dose, RP2D, has been 
identified earlier in the study). 
Recommendations will also be given on how to improve the study design and 
statistical analysis for the case study that motivated this research. 
1.6 Overview of Remaining Thesis Chapters 
Before recommendations can be given on how to improve the design and analysis of a 
Phase 2 clinical trial for which expert beliefs are available, it is necessary to summarise 
the available literature on clinical trial designs used to evaluate early phase objectives 
(see Chapter 2) and the literature on elicitation (see Chapter 3). In general, 
recommendations which may have problems with practical implementation would be 
unlikely to be widely adopted and so part of the research was to involve practical 
applications to assess the feasibility of expert elicitation in a pharmaceutical company 
and an academic setting, hence elicitation sessions were planned and conducted in a 
structured manner. These elicitation sessions are described in Chapter 4 
(pharmaceutical setting) and Chapter 5 (academic setting). The elicitation session 
conducted in the pharmaceutical setting is an extended description of the version that 
appears in Kinnersley and Day (2013), see also reprint in Appendix B. For simplicity 
this is referred to as the Kinnersley-Day case study. Similarly, the elicitation session in 
the academic setting is referred to as the kisspeptin case study. 
If recommendations were to be made for the increased use of the EWOC design 
outside its traditional use in oncology trials (where safety, tolerability and 
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pharmacokinetic objectives generally prevail) then it would be important to assess its 
performance across a range of study design scenarios, including those in which 
informative priors based on expert beliefs may be considered. Performance could 
either be assessed empirically (e.g. designing and running many clinical trials in a 
range of settings) or through simulation. Since it would be impractical to design and 
run a substantial number of studies using an EWOC design in a timely manner then 
simulation was chosen to evaluate its performance. Chapter 6 provides a thorough 
description of the design of the simulation study that has been used to evaluate the 
operating characteristics of the 2-parameter Bayesian logistic dose-response model 
that forms the basis of the EWOC design. The results of the simulations are presented 
in Chapter 7. Recommendations for improvements to the study design and analysis of 
the kisspeptin trial are also provided in Chapter 7 in the context of the central 
research objective to maximise the information arising from (small) Phase 2 studies 
with the aim to improve the design of Phase 3 trials. 
Chapter 9 includes discussion of the novel contributions in this thesis and conclusions 
of the small sample properties of the EWOC design across a range of response rates 
and dose-response models. Proposals for future research are also discussed. 
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2. Current Approaches to Early Phase Designs 
2.1 Outline of This Chapter 
In Section 1.3, the objectives of early phase trials were described and such objectives 
could be attained using a variety of study designs, hence in this chapter the most 
frequently used early phase designs are summarised. Much has been written about the 
pros and cons of the available clinical trial designs for evaluating objectives of early 
phase trials (see for example (Cheung, 2011; Chevret, 2006; Crowley & Hoering, 2012; 
Harrington, 2011; Julious et al., 2010) and the intention is not to repeat that work in 
full, but rather to focus on providing a brief overview of the available designs and then 
focus the literature review on the current appraisal of those designs which are used 
more frequently. An in-depth description is provided of the Bayesian 1- and 2-
parameter logistic designs that form a central part of the research in this thesis. It is 
acknowledged that such a focus will necessitate only cursory mention of recently 
developed designs for which widespread practical implementation cannot be expected 
to have occurred (Jaki, 2013), however, the interested reader is encouraged to read the 
cited articles on these novel designs where provided. 
2.2 Overview of Early Phase Trial Designs 
Before proceeding to an overview of the available published clinical trial designs it is 
important to understand that any design that is being considered for implementation 
must adhere to legal and ethical constraints. From a legal perspective, the definitions 
of Phase 1, 2 and 3 are enshrined in United States law through the Code of Federal 
Regulations (U.S.C., 2013) and in Europe through European Union Directives, e.g. EU 
Directive 2001/20/EC (O.J. L, 2001), valid until 28 May 2016. These Statutory 
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Instruments may then be coded into Guidance documents that provide more detail in a 
specific setting, for example, the FDA issued a recent draft Guidance entitled 
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene 
Therapy Products (FDA, 2013b). 
This overview is confined to the situation in which the early phase objective is to find 
the dose (or doses) that lead to a specific response. For example, when considering 
safety, the estimation of the maximum tolerated dose (MTD) or when considering 
efficacy, the minimally effective dose (MED). A frequently employed approach is to 
allocate a specific dose to a small number of patients then responses are observed 
before proceeding to administer other doses to a further (small) number of patients 
(Tourneau et al., 2009). These type of designs are generally referred to as dose 
escalation studies though it should be born in mind that dose de-escalation may occur 
(Chevret, 2006). 
Dose escalation studies can be further classified into two broad categories, those that 
follow a set of rules (or algorithm) and those that pre-specify a dose-response model 
and use data to estimate parameters of the model. Terminology for these two 
approaches varies in the literature and so for the sake of consistency within this thesis, 
the terminology introduced by Oron et al. (2011) which in itself was an extension of 
terminology introduced by O’Quigley and Zohar (2006) is used. The two terms are: 
• Short memory designs 
• Long memory designs 
In the next section more detailed examples of such designs are given but, in brief, 
rule/algorithmic designs fall into the category of short memory designs whereas 
model-based designs generally fall into long memory designs.  In the earlier 
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terminology of O’Quigley and Zohar (2006) they used the term memoryless for the 
rule/algorithmic designs but here the term short memory is used to reflect that at 
least some “borrowing” of information from earlier in the trial may be employed. 
These classifications are now described in more detail. In general, the short memory 
designs do not rely on mathematical concepts so there is minimal use of formulae in 
the next section, whereas full algebra is provided for the long memory designs 
described thereafter. 
2.3 Short Memory Designs in Early Phase Trials 
More detail is provided on the most popular short memory design often referred to as 
the “Up-and-Down” design (with its variants) before going on to describe other 
designs which follow an algorithm (or rule). 
2.3.1 Up-and-Down Designs 
The Up-and-Down design was introduced by Dixon and Mood (1948) in their work on 
explosives research and extended to small samples with applications in bioassay 
(Brownlee et al., 1953; Dixon, 1965). When used in the evaluation of anti-cancer 
therapies it is better known as the 3+3 design (Storer, 1989). An initial dose (usually 
very low) is given to 3 subjects and they are monitored for safety and tolerability. If all 
three patients tolerate the treatment then the next 3 subjects are given the next dose 
level. However, if one patient experiences tolerability issues, then 3 further patients 
are given the same dose. The trial continues until 2 patients within a cohort of 3 or 6 
patients experience tolerability issues. Lin and Shih (2001) demonstrated that the 3+3 
design does not have the target toxicity level of 33% and, as noted by Tourneau et al. 
(2009), the 3+3 design may converge to a dose that corresponds to a probability of a 
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Dose Limiting Toxicity (DLT) as high as 50%, which is somewhat higher than the 33% 
threshold typical in many anticancer trials. 
As can be seen intuitively from this algorithmic based design, there is no borrowing (or 
memory) of the information gleaned from earlier cohorts in the estimation of the MTD. 
Furthermore, the actual dose value (and spacing between doses) is not used when 
determining the MTD. It is also not possible to estimate the dose expected to lead to 
any specific response rate. Despite these shortfalls, the 3+3 design has been widely 
used. For example, through a systematic search covering the period 1991 to 2006, 
Rogatko et al. (2007) revealed that 1215 of 1235 Phase 1 cancer trials (98.4%) followed 
variations of the 3+3 design. A further example from Tourneau et al. (2009) provides a 
list of 20 Phase 1 anticancer trials (some also identified by Rogatko et al. (2007)) that 
employed the 3+3 design for which FDA eventually approved the agent in the period 
1992 to 2008. This should not be interpreted that sponsors using the 3+3 design will 
automatically receive FDA approval (nor vice-versa) but the 3+3 design is a design 
with a wealth of empirical experience to support its usage. For example, Ji et al. (2007) 
report that during the period April to May 2006, 20 of the 22 Phase 1 protocols 
submitted for Institutional Review Board approval at the M.D. Anderson Cancer Center 
used the 3+3 design. 
Some of the variants of the original 3+3 design are now described in order to 
acknowledge their existence although, since algorithmic designs are not the focus of 
this thesis, their review is relatively brief. 
2.3.2 Overview of Other Short Memory Designs 
Variations of the original “Up-and-Down” design have generally tried to either reduce 
the total number of patients recruited (Simon et al., 1997) or reduce the time to 
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conduct a study (Skolnik et al., 2008). A useful review was provided by Storer (1989) 
just one year before the landmark publication of what is widely accepted as the first 
model-based design by O’Quigley et al. (1990). In Storer’s review, he describes 
variants of 3+3 where: 
• dose escalation or de-escalation decision is made after every patient (rather 
than every 3 patients) 
• only one patient is treated at a time but two consecutive non-toxic responses 
are required before escalation but de-escalation would occur after a single 
toxic response 
• three patients are treated but escalation occurs so long as no toxicity is seen; 
de-escalation occurs if more than one toxicity; same dose if single toxicity 
Storer also considers the case for 2-stage designs where Stage 1 uses single patient 
escalation rules for the first 8 patients then the rules are followed for three-patient 
cohorts. Through simulations, Storer concludes that two-stage designs perform better 
than single stage designs. 
The 3+3 design has been generalised to the A+B design (Lin & Shih, 2001) where 
cohort sizes other than 3 are considered, for which its properties have also been 
studied (Ivanova, 2006). Other algorithmic designs include biased coin (Efron, 1971) 
and Rolling 6 (Skolnik et al., 2008) and the interested reader is referred to the 
overviews in Chevret (2006), Ting (2006) and Tourneau et al. (2009). 
Overall, the main advantages of short memory (algorithmic) designs are their simplicity 
to explain and to implement which in turn has led to extensive usage. The drawbacks 
outlined above led to a wealth of research in the 1990s which continues today on the 
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use of model-based designs that can borrow information gained from earlier in the 
trial. A summary of the relevant literature is provided in the next section. 
2.4 Long Memory Designs in Early Phase Trials  
As discussed earlier, when estimating the MTD, the term Long Memory designs refers 
to those designs which use information from multiple cohorts through imposition of a 
model on the form of the dose-response relationship. These include the designs 
termed continual reassessment method (CRM) (O’Quigley et al., 1990) and escalation 
with overdose control (EWOC) (Babb et al., 1998). The focus of the research in this 
thesis is a Bayesian 2-parameter logistic model which has been used in the EWOC 
design (Lonial et al., 2010), so it is described in more detail here. The CRM design was 
introduced earlier than EWOC and is frequently compared in the literature with EWOC 
and other long memory designs, so it is described first. 
2.4.1 Continual Reassessment Method (CRM) 
The CRM is a model-based design and its proponents claim it has an advantage over 
designs with short memory because CRM is able to provide an estimate of the MTD as 
a dose other than doses actually studied in the clinical trial (Piantadosi et al., 1998). 
The CRM was introduced by O’Quigley et al. (1990) in the context of Phase 1 oncology 
trials and so its formulation is described in terms of toxicity (yes/no binary endpoint) 
but (as noted earlier) it has been used in an efficacy setting where a yes/no binary 
response indicates improvement. 
The CRM is an iterative process whereby a target toxicity is defined e.g. Dose Limiting 
Toxicity (DLT) rate of 25% and the first patient is assigned the lowest available dose. A 
dose-toxicity model is fitted to the accruing data and each subsequent patient is 
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assigned the dose closest to the target toxicity level. Such a process requires pre-
specification of the functional form of the dose-toxicity model and initial estimates of 
the toxicity rates on each dose. 
In the terminology of O’Quigley et al. (1990), suppose there are k dose levels, 𝑥𝑖 
(i=1,…,k) and let 𝑌𝑗 be a binary random variable (0,1) where 1 represents a toxicity for 
the j th patient (j=1,…,n). Suppose the target toxicity is represented by θ and this 
corresponds to a dose level 𝑥∗ (not necessarily an available dose). O’Quigley et al. 
considered a very general form for the dose-response function E(𝑌𝑗) = ψ(𝑥𝑖, a) in which 
the function ψ(·) is monotonic in 𝑥𝑖 and a. Furthermore, of all possible values of the 
parameter a, there exists a value, say 𝑎0 such that ψ(𝑥∗, 𝑎0) = θ. In other words, for a 
known dose-response function dependent on the single parameter 𝑎0 the dose level 𝑥∗ 
leads to the target toxicity level, θ. 
The three most popular mathematical dose-response models for ψ(·) have been: 
• empiric (power) model  ψ(𝑥𝑖, a) = 𝑥𝑖𝑎    (O’Quigley et al., 1990) 
• hyperbolic tangent  ψ(𝑥𝑖, a) = �(tanh𝑥𝑖+1)2 �𝑎    (O’Quigley et al., 1990)  
• 1-parameter logistic  ψ(𝑥𝑖, a) = � 𝑒
3+𝑎𝑥𝑖
1+ 𝑒3+𝑎𝑥𝑖�  (Goodman et al., 1995)  
These models are represented in Figure 2 for a range of values of the parameter “a”. 
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Empiric/Power 
 
Hyperbolic 
 
1-parameter logistic 
Figure 2 Examples of 1-Parameter Dose-Response Models 
A crucial step in CRM methodology is to transform dose values into dose labels. This 
can be done by backwards transformation of an initial guess of the toxicity probability 
on each dose. For example, consider the 1-parameter logistic model within the CRM 
framework (as proposed by Goodman et al. (1995)) and that dose level 3 will lead to 
the target toxicity θ of 0.25, furthermore suppose there is an a priori belief that a=1 
then back-transformation of the following can be performed: 
0.25 = � 𝑒
3+𝑥3
1+ 𝑒3+𝑥3� 
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to reveal 𝑥3=-1.10. Similarly, if a total of 5 doses were to be administered and initial 
guesses were available for the toxicity probability for the 5 doses 𝑝1 to 𝑝5 then the 
CRM would use the dose labels as specified in Table 2. 
Table 2 Example of Dose Labels for Use in CRM 
 𝑝1= 0.05 𝑝2= 0.12 𝑝3 = 0.25 𝑝4 = 0.40 𝑝5 = 0.55 
Dose Labels, 𝑥𝑖 -2.94 -1.99 -1.10 -0.41 0.20 
 
These initial guesses are often called the skeleton of the CRM (Iasonos & O’Quigley, 
2012), see Section 2.4.5 for the impact of choice of skeleton on the properties of the 
CRM. For the purposes of simplicity of terminology, the term dose rather than dose 
label will be used for the remainder of this discussion of CRM. 
Assuming patient i receives dose 𝑥[𝑖] and provides (binary) response data 𝑌𝑖 then the 
likelihood from the first j patients is: 
 L(a) = ∏ �𝜓(𝑥[𝑖],𝑎)�𝑌𝑖𝑗𝑖=1  �1 −𝜓(𝑥[𝑖],𝑎)�1−𝑌𝑖 ( 2.1 ) 
Assuming the prior knowledge of parameter a is entirely captured by the function g(a) 
then Bayes’ Theorem can be applied to calculate the updated (i.e. posterior) 
distribution for the parameter a. The posterior distribution for a is thus: 
 h(a) = 𝑔(𝑎)𝐿(𝑎)
∫𝑔(𝑢) 𝐿(𝑢)𝑑𝑢 ( 2.2 ) 
To identify the dose for the next patient, O’Quigley et al. (1990) proposed using the 
Expected Value of a (i.e. mean) from this posterior distribution (denoted 𝑎�) and then 
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inverting the dose-response model at target toxicity θ to find the corresponding dose. 
In mathematical form: 
 𝑥[𝑗+1] = 𝜓−1(𝜃,𝑎�) ( 2.3 ) 
In practice, this may not correspond exactly to one of the available doses so the 
closest dose may be chosen: 
 𝑥[𝑗+1] = arg min𝑥𝑖|𝜓(𝑥𝑖, 𝑎�) −  𝜃| ( 2.4 ) 
An alternative estimator was also provided by O’Quigley et al. (1990) which is 
computationally more complex to calculate and has not received as much attention in 
the literature (Cheung, 2011, p.20): 
 𝑥[𝑗+1] = arg min𝑥𝑖| 𝐸{𝜓(𝑥𝑖,𝑎)} −  𝜃| ( 2.5 ) 
 where E{·} denotes Expectation over a  
Whichever estimator is chosen, this process continues either until a predetermined 
fixed sample size, or some other trial terminating condition is satisfied, for example, 
Whitehead and Williamson (1998) considered continuing until reaching the required 
precision of the posterior. 
Published examples of CRM are fewer than for the 3+3 design, however, numerous 
applications are discussed in Cheung (2011) along with references for software to 
implement the analysis. In a recent review by Iasonos and O’Quigley (2014), the 
authors identified 53 trials in which the CRM and its variants had been implemented 
and published between 2003 and 2013 and found that on average, these trials 
required 25 patients to test five to six dose levels. The average observed DLT rate of 
these studies was 18%. In a regulatory setting, the Committee for Medical Products for 
Human Use (CHMP) produced guidance on developing medicines in orphan 
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diseases/small populations and suggested the use of CRM-type designs over 
algorithmic (i.e. short memory) designs (EMEA, 2006). Before considering extensions 
of the original CRM this chapter continues by describing in more detail the EWOC 
design that is based on a Bayesian 2-parameter logistic model. 
2.4.2 Escalation with Overdose Control (EWOC) design 
Like the CRM, the EWOC design is able to provide an estimate of the MTD as a dose 
other than doses actually studied in the clinical trial (Piantadosi et al., 1998). The 
EWOC was introduced by Babb et al. (1998) as an alternative to the CRM that sought to 
control the chance of over-dosing patients during dose escalation. In brief, there are 3 
key differences from the Goodman et al. (1995) formulation of the CRM, namely: 
• 2-parameter Bayesian logistic model replaces the 1-parameter 
• a loss function is incorporated formally to identify the dose for subsequent 
patients 
• dose (or standardised dose e.g. each dose is divided by a reference dose) values 
can be modelled directly 
The 2-parameter Bayesian logistic model had been considered earlier by other authors 
e.g. Gatsonis & Greenhouse (1992) but Babb et al. described a criteria that could 
estimate the probability of over-dosing subsequent patients. In more detail, and as 
with CRM, suppose the target toxicity is represented by θ and this corresponds to a 
dose level 𝑥∗ (not necessarily an available dose). Babb et al. (1998) consider the 
general 2-parameter dose-response model: 
 P(𝑌𝑗 =1 | Dose=𝑥𝑖) = F(𝛽0 +  𝛽1𝑥𝑖) ( 2.6 ) 
where F(·) is a specified cumulative distribution function, for example, logistic leads to: 
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 P(𝑌𝑗 =1 | Dose=𝑥𝑖) = �
𝑒𝛽0+𝛽1𝑥𝑖
1+ 𝑒𝛽0+𝛽1𝑥𝑖� ( 2.7 ) 
This model is represented in Figure 3 for a range of values of the parameters 𝛽0 and 
𝛽1. 
 
Figure 3 Examples of Two-parameter Logistic Dose-Response Models 
Analogous to the Bayesian approach for CRM (see Equation ( 2.1 )), the likelihood can 
be expressed in terms of the parameters 𝛽0 and 𝛽1 then combined with priors (for 𝛽0 
and 𝛽1) to obtain posteriors, however, Babb et al. (1998) chose to re-parameterise the 
logistic model because specifying priors for regression parameters is not 
straightforward (Kadane et al., 1980). The alternative formulation is in terms of 𝜌0 and 
γ, where 𝜌0 is the probability of DLT at the minimum dose (denoted Xmin) and γ is the 
MTD. For target response rate, θ, the logistic model can now be expressed as: 
 logit (𝜌0) = 𝛽0 + 𝛽1Xmin ( 2.8 ) 
and logit (θ) = 𝛽0 + 𝛽1γ ( 2.9 ) 
By subtraction, these two equations for 𝛽0 and 𝛽1 become: 
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 𝛽0 = 
1
𝛾− 𝑋𝑚𝑖𝑚 {𝛾 𝑙𝑙𝑙𝑙𝑙(𝜌0) −  𝑋𝑚𝑖𝑚𝑙𝑙𝑙𝑙𝑙(𝜃)} ( 2.10 ) 
and 𝛽1 =
1
𝛾− 𝑋𝑚𝑖𝑚 {𝑙𝑙𝑙𝑙𝑙(𝜃) −  𝑙𝑙𝑙𝑙𝑙(𝜌0)} ( 2.11 ) 
In the original article, Babb et al. (1998) considered placing (bounded) independent 
Uniform priors on 𝜌0 and γ. This was later extended by Tighiouart et al. (2005) to 
include a set of four alternative priors of which two incorporated correlation between 
𝜌0 and γ.  
As with CRM (see Equation ( 2.1 )), the first patient receives the first dose i.e. 𝑥1=𝑋𝑚𝑖𝑚 
and provides (binary) response data 𝑌𝑖 then the Likelihood (in terms of 𝜌0 and γ) from 
the first j patients can be written as:  
 L(𝜌0,𝛾)= ∏ � 𝑝(𝜌0,𝛾, 𝑥[𝑖])�𝑌𝑖𝑗𝑖=1  �1 − 𝑝(𝜌0,𝛾, 𝑥[𝑖])�1−𝑌𝑖 ( 2.12 ) 
where 
𝑝(𝜌0, 𝛾, 𝑥[𝑖])= 𝑒�𝑙𝑚� 𝜌0(1−𝜌0)�+𝑙𝑚�𝜃(1−𝜌0)𝜌0(1−𝜃)� 𝑥[𝑖]𝛾 �
1+𝑒
�𝑙𝑚�
𝜌0(1−𝜌0)�+𝑙𝑚�𝜃(1−𝜌0)𝜌0(1−𝜃)� 𝑥[𝑖]𝛾 �   
( 2.13 ) 
Although these expressions appear unwieldy, it does allow us to specify priors on 
parameters that are intuitively more appealing to clinical researchers since the two 
parameters reflect observable quantities (Bedrick et al., 1996; Huson & Kinnersley, 
2009; O’Hagan et al., 2006, p.145). 
After the responses from j patients are available the (marginal) posterior distribution 
for γ can be written in a similar manner to Equation ( 2.2 ) for which the cumulative 
distribution function (CDF) for γ will be denoted by ∏ (𝑥)𝑗 . Assuming the first patient 
has no toxicity on dose 𝑥1=𝑋𝑚𝑖𝑚 the dose for the next patient is identified by selecting 
a probability (denoted alpha) for which the chance of over-dosing is bounded (Zacks 
et al., 1998). For example, alpha=0.25 means the selected dose has only a 25% 
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chance of being higher than the true MTD, γ. This dose (for the j+1th patient) is 
identified from: 
 � (𝑎𝑙𝑝ℎ𝑎)−1
𝑗
 ( 2.14 ) 
Stopping rules can be applied as for CRM and at the end of the trial, an appropriate 
quantity can be derived from the marginal probability density for γ, for example 50th 
percentile (median), mode or mean (expected value). Tighiouart et al. (2005) show 
that the dose 𝑥[𝑗+1] selected for the j+1th patient corresponds to the asymmetric loss 
function: 
 𝑙𝑎𝑎𝑎ℎ𝑎(𝑥, 𝛾) = �𝑎𝑙𝑝ℎ𝑎(𝛾 − 𝑥)             𝑙𝑖 𝑥 ≤ 𝛾    i. e. underdose(1 − 𝑎𝑙𝑝ℎ𝑎)(𝑥 − 𝛾)      𝑙𝑖 𝑥 > 𝛾   i. e. overdose ( 2.15 ) 
As such, any loss incurred by treating a patient above the MTD is penalised 
(1-alpha)/alpha times greater than the loss from equivalent under-dosing. 
In the (common) situation when a clinical trial only has a discrete set of doses available 
then Tighiouart and Rogatko (2010) argue that the dose 𝑥[𝑗+1] should be selected 
based on defining a tolerance criteria: 
 𝑥[𝑗+1] = max𝑥𝑖�(𝑥𝑖 −  𝑥[𝑗+1] ≤  𝑇1) 𝑎𝑎𝑎 (∏ (𝑥𝑗+1)  −  𝑎𝑙𝑝ℎ𝑎 ≤  𝑇2)𝑗 � ( 2.16 ) 
where 𝑇1and 𝑇2 are non-negative numbers (referred to as tolerances). 
In non-mathematical terms, the trialist needs to pre-specify a tolerance for: 
• discrepancy between the recommended and available doses 
• discrepancy between pre-specified overdose probability (alpha) and the 
corresponding overdose probability from an available dose 
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Tighiouart and Rogatko (2010) provide no recommendations on reasonable values for 
𝑇1 and 𝑇2 and further evidence of the implications for such choices is warranted. 
In contrast to the dose allocation rule of O’Quigley et al. (1990) in which the 
probability of overdose is a component of the rule when only discrete doses are 
available (see Equations ( 2.4 ) and ( 2.5 )), there may be clinical trial settings in which 
the investigator is willing to base the choice of next dose only on the difference 
between the dose increments. Hence, consider an alternative estimator which is a 
special case of Equation ( 2.16 ) i.e. setting  𝑇1= {half of the dose-spacing} and  𝑇2= 1-
alpha, which can be expressed equivalently as: 
 𝑥[𝑗+1] = min𝑥𝑖��𝑥𝑖 −  𝑥[𝑗+1]�� ( 2.17 ) 
Since little attention has been paid to the choices of 𝑇1 and 𝑇2 , the properties of the 
estimator in Equation ( 2.17 ) have also not been widely studied in the literature.  
Practical use of this estimator can be demonstrated by the example in Figure 4 for 
which a target response rate of 0.4 would imply the next patient should be allocated 
dose 1.5766 (see Figure 4(a)), however, in the relatively common situation in which 
only discrete doses are available (in this example 0, 1, 2 and 3) the estimators from 
Equations ( 2.4 ) and ( 2.5 ) would recommend Dose=1 for the next patient (see Figure 
4(b)) since the difference in probability of a response=0.4 is smaller on Dose=1 than 
Dose=2 (i.e. 0.4-0.0474 is smaller than 0.8176-0.4). As argued above, if the targeted 
response is an efficacy parameter and the investigator is satisfied with the observed 
safety of the new treatment thus far, then he/she may wish to administer Dose=2 
since it is not too much of a dose increase and it is mathematically closer to the 
recommended dose. 
- 45 - 
 
 Figure 4(a) Target Response Rate=0.4 Figure 4(b) Estimated Response Probabilities 
for Next Available Dose Allocation 
  
Figure 4 Estimated Response Probabilities for Available Doses 
2.4.3 Applications of EWOC 
The first application of EWOC was described in the original paper by Babb et al. (1998) 
in the setting of a Phase 1 cancer study with 12 patients, a target toxicity θ=0.33, 
over-dose probability alpha=0.25 and independent Uniform priors on 𝜌0 and γ. Since 
the experimental drug was only available in tablet strengths of 50mg and 100mg, the 
actual doses given to patients were rounded to the nearest 50mg. No further details 
were provided on the impact of rounding the choice of doses. More recent applications 
of EWOC in Phase 1 cancer trials include those by Lonial et al. (2010), Sinha et al. 
(2012) and Harvey et al. (2013). 
Standalone software to implement EWOC is available (Wang et al., 2013), however, in 
the situation when only a discrete subset of doses is available, the supporting 
documentation for this application indicates that the dose below the current estimate 
is taken rather than the closest dose even if that dose is higher (see equation ( 2.16 )). 
EWOC can also be implemented using R packages, see for example Sweeting et al. 
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(2013). The simulations based on EWOC described in Chapter 6 were programmed de 
novo using SAS/STAT® software, Version 9.2 and 9.4 (SAS Institute Inc, 2008). 
Since the publication of the original CRM and EWOC designs there have been 
numerous extensions, see for example, the thorough review by Tourneau et al. (2009) 
and so the next section considers only the subset that address shortcomings 
highlighted earlier in the literature review. 
2.4.4 Overview of Extensions and Other Long Memory Designs 
Cheung (2011) provides a comprehensive review of the original CRM as well as the 
many extensions such as those introduced allowing for cohorts with multiple patients 
(Goodman et al., 1995), 2-step CRM (Moeller, 1995), estimation by likelihood 
(O’Quigley & Shen, 1996), time-to-event endpoints (Cheung & Chappell, 2000), 
bivariate binary endpoints (Braun, 2002) and trivariate endpoints (Zhong et al., 2012). 
Yin and Yuan (2009) consider the problem of model misspecification using the 
technique of Bayesian Model Averaging in which a range of models are considered as 
plausible and those models with better fit to the accumulating data are given higher 
weight. More recently, Takeda and Morita (2014) proposed a method that uses data 
from a short memory design (i.e. “3+3”) from a Caucasian population to form priors 
for a subsequent trial in Japanese patients that was designed using a 2-parameter 
Bayesian logistic model. 
Much of the early work characterising the properties of the long memory designs 
assumed a single value (e.g. probability=0.3) for the target tolerability though 
Neuenschwander et al. (2008) considered a tolerability interval approach (under-
dosing=[0,0.2]; targeted toxicity=(0.2,0.35]; excessive toxicity=(0.35,0.6]; 
unacceptable toxicity=(0.6,1.0]). These authors justified the use of a 2-parameter 
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logistic model after observing difficulties with fitting the 1-parameter CRM-type model 
(in which the intercept is fixed at a value of 3 and the slope is estimated). 
Chu et al. (2009) provide the conditions under which CRM and EWOC are equivalent, 
namely, by setting the Bayesian Feasible Level (BFL), equal to 0.5. In other words, 
choose the dose for which the probability of it exceeding the MTD is 0.5 i.e. taking the 
median of the CDF. The BFL is usually denoted by the Greek word alpha or equivalent 
symbol α. To avoid any potential confusion with the use of the symbol α to mean the 
Type I error in tests of statistical significance, this thesis will use the Greek word alpha 
when referring to the BFL. Chu et al. (2009) also introduce a hybrid CRM-EWOC design 
by allowing the BFL alpha value to increase during the course of a trial. In practise, this 
means that dose escalation is relatively slow (i.e. conservative) when only a few 
patients have been recruited (e.g. by setting BFL alpha=0.1) but speeds up as more 
patients are recruited (e.g. by setting BFL alpha=0.5 for later cohorts). This procedure 
is straightforward to implement since the recommended dose for the next patient is 
found from the corresponding BFL quantile of the current estimate of the dose-
response curve. 
2.4.5 Evaluating Performance of Long Memory Designs 
The most common metric for assessing the performance of these competing designs is 
convergence, which is calculated as the proportion of times a simulation recommends 
the true MTD. Convergence can be calculated at the end of a simulated trial e.g. see 
(Babb et al., 1998; Goodman et al., 1995; Hu et al., 2013; Iasonos & O’Quigley, 2012; 
O’Quigley et al., 1990) or can be assessed at intervals during a simulated trial (Azriel 
et al., 2011; Chu et al., 2009; Oron & Hoff, 2013) so that researchers can assess how 
quickly a design converges to the MTD. Some authors use the term consistency rather 
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than convergence. (Shen & O’Quigley, 1996; Hu, 1998; Cheung, 2011, p.55). A special 
case of the findings from Hu (1998) demonstrated that if an infinitely continuous set 
of doses were available and if the posterior mean was used to determine the dose for 
the next patient, then the CRM design does converge to the true MTD for large sample 
sizes. 
Although simple in concept, the difficulty with comparing convergence rates for small 
sample sizes across various designs arises because different researchers have chosen 
different simulation scenarios to study the properties of their novel designs. In fact, 
the performance of the CRM is dependent upon the choice of initial toxicity 
probabilities often termed the skeleton (Iasonos & O’Quigley, 2012), likewise for 
EWOC, Chu et al. (2009) concluded that model parameterisation also affects the rate of 
convergence to the MTD and, perhaps more importantly, show that for a range of 
dose-toxicity curves EWOC often under-estimates the MTD when the MTD is above the 
mid-level of the dose range. It is argued that this is due to the safety-focus nature of 
EWOC in providing overdose protection. 
In its most frequent usage, the convergence metric considers neighbouring doses as 
“failures” of the design, whereas in practice, if estimation of benefit-risk is the 
objective of a trial then use of such neighbouring doses may in fact be appealing. 
Furthermore, due to the predominant use of CRM and EWOC in the safety (e.g. 
oncology) setting then many simulation studies have implemented the strict rule of not 
allowing a (simulated) patient to be allocated a dose level more than 1 dose level 
higher (Chu et al., 2009; Goodman et al., 1995; Iasonos & O’Quigley, 2012), whereas 
in an efficacy setting it may be useful to have the flexibility to allocate any dose. Thus, 
a researcher wishing to choose a long memory design in a new study cannot rely on 
the literature to provide a one-size fits all design but instead must simulate and then 
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evaluate the properties of a range of designs before selecting a final trial design 
(Sweeting et al., 2013). 
In early phase trials with relatively small sample sizes, it is important to understand if 
the asymptotic properties of CRM-type designs can be relied upon. Chu et al. (2009) 
investigated this aspect through simulation across a range of sample sizes from 10 to 
60 patients and reported the convergence rates i.e. the percentage of times that the 
correct MTD was estimated by the procedure for 10 to 60 patients. However, for any 
(single) real clinical trial it will never be known if the estimated MTD matches the true 
MTD, so it is important to understand how far away (on some scale) are the estimated 
and true MTD (i.e. the bias of the design).  
Oron and Hoff (2013) considered the estimation of MTD in small sample Long Memory 
designs (i.e. N<30) and described the phenomenon of “settling”. Oron and Hoff only 
considered the single target response rate of 0.3 but found that a non-negligible 
proportion of simulations produced estimates of MTD that settled on an incorrect MTD 
early on. In particular, by considering the criteria “5 consecutive identical allocations” 
approximately half of their simulations encountered incorrect settling by 16 patients. 
In the scenario of assessing high response rates (e.g. much higher than the typical 0.2 
to 0.33 in Phase 1 toxicity setting), the properties of the 1-parameter CRM have 
recently been studied by Ivanova and Xiao (2013). Applications of the 1-parameter 
CRM with high response rates appeared recently in Dai et al. (2012) and Thévenin et al. 
(2008). The use of (2-parameter) EWOC with a range of response rates appears to be 
less well documented and thus its properties need to be more fully characterised 
before widespread implementation can be advocated. 
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For a more detailed comparison of CRM and EWOC plus their corresponding 
extensions the reader is referred to the review by Tourneau et al. (2009). A more 
general Bayesian perspective of logistic dose-response models for early phase designs 
is available in Whitehead & Williamson (1998). 
The majority of the literature on CRM, EWOC and related designs assumes minimal 
prior information on the response rates will be incorporated into the design and 
analysis of a subsequent trial, however, as seen in the motivating case study, there are 
situations when information external to the trial is available. Furthermore, some 
authors have advocated use of informative priors to formally incorporate external 
information (e.g. Pocock & Spiegelhalter (1992); Senn (2007) ) or to improve precision 
when using long memory designs (Neuenschwander et al., 2008). 
2.5 Conclusions 
• Application of model-based Long Memory designs has tended to focus on 
dose-finding to a pre-specified response rate (often denoted, θ) but, in reality, 
recommending a dose for future investigation is part of an overall benefit-risk 
assessment. As such, it is unrealistic to expect a pre-specified, single-valued 
response rate to apply equally throughout an ongoing trial. 
• The most common metric (i.e. convergence) used to assess performance of the 
available Long Memory designs considers neighbouring doses as “failures” of 
the design, whereas in practise, when estimation of benefit-risk is the focus 
then such neighbouring doses may be attractive to use. It is therefore 
worthwhile to investigate other measures of study design performance such as 
bias, mean square error (MSE) and convergence to the true value. 
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• When using EWOC, the Bayesian-feasible level (denoted alpha) is only 
guaranteed when the “tolerance” values T1 and T2 are both zero which implies 
continuous doses are being used in the trial, so it is important to characterise 
EWOC properties when only a subset of doses is available. 
• When using the EWOC design with a discrete subset of doses there needs to be 
further research into the impact of always using the dose immediately below the 
current estimate of the target dose (as opposed to using the closest dose above 
or below). 
• When using the EWOC design with a discrete subset of doses for which there is 
no constraint on skipping dose levels, there needs to be further research into 
how the design performs, particularly in the situation of small sample sizes 
where asymptotic properties may not hold. When EWOC is used in an efficacy 
setting (i.e. targeting high response rates) it may be undesirable to restrict 
escalation rules to 25%, 50% or 100% of the previous dose (as often 
implemented in a safety setting). 
• Since the convergence metric and the Bayesian-feasible level for the EWOC 
design are dependent on the sample size, choice of prior and model 
parameterisation, additional research is required to characterise the 
performance of the Bayesian 2-parameter logistic for a variety of priors and 
parameterisations under a wider variety of conditions than those typically 
observed in Phase 1 oncology settings (where θ lies between 0.2 and 0.33). 
• When information external to the currently planned trial might be used, 
additional empirical evidence is needed to assess the feasibility and operating 
characteristics of the available elicitation methods in the clinical trial domain. 
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Thus, for the researcher interested in balancing benefits and risks across a range of 
response rates when clinical trial data are accumulating, it is important to understand 
the small sample properties of designs based on Bayesian 2-parameter logistic models 
when both uninformative and informative priors are considered. 
Although informative priors may be formed using data from previous trials (e.g. see 
Pocock (1976), Neuenschwander et al. (2010), Viele et al. (2014)), such priors may also 
be formed by eliciting expert beliefs, hence this thesis continues with an overview of 
the literature on elicitation of expert beliefs and the subsequent formation of prior 
distributions. Such priors may be used in the design and/or Bayesian analysis for the 
specific case of the 2-parameter logistic model which forms the basis of the EWOC 
design (which is the main focus for this thesis) or for other clinical trial designs.   
- 53 - 
 
3. Overview of Elicitation and Formation of Priors 
3.1 Introduction 
In any particular drug development scenario, data may be available with which to form 
a prior distribution directly (e.g. see Pocock (1976), Neuenschwander et al. (2010), 
Viele et al. (2014)), however, the focus of this thesis is on the situation when previous 
knowledge (and/or data) may be available from one or more experts but the manner in 
which it should be incorporated is unclear. It is therefore important to review the 
available methods for forming prior probability distributions from expert opinion. 
3.2 Elicitation of Expert Beliefs 
A full treatment of the available methods is beyond the scope of this overview but the 
interested reader is referred to the comprehensive texts by O’Hagan et al. (2006) and 
Kynn (2008). A substantial portion of the following literature review was performed as 
part of the research for this thesis and appears in Kinnersley & Day (2013) (see also 
reprint in Appendix B) with extensions to reflect more recent publications. 
In a key paper by Morris (1974) that used the Bayesian framework for decision analysis 
he describes an expert as “a person who provides a judgment concerning uncertain 
matters”. In a medical context with public health implications, Kadane (1986) argues 
that who qualifies as an expert contains political components “While the politics 
involved rarely includes Congress, it usually does have to do with the pecking order 
among physicians and scientists”. In a rather unusually open approach, Blanck et al. 
(1996) describe a trial in which they list the actual names, job titles and previous 
relevant experience for each of the five experts who took part in an elicitation exercise 
for a clinical trial. It has not been possible to identify other examples of this fully open 
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approach in the clinical trial literature, however, its intuitive appeal of openness is to 
be commended as a way to reduce perceived bias and increase the integrity of 
resulting conclusions.  In a contrasting approach, Myung et al. (1996) introduce a 
mathematical definition of expert competence as “a function of the deviation between 
the observed outcome and the predicted outcome”. Garthwaite et al. (2005) recognise 
that bias can be introduced if an expert has a personal interest in the result. Although 
definitions of an expert may vary amongst different authors it is abundantly clear that 
for trials in which the prior carries high weight (i.e. the likelihood does not dominate 
the posterior) then the credibility of inferences from the resulting trials relies heavily 
on the transparency of the process to identify and incorporate expert beliefs. Ensuring 
a formal method is available for increasing transparency is thus an important step in 
the elicitation process. 
Before proceeding to describe the available frameworks for conducting elicitation it is 
important to distinguish the types of uncertainty that a researcher may wish to elicit. 
In the context of hazard waste management, Hora (1996) uses the terms aleatory 
uncertainty (i.e. induced by randomness) and epistemic uncertainty (i.e. due to lack of 
knowledge). In the case of clinical trials estimating response rates, epistemic 
uncertainty is of most interest (i.e. the true value of the response rate). Arguably, in 
very large trials (e.g. 10,000 patients) then elicitation would be essentially of the 
epistemic uncertainty but for trials of much smaller sample sizes both aleatory and 
epistemic uncertainty are present. The statistical literature is unclear as to whether 
experts can accurately separate aleatory and epistemic uncertainty when providing 
their beliefs (O’Hagan et al., 2006). 
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3.3 Frameworks for Conducting the Elicitation Session 
Some authors (Cooke & Goossens, 2000; Hardaker & Lien, 2005; Choy et al., 2009) 
have recognized that it is impractical for the typical researcher to distil the critical 
pieces of information into a set of working practices (or ‘elicitation protocol’) that can 
be used to inform the design of a new experiment. In the ecology setting, Kuhnert et 
al. (2010) argue that without such a framework, the researcher can be tempted to start 
the elicitation process directly without due consideration for the subsequent 
inferences that need to be made. 
Several features are present in a number of the frameworks and these have been 
elegantly described in six key steps by Choy et al. (2009) as: 
• determining the purpose and motivation for using prior information 
• specifying the relevant expert knowledge available 
• formulating the statistical model 
• designing effective and efficient numerical encoding 
• managing uncertainty 
• designing a practical elicitation protocol 
These 6 steps are further divided into 18 sub-steps described by Choy et al. and, as 
with Cook and Goossens (2000), the majority could apply to the drug development 
domain. 
3.4 Avoidance of Bias 
A key early description of the types of bias that can be introduced during elicitation is 
available in Tversky and Kahneman (1974) in which they describe the three types as: 
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• representativeness: when people are asked whether an event belongs to a 
particular class they may ignore an important conditioning, for example, 
occurrence of the event in the population should be taken into account but 
often is ignored. 
• availability: when people are asked to assess frequency or plausibility of an 
event there can be a tendency to produce estimates according to how easy they 
come to mind e.g. more recent or high profile occurrences. 
• anchoring: when a value is made available to experts before asking for their 
beliefs the experts may propose values unreasonably close to this “anchor” 
value. 
This work was extended by other authors and is summarised by Kadane and Wolfson 
(1998) to include hindsight bias (where elicited priors have already been updated by 
data) and overconfidence (where there is difficulty assessing the tails of a 
distribution). Through empirical research in which people were asked to specify 
intervals as responses to general knowledge questions (e.g. population of Spain), 
Teigen and Jorgensen (2005) concluded that interval width and degree of confidence 
have different determinants, and cannot be regarded as equivalent ways of expressing 
uncertainty. The authors observed that feedback to the individuals could be used to 
improve performance in future. In their meta-analysis of 3 studies involving 79 
experts in the fields of epidemiology, public health and ecology, Speirs-Bridge et al. 
(2010) quantify the extent of over-confidence as 11.9% as determined by estimating 
the average difference between nominal versus actual width of the prediction intervals 
provided by experts during elicitation sessions. As well as the usual elicitation of 
lowest, highest and best estimate, Speirs-Bridge et al. introduce a fourth element 
during elicitation, namely for the expert to specify their level of confidence in the 
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interval they created. The same authors also cite other work from the general 
population where 90% intervals may contain the correct answer only 50% of the time. 
Further empirical evidence is required before the Speirs-Bridge et al. approach can be 
shown to reduce overconfident estimation in clinical trials. 
A review of both the psychology and statistical literature (Kynn, 2008) demonstrated 
that “in applied contexts we should be equally concerned with not only what we ask 
experts to assess, but how we ask it” (original author’s emphasis). Kynn was heavily 
critical of the statistical literature’s reliance on the earlier 1974 work of Tversky and 
Kahneman and failure to use emerging findings from the psychology/cognitive 
models that emerged since 1974.  
Through use of hierarchical modelling, Kadane & Winkler (1988) offer a mathematical 
approach to resolving the issue of (inadvertent) bias by eliciting the extent of the 
“stakes of the expert” though recognise that this may be difficult in practice. 
The question of how many experts to involve has been covered on both a 
mathematical and empirical basis. Johnson et al. (2001) show that the number of 
required experts is approximately inversely proportional to their independence, while 
the empirical evidence reveals a wide range in the number of experts employed; the 
example of five experts from Chaloner (1993) serves as a practical guide that strikes 
the balance between ease of conduct with a single expert to the postal methods used 
for elicitation of 49 experts in Chaloner and Rhame (2001). 
Johnson et al. (2010) performed a systematic review of 33 observational studies and 
RCTs in which they assessed elicitation methods from a measurement science 
perspective in order to evaluate the characteristics of a range of elicitation methods. In 
contrast to  Kadane and Wolfson (1998) who had proposed that such characteristics be 
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assessed using the three terms reliability, coherence and calibration, Johnson et al. 
(2010) described the currently accepted measurement science criteria (Kottner et al., 
2011) of validity, reliability, responsiveness and feasibility.  
• validity: which is further divided into: 
o face validity: measures what it purports to measure  
o content validity: evaluates if the elicitation captures all relevant aspects 
of the belief 
o criterion validity: correlation with the gold standard 
o construct validity: relationship between methods (either convergent or 
divergent) 
• reliability: intra- and inter-rater reproducibility 
• responsiveness: ability to detect a meaningful change in belief over time 
• feasibility: the ease of use of the technique 
These criteria were used to assess the 33 trials on a retrospective basis, in other 
words, the purpose of the original trials had not been to study the measurement 
science characteristics of the elicitation methods but rather that the 33 articles used 
elicitation as part of the design of the trial in question. Johnson et al. (2010) 
concluded that from a measurement science perspective they could not recommend a 
“best” elicitation method due to the lack of empirical data. 
Assuming one has been able to select appropriate experts it is important to be able to 
capture their beliefs in a form that will eventually be suitable for use in a statistical 
analysis. This chapter continues with an overview of the available methods. 
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3.5 Instruments for Conducting Elicitation 
When eliciting beliefs for responses to treatment (as with the motivating case study), 
an expert may have some uncertainty about the exact value so a probability 
distribution can be elicited to reflect the uncertainty (O’Hagan et al., 2006, pp.100–
104). A variety of methods have been developed and largely fall into two categories, 
namely, (i) providing probabilities given some value of the endpoint or (ii) by 
specifying some quantiles having been given some probabilities. For example, if the 
expert is given the median value plus the lower and upper quartile then a probability 
distribution can be fitted to the expert’s values (Winkler, 1967; Chaloner et al., 1993). 
Gore (1987) introduced an alternative method called Roulette method (also known as 
Chips in Bins method), which requires experts to place n counters (or chips) into m 
equally spaced bins covering the allowable range of values. The Roulette method was 
validated and implemented in an inflammatory disease setting (Johnson, Tomlinson, 
Hawker, Granton, Grosbein, et al., 2010; Johnson et al., 2011). 
It is worth noting the increasing use of technology supporting the process of 
elicitation, for example, by Choy et al. (2009) who developed the software application 
Elicitor as a chargeable add-on for WinBUGS (Lunn et al., 2000). Another general 
purpose framework that incorporates (open-source) software is SHELF as developed by 
Oakley and O’Hagan (2010) and later extended to be available on the internet as the 
web application MATCH (Morris et al., 2014). 
3.6 Formation of Prior Probability Distributions  
The literature reveals two general approaches to forming prior probability distributions 
using elicited opinion, generally referred to as mathematical and group aggregation. 
Whichever approach is selected it should be noted that multiple prior distributions 
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could be formed in order to assess the characteristics of those priors. Ultimately, when 
developing drugs, pre-specifying which prior has been selected for combining with 
trial data will increase the integrity of the study. For example, Spiegelhalter et al. 
(1994) use the terms sceptical and enthusiastic priors to advocate formation of priors 
at either end of plausible beliefs so that those interpreting the trial results would have 
a vehicle against which to judge their own priors (note that the authors acknowledged 
that Cornfield (1966) introduced the term “sceptical”). 
3.6.1 Mathematical Aggregation 
In this section it is assumed that multiple experts have already provided their opinion 
and the task is to create an informative prior distribution. 
The original exposition of mathematical pooling was by Stone (1961) and since then 
various methods have been proposed for how to convert expert beliefs into an 
informative prior distribution using algorithmic approaches. As summarised by 
Garthwaite et al. (2005), the methods tend to fall into two main types: the linear 
opinion pool and the logarithmic opinion pool. The linear opinion pool can be stated 
as follows: suppose the elicited probability distributions of the k experts are 
represented as 𝑝𝑘(𝜃), the pooled probability density function, f(θ), is formed by 
selecting weights 𝜆1,…, 𝜆𝑘(with ∑ 𝜆𝑖𝑘𝑖=1 = 1and 𝜆𝑖 ≥0) and calculating: 
 f(θ) = ∑ 𝜆𝑖𝑘𝑖=1 𝑝𝑖(𝜃) ( 3.1 ) 
Selecting weights 𝜆𝑖=1𝑘 for all k implies equally weighted opinions but other weights are 
possible in order to give more weight to some experts than others. The logarithmic 
opinion pool is an alternative weighting scheme based on taking the geometric (rather 
than arithmetic) average of the weights, i.e. 
- 61 - 
 
 f(θ) = c ∏ 𝑝𝑖𝑘𝑖=1 (𝜃)𝜆𝑖  ( 3.2 ) 
where c is a normalising constant that ensures f(θ) integrates to 1. As with the linear 
opinion pool, equal weights 𝜆𝑖 can be assigned to give equal weights to each experts 
probability distribution. Due to two mutually exclusive properties of these two pooling 
methods (which are described below), the practising statistician must make a key 
decision in selecting how to combine opinions from multiple experts.  
The two mutually exclusive properties were summarised by Genest (1984) by referring 
to the work of Madansky (1964) who showed that the linear opinion pool is not 
externally Bayesian i.e. it fails to yield the same result when the pooling is performed 
before or after updating the expert beliefs in the light of new information; as such the 
experts cannot be perceived as acting as a single Bayesian. Genest (1984) also 
describes the result of McConway (1981) who showed that the linear opinion pool does 
preserve another important property of pooling, namely that of marginalisation i.e. 
that independence of original events is preserved when pooled. McConway also 
demonstrated that if instead of using the linear pooling, logarithmic pooling is used 
then such a combination is externally Bayesian. In short, it is not possible to have a 
mathematical pooling that is both externally Bayesian and satisfies the marginalisation 
criterion. 
For a clinical trial example of the linear pooling see the description of the CHART trial 
pooling in Spiegelhalter et al. (1994). Chaloner and Rhame (2001) acknowledge that 
mathematical aggregation in their trial of 58 experts treated all experts equally despite 
substantial (known) differences in expertise. O’Hagan et al. (2006, p.184) report that 
the logarithmic opinion pool has been largely ignored in the literature due to its 
unrealistically strong aggregated beliefs. For the reader interested in the graphical 
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interpretation of the two forms of mathematical pooling O’Hagan et al. (2006, p.183) 
provide helpful schematic representations. 
A more recent novel approach by Huson and Kinnersley (2009) employed a weighting 
scheme based on bootstrapping the expert data and revealed results consistent with 
the other available methods. 
3.6.2 Behavioural Aggregation 
Behavioural aggregation can be considered as combining the beliefs of multiple 
experts in a consensus (or other) manner. O’Hagan et al. (2006, pp.186–192) provided 
an extensive review and covered some of the more long-standing methods such as 
Delphi (in which experts are not permitted to share views) and related variants where 
limited feedback is permitted. The work of Reagan-Cirincione (1994) is reported by 
O’Hagan et al. (2006, p.190) and showed that small group elicitations can outperform 
their best individual member if the elicitation combined three features: 
• Impartial facilitation that is responsive to the potential for biases in the group. 
• A well-designed protocol that involved careful structuring and decomposition 
of the elicitation task. 
• Continuous feedback (perhaps also using computer technology) of the 
implication of the experts’ judgements. 
The increasing availability of electronic technologies for participative elicitation, 
coupled with the ever-increasing speed of sharing emerging scientific evidence makes 
large-scale group elicitation and aggregation viable. In turn, this should ensure that 
the breadth of aleatory and epistemic uncertainty associated with drug development 
can be incorporated into clinical trial designs in a transparent manner. 
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Since the EWOC design is based upon a Bayesian 2-parameter logistic model, the 
chapter continues with an overview of the elicitation literature for generalised linear 
models. 
3.7 Elicitation for Generalised Linear Models 
Building on the earlier work of Kadane et al. (1980) in linear regression in which expert 
beliefs are elicited on observables rather than regression coefficients, Bedrick et al. 
(1996) provided a detailed account of a method to collect expert beliefs for 
generalised linear models. Experts are asked to provide their beliefs in terms of mean 
responses for fixed covariates and then a prior is induced on the regression 
coefficients. By taking values of the covariates at widely spaced intervals, Bedrick et al. 
(1996) assumed independence of the resulting priors. 
For example, assuming the logistic model of ( 2.7 ) and suppose covariate values of 
𝛽1= 55 and 𝛽1= 75 and common intercept 𝛽0= 1 are selected, then in matrix notation 
this is written as: 
logit �𝑎55𝑎75� = �
1 551 75� �𝛽0𝛽1� 
Hence, solving for 𝛽0 and 𝛽1 to obtain: 
𝛽0 =�
75
20
  logit(𝑝55)�  + �−55   20   logit(𝑝75)� 
and 
 𝛽1 =�
−1  20   logit(𝑝55)�  + � 120   logit(𝑝75)� 
Thus, when using a Bayesian framework with Markov chain Monte Carlo (MCMC), one 
need only specify a prior distribution for the probabilities 𝑝55 and  𝑝75 and then use 
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MCMC to induce the priors for 𝛽0 and 𝛽1. Due to its highly flexible 2-parameter shape, 
the Beta distribution has frequently been used as a suitable choice for priors of 
probabilities (Babb et al., 1998; Chaloner & Duncan, 1983; Gajewski & Mayo, 2006; 
Tighiouart et al., 2005). However, as noted by McInturff et al. (2004) and further 
described by Seaman et al. (2012) extreme care needs to be taken when inducing such 
priors since a non-informative prior under one parameterisation may be informative 
on another parameterisation. This motivates the study of how to evaluate the impact 
of the choice of prior on study results and conclusions. 
Morita et al. (2008) developed a measure of the Effective Sample Size (ESS) for a given 
parametric prior and through a later description of six examples Morita et al. (2010) 
showed how ESS could be calculated in practice. Their measure permits comparison of 
the number of hypothetical patients that are represented by the prior in comparison to 
the number in the planned study; should the ratio be too high a revision of the prior 
may be performed before the study commences. 
3.8 Applications in Elicitation 
The clinical trial literature on elicitation of expert opinion has developed in parallel 
with the literature from other fields, for example bacteria transmission, ecology, 
psychology, finance, metrology, space and nuclear industries (Arkes et al., 1997; Choy 
et al., 2009; Babuscia & Cheung, 2014; Denham & Mengersen, 2007; Drescher et al., 
2013; Kascha & Ravazzolo, 2010; Hora & Winterfeldt, 1997; Murray et al., 2009; 
O’Hagan, 2014; O’Leary et al., 2009; Tableau et al., 2013; Truong & Heuvelink, 2013; 
Van der Fels-Klerx et al., 2005). 
Where the elicitation literature does refer to approaches that could be used across 
application areas, the empirical evidence from clinical trial design and analysis is 
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sparse. Notable exceptions include the bioassay example to estimate LD50 (Racine et 
al., 1986), toxoplasmosis prophylaxis collective trial (Chaloner et al., 1993), the 
CHART trials (Parmar et al., 1994), the subset effects in the CHARM trials (White et al., 
2005), the hepatocellular carcinoma trial described by Tan et al. (2003) and the breast 
cancer trial by Morita et al. (2004). A list of 40 trials employing Bayesian methodology 
is provided by Sung et al. (2005) in their review of publication standards; it includes 
use of both non-informative and informative priors. 
Morita and Sakamoto (2006) described the design (but not results) of a gastric cancer 
trial where informative (Dirichlet) priors were constructed in a two-step process 
whereby 67 clinicians who worked on earlier trials with the drug  provided their 
individual opinions and then four other gastric cancer experts were consulted to 
assess the adequacy of the constructed prior. The authors also described the steps 
they took to assess the (frequentist) operating characteristics of the resulting design. 
In a more recent similarly large medical example, Diamond et al. (2014) used the 
Roulette (i.e. Chips and Bins) method to conduct the elicitation session with 60 
clinicians for the beliefs of the proportion of patients who would exhibit viral infection. 
Soares et al. (2011) provide a comprehensive elicitation exercise in a health economics 
setting. 
During my review of the literature (including the systematic search described below for 
the specific case of long memory designs), I encountered just 22 clinical trial examples 
in which elicitation had been described as a prospective element of the trial design. 
These are summarised in Table 3 
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Table 3 Recently Published Studies Using Prospective Expert Elicitation 
Author (Year) Study Details & Sponsor Number 
Experts 
Elicitation 
Technique 
Aggregation Method to 
Form Priors 
Freedman and 
Spiegelhalter 
(1983) 
Design of trial in bladder 
cancer 
(NP) 
18 Interviews 
 
B 
Spiegelhalter 
and Freedman 
(1988) 
Design of trial in  
osteosarcoma 
(NP) 
7 Interviews 
 
B 
Errington et al. 
(1991) 
Neutron therapy for pelvic 
cancer 
(NP) 
10 Interviews 
 
M and B 
Chaloner et al. 
(1993) & 
Carlin et al. 
(1993) 
Design & monitoring of 
trial in HIV 
(NP) 
5 Interactive 
graphics and 
questionnaire 
M 
Parmar et al. 
(1994) 
Radiotherapy in head & 
neck cancer 
(NP) 
9 Postal 
questionnaire 
M 
Blanck et al. 
(1996) 
Design of trial in 
hypertension 
(NP) 
5 Telephone 
interviews 
NS 
Fayers et al. 
(1997) 
Monitoring of a trial in 
oesophageal cancer 
(NP) 
NS Telephone 
interviews 
NS 
Gore (1999) Planning paediatric trial 
(NP) 
15 Delphi Statistician decided 
using adjusted expert 
beliefs 
Fayers et al. 
(2000) 
Planning of a trial in 
gastric cancer 
(NP) 
26 Interviews B 
Chaloner and 
Rhame (2001) 
Design and monitoring of 
a trial in opportunistic 
infection 
(NP) 
58 9 by telephone, 
49 by postal 
questionnaire 
M 
Tan et al. 
(2003) 
Design of Phase 3 
hepatocellular carcinoma 
trial 
(NP) 
12 Questionnaire M 
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Author (Year) Study Details & Sponsor Number 
Experts 
Elicitation 
Technique 
Aggregation Method to 
Form Priors 
White et al. 
(2005) 
Investigation of subset 
effects in CHARM trials 
(P) 
4 Questionnaire M 
Morita and 
Sakamoto 
(2006) 
Design of a gastric cancer 
trial 
(NP) 
67 then 4 67 for Delphi 
then 4 for 
consensus 
M and B 
Wu et al. 
(2008) 
Phase 1 study in CLL and 
NHL 
(NP) 
1 Interview M 
Huson and 
Kinnersley 
(2009) 
Phase 1 dose-response 
safety 
(P) 
5 Interviews using 
graphical and 
tabular forms 
M 
Bond & White 
(2010) 
Assessment of non-trial 
treatments in a paediatric 
HIV trial 
(NP & P) 
5 Questionnaire M 
Johnson et al. 
(2011) 
Design of a trial in SSc-
PAH and IPAH 
(NP) 
45 Interview M (for trial justification 
and planning 
purposes) 
Morita et al. 
(2011) 
Design of Phase 1 study in 
new population 
(NP) 
NS NS NS 
Zohar et al. 
(2011) 
Phase 1 design 
simulations of DNA 
vaccine 
(NP) 
13 Questionnaire M (for simulation 
purposes) 
Johnson et al. 
(2012) 
Retrospective review of 
patient charts (NP) 
10% of 
N=45 from 
Johnson et 
al. so 
unclear if 4 
or 5 
Interview M 
Diamond et al. 
(2014) 
Planning a Bayesian 
designed trial in liver 
disease (NP) 
60 Interview M (re-sampling from 
each expert’s 
distribution) 
Hampson et 
al. (2014) 
Planning a Bayesian 
designed trial in 
polyarteritis nodosa (NP) 
15 Interviews using 
questionnaire 
B 
P=Pharma; NP=Non-Pharma; NS=Not Specified; M=Mathematical; B=Behavioural; 
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For the specific case of long memory trials, published applications of elicitation in the 
clinical literature are rare. A systematic search in SCOPUS with the following search 
criteria revealed no prospectively designed and analysed clinical trials (search 
submitted 15th February 2015): 
• TITLE-ABS-KEY( (crm) OR (ewoc) OR (mcrm) or (logistic dose response) ) 
 AND ((elicit) OR (elicitation)) AND NOT ( (customer relationship 
 management) or (crew resource management) or (CRM-positive) or 
 (confocal Raman microscopy) or (cross-reacting material) )  
AND PUBYEAR > 1990 
AND (( DOCTYPE= "AR" ) OR ( DOCTYPE= "IP" ) OR ( DOCTYPE, "CP" ) ))  
AND ( EXCLUDE(SUBJAREA,"PHYS" ) OR EXCLUDE(SUBJAREA,"MATH" ) OR   
 EXCLUDE(SUBJAREA,"ENGI" ) ) 
AND (LANGUAGE="English" ) 
There may, of course, have been trials conducted using a long memory design in 
which elicitation had been performed but either these have not been published or they 
would only be revealed using a different search criteria. However, such trials are 
unlikely to have wide readership and thus limited scope for informing researchers 
interested in designing and conducting more efficient long memory trials. 
3.9 Conclusions 
Though the 22 published articles in Table 3 describe how elicitation was performed in 
their specific settings (i.e. with endpoints and elicitation instruments applicable to that 
disease), there is a lack of clinical trial literature on the general issues that apply 
across a range of clinical trial designs. Hence, a future researcher planning to design a 
trial (long-memory or otherwise) would need to synthesise the information across 
these case studies and the general elicitation literature.  
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For the specific case of (early phase) long memory trials, published applications of 
elicitation in the clinical literature are rare and so additional empirical evidence is 
needed to assess the feasibility and operating characteristics of the available elicitation 
methods in the clinical trial domain. As such, Chapters 4 and 5 describe two elicitation 
sessions, one conducted in a pharmaceutical company and one in an academic setting, 
respectively. Generalisations and recommendations for planning and conduct of future 
clinical trial elicitations are also provided in Chapter 4. 
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4. Elicitation Case Study in a Pharmaceutical 
Company 
Having motivated the need for more empirical evidence of the feasibility of elicitation 
in the clinical trial domain, Chapters 4 and 5 provide two case studies of elicitation of 
expert beliefs. Much of the writing style in this chapter is in the first person so that 
specific, novel contributions are clear. For work conducted in collaboration with 
others, the pronoun “we” is used; otherwise the third person is used to refer to work 
performed without specific attribution. 
4.1 Outline of this Chapter 
In late 2010 and throughout 2011, I led a group of five statisticians who prepared and 
delivered a series of seminars in Bayesian methods to statisticians working in the UK 
office of Roche Products Ltd. All statisticians attending the seminars had previous 
experience of statistical methods for drug development (which is predominantly 
performed in a frequentist manner) as well as a theoretical understanding of Bayesian 
methods from undergraduate and postgraduate studies. With the increasing demand 
for Bayesian approaches in drug development the series of seminars aimed to remind 
the audience of some aspects of the theory but to supplement with hands-on practical 
sessions to ensure the concepts could be implemented with confidence after the 
seminars. 
The fourth seminar in the series was on the topic of elicitation of expert opinion in 
order to form subjective priors. This case study describes the preparation and conduct 
of that session for the purpose of identifying the key steps in the process of eliciting 
expert opinion for the design of a hypothetical clinical trial. 
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This case study continues by describing the purpose of the seminar and the chosen 
approach. Description of the challenges and the solutions are then provided before 
presentation of conclusions. This work also appears in an extended form in Kinnersley 
and Day (2013) (see also reprint in Appendix B) and for simplicity is referred to as the 
Kinnersley-Day case study. 
4.2 Planning the Elicitation Session 
Feedback from previous seminars in the series indicated that the audience benefitted 
more when the format included a mix of lecture and practical elements. As such, we 
planned the session to include presentations on: 
• the relevant literature on the use of informative priors (i.e. use of historical 
data and/or expert opinion) 
• published methods to elicit expert opinion, together with any open problems 
• description of at least one case study from the clinical trial literature 
After the presentations, a mock elicitation session would be conducted that aimed to: 
• show a clinical trial design scenario that could benefit from use of a subjective 
prior 
• identify the appropriate questions to ask the experts during the elicitation 
session 
• highlight the issues with identifying the attributes of an expert who would 
participate in the elicitation session 
• show how to conduct an elicitation session for a specific clinical trial design 
objective 
• show how to convert the elicited beliefs into a (subjective) prior 
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• provide a forum to discuss how an expert makes choices about probability 
distributions 
• provide a forum to discuss issues raised during the session to aid future 
elicitation sessions. 
Performing an elicitation session for a real trial that was undergoing protocol 
development was considered but ruled-out for a number of reasons, most notably that 
the required project team members (and also experts) were not all available in the 
timeframe required to plan the seminar. The consequences of this decision are 
described later. However, it was felt that very similar issues could be highlighted by 
using a hypothetical trial for the elicitation session. Furthermore, we included a plan to 
involve the audience in discussion after the mock elicitation which would highlight the 
issues they perceived would occur when working on a real trial. 
Once the decision was made to create a realistic, but hypothetical, trial scenario it 
became clear that we would need to choose a therapeutic area known to the majority 
of the audience of statisticians. This is not always practical in a global pharmaceutical 
company in which statisticians at one site may work on a variety of different 
therapeutic areas, however, in our case, inflammatory diseases was chosen since a 
number of statisticians and potential experts were available at the site.  
Over the following 3 weeks, the organising team together with a physician outlined a 
hypothetical trial in ankylosing spondylitis (AS) for which it would be hypothesised that 
an existing medicine for inflammatory diseases would be tested in this new disease 
setting of AS. Decisions of which endpoint to elicit were made (i.e. ASAS20, (Anderson 
et al., 2001)). The ASAS scale measures patient improvement and the ASAS20 endpoint 
is defined as a 20% improvement in ASAS score from baseline as well as at least 10 
units improvement on a 100mm visual analogue scale for at least three of the four 
- 73 - 
 
ASAS domains, with no worsening in the remaining scale. ASAS20 was assumed to 
follow a Binomial distribution (n, p) where n corresponds to the sample size and p is 
the probability of achieving ASAS20. The objective was, therefore, to form a prior 
distribution for p using expert opinion as input. 
Typically, one aspect of the planning of a trial involves determining the sample size 
accounting for expected variability of the endpoints, however, for the purposes of the 
hypothetical trial there would be insufficient time during the session to iteratively 
determine the operating characteristics of a chosen prior for various sample sizes so 
the organising team fixed the size of the two treatment groups to be 20 patients each 
(Experimental and Control group). In setting this sample size, the organising team 
discussed if the experts should be informed of this fixing before providing their beliefs 
on the prior distribution of p. It was considered useful to do so and using the work of 
Morita et al. (2008), we would be able to feed back to the experts the Effective Sample 
Size (ESS) implied by the prior that they had formed. 
To ensure the audience were familiar with the relevant terminology, it was felt useful 
to inform them about the two types of uncertainty as described by Hora (1996). These 
were aleatory uncertainty (i.e. induced by randomness) and epistemic uncertainty (i.e. 
due to lack of knowledge). Thus, in our case study, the response rate p represents the 
epistemic uncertainty (i.e. the true value of the response rate). Had we been 
considering a very large trial (e.g. 10,000 patients) then elicitation would be essentially 
of the epistemic uncertainty but for trials of much smaller sample sizes both aleatory 
and epistemic uncertainty are present. 
Other features of the hypothetical molecule and trial design included: 
• the mechanism of action 
• current stage of drug development 
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• the specific trial objective for the planned trial 
• comparison(s) of interest to enable evaluation of the trial objective 
• likely size of such a trial (to mimic time and budget constraints) 
• any relevant supporting (medical) publications for the experts to read. 
During the practical element of the seminar, the team of experts would be asked to 
plan a future Phase 2 study with study size “as small as possible” to establish the 
“Likely effects of the drug”. To ensure a manageable set of literature from which the 
experts would draw knowledge, five articles relating to ankylosing spondylitis were 
distributed to six scientists with expertise in clinical science, drug safety (two people), 
biomarkers, clinical pharmacology and medical statistics. 
There was a need for the organising team to determine which of the available methods 
from the literature would be used to elicit expert beliefs for proportions and since the 
Roulette method (also known as Chips in Bins method, Gore (1987)) had been 
validated and implemented by Johnson et al. (2010; 2011) in another inflammatory 
disease (scleroderma), I recommended that it be selected for the seminar. 
To document the most important features of the session before conducting it, the 
SHEfield ELicitation Framework (SHELF) version 2 (Oakley & O’Hagan, 2010) was 
selected due to my previous familiarity with the framework and because it included an 
open source R package (R Development Core Team, 2014) to display the resulting 
prior probability distribution(s). A full description of the functionality of the R package 
is beyond the scope of this thesis but a brief introduction is provided here (full 
instructions are available at Oakley & O’Hagan (2010)). 
The SHELF R package version 2 supports four different methods to elicit probability 
distributions: 
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• Probability (“P”) method, the facilitator asks the experts for some specified 
probabilities 
• Quartile (“Q”) method, the facilitator asks the experts for their median and 
upper and lower quartiles 
• Roulette (“R”) method, (also known as Chips-in-Bins) where the facilitator asks 
the experts to indicate their probabilities for ten ranges of values, known as 
bins, by placing chips in the bins 
• Tertile (“T”) method, the facilitator asks the experts for their median and upper 
and lower tertiles. 
Accompanying documents provide templates that describe the key aspects of the four 
types of elicitation. For example, the template for the Roulette method is a single page 
containing 16 fields, with titles such as “Definition”, “Evidence”, “Plausible Range”. In 
addition, a version of the template is provided that contains notes about the type of 
information that the Elicitation Facilitator should expect to complete before and during 
the elicitation session. Column 1 in Table 5 is an example of what is provided in the 
blank template for the Roulette (Chips-in-Bins) method. 
The R code provided in SHELF is a self-contained package that is loaded in the 
conventional manner (e.g. from the R menu item “File…Source R code…”) which then 
provides access to the four R functions corresponding to each of the four methods. For 
example, roulette.single()  will invoke the windows associated with placing the 
chips in the 10 bins, as shown in Figure 5. 
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Figure 5 Initial View of Roulette Method in SHELF Software 
Once all chips have been placed in the bins, the user can tick the field “show fit” to 
overlay one of the six available distributions (see Figure 5). The user can also rely on 
the R package to overlay the distribution of “best fit”, where “best” is the distribution 
with lowest least squares value after fitting all of the six available distributions. 
The final decision to be made before the rehearsal concerned the room configuration 
for the experts. The SHELF framework permits each expert to provide their own 
assessment of the probability distribution before going on to form the distribution as 
a group of experts. Hence, it was decided to use the individual elicitation step to reveal 
the thought process of each expert to the audience by assigning a single expert to a 
table in the room and to have audience members sit alongside the expert. During the 
individual elicitation task, the audience would be encouraged to ask the expert to 
justify their choice at each step. For example, to prompt the expert for what evidence 
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they used in order to form their opinion about the shape and location of the 
distribution. 
In summary, the following materials were created for a rehearsal performed two 
working days before the planned seminar: 
• Description of the elicitation protocol to be used by the facilitators during the 
elicitation session using the SHELF framework. 
• (Card) sheets to be used by the experts to place stickers representing their 
individual opinion of the probability distribution for p. 
• Code to run the R package accompanying SHELF to enable visualisation of the 
distribution(s) elicited during the group expert elicitation step. 
I was responsible for producing all elements of the elicitation protocol whereas other 
team members created the sheets for the experts and the R code. The rehearsal 
revealed the issues described in Table 4: 
Table 4 Issues Identified During Rehearsal of Training in Expert Elicitation 
Learning Solution Reason(s) 
• Using five articles as the 
reference material 
introduced substantial 
room for debate that 
caused longer duration to 
conduct elicitation 
• Use only two articles 
as the standard 
reference material in 
the seminar 
• Reducing to 2 articles 
permitted reasonable 
debate within allotted 
timescale without losing 
significant impact on 
seminar objectives. Note 
that for a real trial, all 
relevant articles should be 
included. 
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Learning Solution Reason(s) 
• Restricting range of 
allowable probabilities 
(i.e. narrower than range 
0 to 1) would not 
improve elicitation 
• Keep range 0 to 1 • In some situations (e.g. 
very rare events) restricting 
to a narrow range such as 
0 to 0.01 permits bin 
widths that are wide 
enough to differentiate 
expert opinion, however, 
for the ASAS20 endpoint, 
experts believed restriction 
of range could adversely 
affect their choices. 
• Number of bins for 
experts to place chips 
was felt to be too low by 
some experts and 
therefore not accurately 
reflect their beliefs 
• Keep at 10 • R package accompanying 
SHELF version 2 does not 
support changing the 
number of bins. 
• Elicitation of beliefs 
based on likely response 
rates observed in a small 
trial is different from 
elicitation of beliefs for 
true (but unknown) 
response rate in “infinite” 
population 
• Retain questioning 
focussing on smaller 
trial size but ask 
audience at each table 
to pose questions to 
the expert at their 
table about likely 
effects in “infinite” 
population 
• Theoretically desirable to 
ask for epistemic 
uncertainty (i.e. infinite 
population) but wanted to 
be able to feedback 
Equivalent Sample Size 
estimates (ESS) to experts 
following elicitation in 
real-time. 
• Clinical trial group size of 
20 patients was too low 
to permit experts to 
differentiate between 1 
and 2 responders 
• Amend target trial size 
to 60 patients with 2:1 
randomisation 
(Experimental:Control) 
• Greater ability to 
differentiate beliefs for 40 
patients on Experimental 
when using 30 chips. 
 
Following the rehearsal, amendments to address issues identified in Table 4 were 
made by me to the elicitation protocol and the resulting final document appears in 
Table 5. In brief, the objective of the session was to elicit the proportion of responders 
in the Experimental group in a planned trial of 60 ankylosing spondylitis patients 
randomized in a 2:1 ratio (Experimental: Control). 
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Table 5 Elicitation Protocol for Kinnersley Day Case Study 
Elicitation title Elicitation of a Proportion for the Experimental group response in a 
planned trial of Ankylosing Spondylitis patients randomized to placebo or 
Experimental  
Session 1 of 1 
Date 6 Sep 2011 
Quantity Proportion of patients who display at least 20% improvement in the 
ASsessment in AS International Working Group criteria (ASAS20) at 
Week 14.  
Start time 13:00 
 
Definition ASAS20 is defined as per Anderson et al. (2001) and in this Phase 2 
study a patient is considered as providing valid results if all component 
measures for ASAS are recorded at both baseline and Week 14. 
The denominator for the proportion is the set of patients: 
• meeting the protocol-defined definition of Ankylosing 
Spondylitis 
• DMARD-Inadequate Responder 
• with BASDAI (Disease Activity) score ≥ 4 
• CRP level >1.5 mg/dl and mean age 40y (range 30-50) 
• and who are randomised to the Experimental treatment arm 
(regardless of what treatment they actually received) 
The numerator for the proportion is the subset of patients (from the 
denominator) who: 
• have a CRF field completed showing evidence that they 
achieved an ASAS20 at Week 14 
Evidence • Anderson J.J., Baron G., van der Heijde D., Felson D.T., Dougados 
M. Ankylosing Spondylitis Assessment Group preliminary definition 
of short-term improvement in ankylosing spondylitis. Arthritis & 
Rheumatism 2001; 44: 1876–86. 
• Inman, R.D., Davis, J.C., Heijde, D.V.D., Diekman, L., Sieper, J., 
Kim, S.I., Mack, M., Han, J., Visvanathan, S., Xu, Z., Hsu, B., 
Beutler, A. and Braun, J. (2008), Efficacy and safety of golimumab 
in patients with ankylosing spondylitis: Results of a randomized, 
double-blind, placebo-controlled, phase III trial. Arthritis & 
Rheumatism; 58: 3402–3412 
Plausible range The Facilitator will ask the experts (as a collective) to consider a 
planned Phase 2 trial that should enrol as few patients as possible 
(target 60 total, with 40 on Experimental) and to identify range of values 
(between 0 and 1) in which it is extremely unlikely that the ASAS20 will 
lie outside (i.e. for the proportion of the Experimental group achieving 
ASAS20). 
Alternative way to think about this is to specify a range (for the  
Experimental group) outside of which the trial’s credibility would be 
questioned. 
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Expecting to keep entire 0-1 range but explain to audience that other 
scenarios may benefit from reducing scale at outset e.g. rare AEs where 
1:1000 versus 1:100000 may require narrower plausible range 
Chips in bins One expert will be assigned to each table in the room, at which will also 
be seated a number of statisticians who are mainly considered observers 
(since they constitute the audience being trained) but who may also 
question/interact with the expert during the initial elicitation step (see 
later). If there are more experts than tables then groupings will be made 
such that every expert has a “group” with whom he/she may interact.  
Within the expert’s assigned table (and without consulting the other 
experts at other tables), each expert will be given 30 chips to place in 10 
bins. The bins will span the range identified in the “Plausible Range” 
question above. 
The Facilitator will use the “Definition” field above to ask the experts to 
start by considering where they think the most likely value will occur 
and place some chips in that bin. Each expert should be willing to 
explain their rationale to the other people at their table. 
Next, the expert should consider what is the lowest value (on 
Experimental) that is likely to be observed in the planned study and they 
should place 1 or more chips in that lowest bin. Again, the expert should 
be willing to explain their rationale. 
Repeat the process for the largest value that might be observed; then 
place remaining chips to form the entire distribution representing that 
expert’s beliefs. 
It is permitted for an expert to revise his/her choice throughout this 
process and the expert is encouraged to explain their reasons for 
revising to the other people at his/her table.  
Fitting For each expert’s placing of chips, the Session Facilitator will join the 
expert at their table and superimpose a single probability distribution 
that most closely captures the expert’s beliefs. Feedback to the expert is 
not expected at this stage but may be accepted if the expert is insistent 
that the fitted distribution is a poor reflection of his/her beliefs. 
NOTE: capturing the individual beliefs permits identification of the 
divergent views prior to group elicitation. 
The distributions for each expert will be brought to the front of the room 
and revealed to everybody. 
Group elicitation After discussion of the distributions of the different experts, and sharing 
of knowledge and reasoning about the differences, the facilitator will 
lead a session to create and record a group allocation of chips to bins. 
This will use an interactive software application to represent the placing 
of chips into bins: 
• start with a blank sheet with 10 bins 
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• ask for agreement on the most probable bin and allocate a chip 
there 
• then ask for agreement on the lowest bin in to which at least 1 
chip should be placed 
• repeat for highest valued bin 
• ask for agreement on where to place all remaining chips. 
Before discussion, there are two components of uncertainty in the group 
– uncertainty that each expert has and is expressed in that expert’s set of 
chips, as well as variability between the experts’ judgements. The agreed 
bin probabilities should reflect the group’s overall uncertainty that 
remains after the discussion. 
(example screenshot attached) 
 
Fitting and 
feedback 
The facilitator first fits a distribution to the group’s elicited 
probabilities. This is shown to the experts, and the fitted probabilities 
compared with elicited values. The experts are invited to consider 
whether the fit is acceptable. The facilitator then feeds back to the 
experts some implied probabilities in the fitted distribution, such as the 
10th and 90th percentiles, or the median and quartiles. The experts are 
invited to consider whether these are reasonable reflections of the 
group’s knowledge. 
Example screenshot attached but ideas in following bullets will be 
adapted in real-time during the actual elicitation 
–  shows 0.1 and 0.9 quantiles i.e. we think there’s a 10% chance that 
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the ASAS20 response is below 0.15 and a 10% chance it will be 
above 0.44 with a mean value of 0.29 
– this assumes a Beta Distribution is a good fit to the group of 
experts’ beliefs 
– Facilitator will feedback the Effective Sample Size that the Beta 
Distribution represents e.g. 4.38+10.7= “15.08 patients worth of 
data”. The Facilitator will then ask the group of experts if this ESS 
is a reasonable size given their preliminary thoughts on the 
eventual size of the planned Phase 2 study 
– The Facilitator will also convey that a Statistician can then start an 
iterative process to compute the sample size given this Prior. For 
example, by choosing trial size n such that 95% Credible Interval of 
the Posterior mean is of certain width. 
 
Chosen 
distribution 
The finally fitted distribution will be recorded here.   
Discussion The facilitator should record here any difficulties that arose during the 
elicitation of this distribution. Also the experts’ reactions to the process 
and to the finally fitted distribution.  
The elicitation record should be open about any concerns with the 
finished distribution. The SHELF protocols are designed to avoid many 
of the pitfalls of elicitation, but no process is perfect. It is important to 
be critical and realistic about the result. Nevertheless, it is important 
also to remember that, despite whatever deficiencies it might have, the 
elicited distribution is our best attempt. It has been developed using a 
robust protocol, and since expert knowledge is needed in the wider 
organisation there is no alternative! 
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4.3 Executing the Elicitation Session 
The need for flexibility over available personnel was also underlined by assignment of 
a different expert statistician at the rehearsal (Dr Jianmei Wang) compared with the 
expert statistician at the seminar (Dr Simon Day). 
4.3.1 Introducing the Elicitation Scenario 
One of the planned experts (in biomarkers) was unexpectedly unavailable on the day 
of the elicitation session but since this was a hypothetical clinical trial scenario we 
proceeded with the session. However, for a real clinical trial, the facilitator would need 
to discuss with the remaining experts if sufficient expertise was still present and 
decide whether to proceed. This aspect will be discussed in further detail later. 
At the start of the seminar I gave the short presentation that described relevant 
terminology, the available published elicitation methods (with recommendations for 
usage) and a published clinical trial case study using the article by Tan et al. (2003) in 
hepatocellular carcinoma. Next, I provided the description of the hypothetical trial 
together with the structure of the 1 hour elicitation session. The audience then 
separated into groups at five tables such that each table had an expert and four (or 
five) audience members (i.e. statisticians). I took the role of the facilitator and 
proceeded to conduct the elicitation session according to the protocol in Table 5, 
starting with individual elicitation, then group elicitation. 
4.3.2 Elicitation of a Distribution from Individual Experts 
To encourage audience participation in the part of the practical where experts were 
forming their individual probability distributions, the audience were asked to observe 
occasions when the expert was thinking in terms of both aleatory and epistemic 
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uncertainty. The audience were also asked to request the expert at their table to justify 
his/her choices for where the chips were placed. For example, upon what evidence was 
the expert basing his/her judgements. 
Using the final elicitation form (as appears in Table 5), I confirmed the pertinent details 
of the trial and the elicitation steps, namely: 
• Elicitation of a proportion for the active group response in a planned trial of 
Ankylosing Spondylitis patients randomized to Control or Experimental 
• The definition and timing of a response (i.e. ASAS20 at Week 14) 
The experts confirmed the appropriateness of the literature under consideration and 
that the range 0 to 1 was an acceptable range for the response on Experimental. Using 
the card marked with 10 equally spaced bins, the experts were asked to place their 
first sticker at the most likely value for the response proportion on Experimental 
(without conferring with other experts). This task was considered to be relatively 
straightforward by each expert and some justification for their choices were provided 
to the audience at each table e.g. citing the published articles. 
The next part of the elicitation process for describing the full shape of the response 
distribution was deemed by the experts to be somewhat harder. The experts were 
asked to place a sticker on the lowest value on Experimental that was likely to be 
observed in the planned study. Some of the experts considered the true (but unknown) 
parameter value for the response rate (i.e. purely epistemic uncertainty) while others 
incorporated the target sample size (40 patients on Experimental) into their choice (i.e. 
combination of aleatory and epistemic uncertainty). For the latter, it was thus possible 
to calculate the set of response rate values arising from such a trial (0/40, 1/40, 2/40 
etc) and then to place a sticker in the bin corresponding to their belief of the number 
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of responses out of 40. A similar step was then performed for the experts to specify 
the largest response rate value on Experimental in the planned trial. For each of the 
last two steps, I provided an additional verbal interpretation as a way for the experts to 
assess their own choice: 
• “If you saw a published trial using an IL-17 molecule for which the Week 14 
response rate was lower than your lowest value, would you question the 
conduct of such a trial?” 
I repeated the question for “highest value”. Such questioning is designed to assess if 
the expert’s specified lowest/highest value is consistent with how that expert would 
evaluate findings of competing research. At this point, the experts had used three of 
their 30 stickers so next they were asked to form their entire distribution using the 
remaining stickers. Initially, one expert struggled with forming the entire distribution 
because he believed that the shape had to be informative (e.g. some sort of regular or 
skewed bell-shaped curve) but with further input from the facilitators, that expert was 
content to form a relatively flat distribution. 
Once all of the experts had completed construction of their individual distributions 
using card & stickers those cards were collected and brought to the front of the room 
in order to share with the audience. Another team member (Lucy Rowell) highlighted 
the differences amongst the distributions from the five experts from a relatively flat 
prior for one expert to the positively skewed distributions of the remaining experts. 
Unfortunately, the cards were not retained after the practical so it is not possible to 
describe the individual results in more detail. The next stage of the practical was to 
use the group of experts to elicit a consensus distribution for the same endpoint. 
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4.3.3 Elicitation of a Distribution from a Group of Experts 
The group of five experts were brought to the front of the room and were seated in a 
panel formation. A computer projector was used to project the R application running 
the SHELF package onto a screen for the experts to visualise the construction of their 
consensus distribution. Using the final elicitation form (as appears in Table 5), I asked 
the experts to agree on the bin number in which to place the first chip before going on 
to ask them to agree in which bin the lowest (then highest) chip should be placed. As 
noted earlier, screenshots from the practical were not taken at every step but only for 
the final output of placing the chips in bins and fitted beta distribution. The final 
placing of the chips resulting from the consensus of the group appears in Figure 6 
below and shows that the experts believed that in the planned trial of 40 patients 
treated with Experimental, the ASAS20 response rate would have a relatively flat shape 
with bounds 0.1 to 0.8 and a slight positive skew. 
 
Key: y-axis represents number of chips; x-axis represents probability scale 
Figure 6 Final Distribution from Group Elicitation 
Figure 6 also highlights that, in this hypothetical scenario, a group of five experts 
could form a consensus distribution using a set of pre-agreed literature. As with the 
first part of the practical where individual experts formed distributions, the easiest 
part of the task in a group situation was to place the first chip (for the most likely 
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value) and the most difficult aspect for the group was to agree on the tails of the 
distribution. 
To assess the representativeness of the distribution formed from chips, another team 
member (Dr Guiyuan Lei) used the SHELF package during the practical to fit a beta 
distribution to the chips. The fitted distribution enabled a smooth shape to be 
visualised by the experts as well as permitting me (as the Lead Facilitator) to provide 
interactive feedback to the experts of various features of the fitted curve. For example, 
confirmation that the proposed beta distribution met the experts’ expectations for: 
• quantiles of the curve (e.g. 10% chance that the ASAS20 on Experimental would 
lie below a particular value) 
• The Effective Sample Size (ESS) induced by the curve was consistent with the 
experts view of the value of the historical information (Morita et al., 2008) 
Though the fitted distributions before the final consensus have not been retained, 
Figure 7 below shows the screenshot of the final fitted distribution from the R package 
corresponding to the chips in bins screenshot in Figure 6 and includes the resulting 
feedback mechanisms which are discussed below. 
 
 
Key: y-axis represents number of chips; x-axis represents probability scale 
Figure 7 Final Fitted Beta Distribution from Group Elicitation 
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The final outcome of the expert group discussion for the planned trial in 40 patients 
treated with Experimental was that a Beta distribution with parameters (3.23, 4.71) 
represented their consensus on the likely effects of Experimental. This consensus was 
reached by checking that the experts confirmed their acceptance of the following five 
features that derived from specific characteristics of a 2-parameter beta distribution: 
• 10% chance that the ASAS20 at Week 14 on Experimental would lie at or below 
0.19 (i.e. 19% response rate) 
• 10% chance that the ASAS20 at Week 14 on Experimental would lie at or above 
0.63 
• The expected value of the ASAS20 at Week 14 for the 40 patients treated with 
Experimental would be 0.407 (i.e. 40.7% response rate) 
• The expert opinion was equivalent to 7.94 patients (i.e. the Equivalent Sample 
Size, ESS) which is found by summing the parameters of the beta distribution) 
• The expert opinion was equivalent to 3.23 of the 7.94 patients achieving 
ASAS20 at Week 14 on Experimental 
Within the remaining few minutes of the allotted hour, the experts confirmed that the 
elicitation session had been a valuable exercise in which they had learnt a great deal 
about implementing a structured approach to documenting uncertainty as part of the 
process of designing a hypothetical Phase 2 clinical trial. Furthermore, the audience of 
statisticians attending the seminar provided feedback that they found the SHELF 
framework a useful format to use for documenting the beliefs of the experts even if 
they would go on to design a clinical trial in a Frequentist manner. 
If more time had been available, a comparison of the consensus distribution with the 
five distributions formed from the first part of the practical (with card and stickers) 
would have been performed to see how changes had occurred moving from individual 
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to group elicitation. Such an exercise would also have permitted discussion by the 
experts about their reasons for making such changes. It has been hypothesised that 
such changes can be due to a variety of reasons such as the “dictator effect” or due to 
the effects of hearing alternative interpretations of the literature by fellow experts 
(O’Hagan et al., 2006, pp.187–188). 
4.4 Lessons Learned 
Implementing a structured expert elicitation session to form a prior distribution for 
use in a hypothetical clinical trial requires careful planning and making decisions on 
the format, content and conduct. Some of the specific lessons learned and 
recommendations are described in Table II of Kinnersley and Day (2013) and 
reproduced here in Table 6 (with minor changes to the formatting of the citations). 
Table 6 Recommendations for Conduct of Training in Expert Elicitation for 
Clinical Trials 
 Topic Recommendation 
1.  Format of training 
Incorporating a presentation of the elicitation literature 
followed by conducting individual elicitation (with 
observers) then by group elicitation is a feasible approach 
to enhance learning of the issues involved with the 
conduct of an elicitation session. 
2.  Content of training 
Choosing a therapeutic area known to the audience 
ensures familiarity of the clinical trial endpoints. From this 
single case study it is not possible to identify the issues 
that would arise if a real clinical trial were used for the 
training and so further empirical research is required. 
3.  Use of an elicitation protocol 
Preparing a document that includes key features of the 
elicitation process and that can be used as record of the 
elicitation session will promote transparency of 
methodology. 
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 Topic Recommendation 
4.  Question structure 
Providing prescriptive questions that closely reflect the 
intended study design and endpoints will minimise 
ambiguity of interpretation by the experts. 
5.  Specialism of experts 
At a minimum, identify those disciplines that typically 
contribute to clinical trial protocol design. This is likely to 
include (but not be limited to) one or more physicians, 
statisticians, pharmacologists, drug safety and biomarker 
experts. 
6.  Availability of experts 
Co-locating all experts facilitates preparation, training and 
discussion during the elicitation session. Implement 
contingency plans for unavailability of experts (for the 
rehearsal and the elicitation session). 
7.  Distinguishing types of uncertainty 
Ensure experts understand the concepts of aleatory and 
epistemic uncertainty. Further research is required to 
discover optimal methods for converting estimates of 
epistemic uncertainty in real-time to implications on 
planned study design. 
8.  Choice of elicitation instrument 
Use of the Roulette (chips in bins) instrument is feasible in 
the context of training; research has also shown its 
validity in other settings (Johnson, Tomlinson, Hawker, 
Granton, Grosbein, et al., 2010; Johnson et al., 2011). 
Evidence of the performance of other instruments is 
currently sparse (Johnson, Tomlinson, Hawker, Granton & 
Feldman, 2010). Assessment of the tails of the distribution 
was more difficult for our experts than elicitation of the 
most likely value. 
9.  Use of technology 
Incorporating interactive visualisations of the prior 
distribution facilitates discussion between the experts 
when constructing a consensus distribution. 
10.  Choice of prior distribution 
To promote transparency, the protocol should justify the 
pre-specified choice of prior distribution used to fit the 
expert beliefs together with a description of how that 
choice might be affected once beliefs are elicited. 
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 Topic Recommendation 
11.  Feedback mechanisms 
Providing quantiles and the equivalent sample size (ESS) 
(Morita et al., 2008) to the experts during elicitation is a 
useful means for them to assess the elicited prior. 
 
4.5 Discussion 
In order to show how a prior distribution can be constructed in a transparent manner 
using a systematic framework, this case study describes how I led a group of 
statisticians at a pharmaceutical company to enlist the help of colleagues to plan and 
execute a hands-on practical designed to construct an informative prior for a 
hypothetical clinical trial. 
The case study revealed that it was possible to: 
• Prepare and present the relevant literature as context for the practical 
• Devise a hypothetical clinical trial design scenario for which an informative 
prior would need to be constructed  
• Recruit a set of colleagues with sufficient knowledge to act as experts for a 
disease under investigation 
• Prepare materials and deliver the elicitation session on the hypothetical trial 
design using both single experts and a group of experts 
• With the aid of a computer application, form a prior probability distribution that 
could be assessed by the group of experts for representativeness during the 1 
hour practical 
The case study also revealed that further empirical research is required before routine 
use of the chips in bins methods can be relied upon to accurately represent expert 
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beliefs. For example, the elicitation questions used in this case study required the 
experts to form the prior distribution for the planned study directly (i.e. combination 
of both aleatory and epistemic uncertainty). Further empirical research is required to 
repeat the case study using questions that ask the experts to consider (only) the true 
(but unknown) parameter value (i.e. from an infinite population) and for the facilitator 
to transform the elicited quantities in real-time to the prior distribution that would be 
used for the much smaller trial being planned. 
Since the clinical trial scenario was entirely hypothetical it was not possible to ascertain 
the extent to which consensus was reached amongst the experts merely to finish the 
exercise rather than to truly devise a distribution that represented their beliefs. 
Anecdotal evidence from the five experts involved in the practical (as well as from 
those additional experts from the rehearsal) revealed that they completed the exercise 
with full intentions. In a related issue, the hypothetical nature also meant that it was 
not possible to assess if the experts behaved in the same way as if they had a vested 
interested in the outcome of the trial (something which has been commented on in the 
statistical literature, e.g see Kadane (1986)). All of the experts found it harder to 
assess the tails of the distribution than the value they felt most likely to occur, an 
observation consistent with the literature e.g. see Kadane & Wolfson (1998). 
In future research, it would be useful to study which shapes for the tails have a large 
impact on resulting inferences. In principle, when the estimation of the mean value is 
of most interest in a reasonable sized clinical trial then slight discrepancies in the tails 
of the prior may have minimal impact and therefore undue time spent fine-tuning the 
tails may be of limited practical benefit. Further research could also include 
investigation of fitted distributions other than beta though the variety of feedback 
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mechanisms of beta distributions are helpful to the experts, as is the variety of shapes 
that can result from settings of the two parameters of a beta distribution. 
A further elicitation session was planned and conducted in a different setting, namely 
an academic institution and furthermore, for a real clinical trial. That case study is 
described in Chapter 5 for the situation of forming prior distributions for the two 
parameters of a Bayesian 2-parameter logistic regression. The resulting priors could 
be used in the design and/or analysis of a study using the EWOC design, for example, 
potential use of the EWOC design with a range of priors in the kisspeptin trial that 
motivated this research.  
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5. Elicitation Case Study in an Academic Institution 
5.1 Outline of This Chapter 
Having described the results in Chapter 4 from the elicitation of priors for a binary 
endpoint in a hypothetical clinical trial it is worthwhile to consider the planning of a 
real clinical trial in which an informative prior could be formed from expert beliefs. In 
this chapter the results are presented of an elicitation session for priors of the 2 
parameters of the Bayesian logistic regression for the original motivating clinical trial 
in ovarian hyperstimulation introduced in Section 1.4. For simplicity, this is referred to 
as the kisspeptin case study. 
5.2 Planning the Elicitation for the Kisspeptin Case Study 
Planning the elicitation of the kisspeptin case study began in early 2012 and thus, 
after the Kinnersley-Day case study, so it was possible to implement some of the 
recommendations which appeared in Table II of Kinnersley and Day (2013). The format 
of those recommendations is used to describe in Table 7 how they were implemented 
for the kisspeptin elicitation. 
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Table 7 Implementation of Kinnersley and Day Recommendations in Kisspeptin 
Elicitation 
 Topic Implementation 
1 Format of training The training element consisted of me preparing and 
then delivering a presentation that lasted 20 minutes 
2 Content of training 
Presentation described the basic EWOC design, 
parameters for which expert beliefs were required and 
the format for the elicitation session 
3 Use of an elicitation protocol 
I prepared an elicitation protocol specifically for kisspeptin 
elicitation. Protocol included key features of the elicitation 
process (see Appendix C). 
4 Question structure I provided prescriptive questions that closely reflect the intended study design and endpoints (see Appendix C). 
5 Specialism of experts 
Three physicians with expertise in treatments for fertility 
and published on use of kisspeptin were identified by me 
through a literature search followed by consultation with 
the Principal Investigator. Apart from the facilitators there 
was no statistician acting as an expert for elicitation. 
6 Availability of experts 
Planned for 3 co-located experts, all being members of 
the same academic department. No contingency plans 
were implemented for unavailability of experts. See 
Section 5.5.2 for impact of one expert being unavailable. 
7 Distinguishing types of uncertainty 
Questions for elicitation were formulated in terms of 
epistemic uncertainty and included in the Elicitation 
Protocol (see Appendix C). 
8 Choice of elicitation instrument 
Implemented the Roulette (chips in bins) instrument due 
to its successful feasibility in Kinnersley-Day case study 
and its validity in other settings (Johnson, Tomlinson, 
Hawker, Granton, Grosbein, et al., 2010; Johnson et al., 
2011). 
9 Use of technology I used the R package for SHELF to assist constructing a 
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 Topic Implementation 
consensus distribution. See Chapter 4.2 for a description 
of SHELF. 
10 Choice of prior distribution 
Elicitation protocol described use of Beta distribution but 
also acknowledged that other distributions may be used to 
assess sensitivity of the fitted distributions. 
11 Feedback mechanisms 
Elicitation protocol described use of quantiles from the 
fitted Beta distribution as a means for the experts to 
assess the fitted prior. 
 
Since there is no empirical evidence of the reliability of experts to provide elicited 
distributions of the two correlated parameters 𝜌0 and γ, the elicitation proceeded 
assuming that the parameters were independent. The simulation results in Chapter 7 
evaluate the impact of a range of independent and correlated priors over a number of 
study designs and response rates. The extent of these simulations is greater than that 
elsewhere in the literature (see Section 6.8). 
The elicitation as individual experts and as a consensus was led by me (acting as a 
facilitator) who followed the steps in each elicitation protocol. Firstly for 𝜌0 and 
secondly for γ, furthermore, elicitation of γ proceeded in two ways: 
1. using the pre-specified doses from the protocol 
2. allowing the experts to choose their own range of doses 
The purpose of providing two methods for estimating γ was to evaluate if experts 
confine their beliefs if the range of doses is bounded to specified values. Since the 
EWOC design is generally employed in trials to determine the MTD then the range of 
available doses would usually cover the MTD, however, in the kisspeptin study where 
an efficacy response was being evaluated there is high uncertainty as to whether the 
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pre-specified list of doses includes the dose which is highly likely to lead to a 
response. For the design of future elicitation sessions it is therefore important to know 
if there is a difference in elicitation results depending on whether the expert is asked 
to provide their beliefs from a pre-specified list of doses or whether free choice of 
doses is available. 
5.2.1 Individual Elicitation 
As stated in the elicitation protocol, 30 counters were issued to each expert to place 
into the bins provided on the “chips and bins” sheets. The order of placement was to 
follow the structured questioning format as described in the elicitation protocol in 
order to form a distribution that represented their beliefs about the two parameters. 
The experts were not to confer throughout the process. The experts were allowed to 
modify their choices throughout until they were content with the final distribution. 
Once all counters were placed, the experts annotated the location of the bars formed 
by their counters and then were asked to add an additional annotation as a smoothed 
version of their probability distribution. A photograph of each completed sheet was 
taken to preserve their responses and discussion between experts was permitted at 
this stage. The sheets were collected upon completion. 
The fitting of a formal probability distribution to each individual’s elicited beliefs is not 
required during the elicitation process but to aid comparison with the finally fitted 
consensus distribution it was decided to fit probability distributions after the 
elicitation session. Since the choice of fitted distribution (i.e. Beta) had been specified 
for the consensus distribution then it was also chosen for the individual distributions 
but sensitivity analyses were performed for other distributions. 
- 98 - 
 
5.2.2 Group Elicitation 
As stated in the elicitation protocol, I used the SHELF software in R to permit the 
experts to form distributions for 𝜌0 and γ as a consensus. As with the individual 
elicitation step, the order of placement of the “virtual chips” was to follow the 
structured questioning format as described in the elicitation protocol in order to form 
a distribution that represented their beliefs about the two parameters. The experts 
were encouraged to confer throughout the process and wherever possible to use 
evidence (e.g. cite publications) to support their beliefs. The experts were allowed to 
modify their choices throughout until they were content with the final distribution. 
Once all “virtual chips” were placed, I used the R software to add a fitted distribution 
and asked the experts if it reflected their views. Adjustment of “virtual chips” was 
permitted until they were content with the final placing of chips and fitted distribution. 
Note that the R software permits fitting of a range of probability distributions once the 
“virtual chips” have been placed. Furthermore, it is the placing of the chips by the 
experts that remains fixed once elicitation is complete whereas the selection of which 
fitted distribution to use at the trial outset could change; the impact of the choice of 
distribution is discussed later. An image of each completed placing of chips and fitted 
distributions was taken to preserve the responses of the experts when acting as a 
group. 
5.3 Results from Eliciting the Required Parameters for the 
Kisspeptin Case Study 
5.3.1 Logistics 
The elicitation session occurred on 19th April 2012 at Hammersmith Hospital, London. 
Although it was planned for three experts to be present, one was unavailable on the 
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day. Of the two remaining experts, one was Professor in Endocrinology & Metabolism 
(and Consultant Endocrinologist) and the other was a Clinical Research Fellow. 
Although their names are not provided here, I confirmed their suitability as an expert 
from their previous, peer reviewed, research on the role of kisspeptin. Key publications 
appear in the list of references that forms part of the SHELF documentation in 
Appendix C. 
At the start of the elicitation session, I had to make changes from my pre-planned 
protocol of the SHELF elicitation (Appendix C) to no longer elicit priors for the effects 
of luteinising hormone (LH) which was hypothesised (by the Principal Investigator) to 
be on the causal pathway between increased kisspeptin levels and oocycte maturation. 
Fewer LH samples were to be taken in the clinical trial for logistical reasons and so the 
following text did not form part of the elicitation protocol used during the session: 
• “and who have measurements of plasma LH, FSH, oestradiol and kisspeptin at 
the baseline administration of kisspeptin” 
Had the full complement of LH samples been taken during the clinical trial then it 
would have provided an opportunity to model the 2-step elicitation process 
(kisspeptin  LH  oocyte maturation) and compare it with the 1-step elicitation 
process (kisspeptin  oocyte maturation). 
The remainder of this results section has been divided into a description of the 
conduct of the training and the elicitation of the prior probability distributions for each 
parameter. 
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5.3.2 Results of Training in Elicitation 
As described in Table 7, the training element consisted of a presentation lasting 
approximately 30 minutes and, through verbal feedback, it appeared to have had its 
intended benefits of orienting the experts to the key features of the logistic dose 
response curve (i.e. that its shape and location are determined by two parameters) and 
the concept of non-informative versus informative priors. 
The experts also appeared to have a good understanding of the meaning of the point 
estimate of the 𝜌0 parameter (i.e. the proportion responding on the lowest dose) and 
the γ parameter (i.e. the dose highly likely to lead to a response). During the training, 
the experts appeared to have understood the meaning of other quantiles of the prior 
probability distributions but during the elicitation session it later became clear that the 
experts did have some difficulty with interpreting quantiles other than the mode of the 
probability distribution, particularly for the γ parameter. Further evidence of this 
finding is described later in Section 5.3. Hence, it is recommended that facilitators of 
future elicitation sessions ensure the experts understand the relevant features of 
probability distributions. 
As non-statisticians, the experts provided feedback that they found it much easier to 
interpret the two parameters 𝜌0 and γ using the schematic representation of the EWOC 
dose response curve (see Figure 8) than the equations (see ( 2.8 ) and ( 2.9 )). 
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Point Estimates for the 2 
parameters (indicated by red 
symbols) 
 
Uniform Priors (on appropriate 
range) 
 
Informative Priors 
Figure 8 Schematic Representation of the two parameters of the EWOC Dose 
Response Curve 
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5.3.3 Results of Elicitation of Parameter 1, 𝝆𝝆, as Individual Experts 
The elicitation of the prior probability distribution for 𝜌0  (i.e. the proportion 
responding on the lowest dose) proceeded as planned using the SHELF framework that 
appears in Appendix C and thus included elicitation of expert beliefs as an individual 
and as a consensus. 
5.3.3.1 Checking of Assumptions 
The activity lasted 25 minutes and started by me (as the facilitator) ascertaining that 
the relevant published kisspeptin literature described in the SHELF framework was 
complete, but that it did not include a relevant unpublished finding. That unpublished 
finding is described here because it became clear that it played an influential role 
during the elicitation task. As part of the study described in Dhillo et al. (2007), 
unpublished data were available from a single volunteer who had unintentionally been 
treated with a high dose of kisspeptin (12.8 nmol/kg) during the pre-ovulatory phase. 
In part, this was retrospectively determined to be due to unreliable estimation of the 
menstrual cycle by the volunteer. However, since the data from that volunteer was 
available to the experts participating in the elicitation then it was agreed permissible 
to be used during the elicitation process. The experts also confirmed that the range of 
plausible probabilities should be the entire range from 0 to 1. 
5.3.3.2 Forming Probability Distributions for 𝝆𝝆 
The template for placing the 30 counters was provided to each expert and the 
facilitator commenced the next stage of the elicitation process by asking them 
(without conferring) to place the first counter in the “bin” corresponding to the most 
likely value of 𝜌0. Next the experts were asked to place their second counter in the bin 
corresponding to the lowest possible value for 𝜌0. The third counter was to be placed 
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in the bin corresponding to the highest possible value for 𝜌0. During placing of the 
third counter, the facilitator described to the experts a recommendation from the 
authors of SHELF to help them determine the highest possible value. The 
recommendation included the phrase “If you were to see a published trial using the 
0.4nmol/kg dose and the reported response rate was higher than your own ‘highest 
value for 𝜌0’ then you would be sceptical about those results”. There was positive 
verbal feedback about the informative nature of this guidance. The experts completed 
their probability distributions using the remaining 27 counters and these are shown in 
Figure 9. 
 
Expert 1 Expert 2 
  
Figure 9 Results of Individual Elicitation for Parameter ρ0 
The range of possible values for 𝜌0 was the same for the two experts (0 to 0.6) and the 
overall shape of the two elicited distributions were similar although Expert 1 had a 
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slightly positively skewed distribution (the mode was in bin range 0.2-0.3 for Expert 1 
versus 0.3-0.4 for Expert 2). Also shown in Figure 9 are the hand-annotated 
distribution curves although no formal fitting of distributions was performed by the 
experts. 
After completion of this step, the experts shared views on why their distributions 
differed slightly and it appeared that the only potential reason was related to a 
possible hyper-sensitivity effect. Under such an effect, a hyper-sensitive patient could 
have a surge in luteinising hormone at a dose much lower than for the majority of 
patients, however, it remains an open question as to what dose that could be. 
5.3.3.3 Fitting Individual Probability Distributions for Parameter 𝝆𝝆 
The fitting of a formal probability distribution to each individual’s elicited beliefs using 
the R software that accompanies SHELF is shown in Figure 10. 
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Expert 1 Expert 2 
Fitted Beta(3.33, 7.41) Fitted Beta(5.27, 10.8) 
  
Best Fit, Beta(3.33, 7.41) Best Fit, Normal(0.324, 0.117) 
  
 
Figure 10 Fitted Individual Probability Distributions for Parameter 𝜌0 
Similar to the findings in Section 5.3.3.2 concerning the mode, the mean value of the 
fitted beta distribution was slightly higher for Expert 2 (0.328, versus 0.31 for Expert 
1). Using the sums of squares measure, the Normal distribution was a slightly better fit 
than the Beta for Expert 2, however, the resulting quantiles were very similar for both 
distributions e.g. Expert 2 was 90% certain that 𝜌0 was below 0.48 when using a fitted 
beta versus 0.47 using a fitted Normal. 
- 106 - 
 
5.3.4 Results of Elicitation of Parameter 2, γ, as Individual Experts 
As with the elicitation of 𝜌0 the elicitation of γ by individual experts lasted 25 minutes 
in total (i.e. when using both approaches of the pre-specified doses available in the 
protocol and the method of allowing the experts to choose their own doses). The 
process started by the facilitator ascertaining that the relevant kisspeptin literature 
described in the SHELF framework was complete for the published literature. Again, it 
was agreed that the unpublished finding from the single volunteer was permissible to 
be used during the elicitation process. For the first method of individual elicitation, the 
experts confirmed the range of doses intended to be used in the clinical trial, namely 
0.4, 0.8. 1.6, 3.2, 6.4 and 12.8 nmol/kg. For the second method, the experts agreed 
on the doses of 0.8, 1.6, 3.2, 4, 5, 6, 8, 12, 24 and 25 nmol/kg. 
5.3.4.1 Forming Probability Distributions for γ (Pre-specified Doses) 
The template form for placing the 30 counters was provided to each expert and the 
facilitator commenced the next stage of the elicitation process by asking them 
(without conferring) to place the first counter in the “bin” corresponding to the most 
likely value of γ. The experts appeared to be able to interpret this instruction 
successfully. However, it became apparent during the next step that there was 
potential for confusion in their original interpretation of that first task. 
In the next step, the experts were asked to place their second counter in the bin 
corresponding to the lowest possible value for γ. The experts expressed confusion so 
an alternative formulation of the question was posed (at short notice), namely “Please 
place your second counter in the bin corresponding to the least likely value for the 
highly likely dose”. This did not appear to increase clarity. A third formulation of the 
question was attempted which re-formulated the task for all counters, namely “By 
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assuming that a dose-response curve has a plateau at the 90% response rate then 
where does that plateau start?”. It is noted that this formulation is not completely 
satisfactory since there is no guarantee that a plateau exists and furthermore γ can 
still be defined even without a plateau. Further discussion of this issue appears later. 
However, within the revised assumption that a plateau exists then the placing of 
counters continued in order to describe the beliefs of the experts for the parameter γ. 
Expert 1 Expert 2 
  
Figure 11 Results of Individual Elicitation for Parameter γ (Pre-specified Doses) 
As shown in Figure 11 and consistent with the similarity of experts for the elicitation 
of 𝜌0, the range of possible values for γ was the same for the two experts (0.8 to 12.8 
nmol/kg) with the distribution for Expert 2 having a slightly higher negative skew 
compared with Expert 1 (the mode was in the bin corresponding to 6.4 nmol/kg for 
Expert 1 compared with Expert 2 who thought γ was equally likely to be 6.4 or 12.8 
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nmol/kg). Also shown in Figure 11 are the hand-annotated smoothed distribution 
curves although no formal fitting of distributions was performed by the experts. 
As was the case when the experts discussed eliciting 𝜌0 earlier, the reasons for the 
differences in beliefs between the experts was thought to be influenced by the dose at 
which a hyper-sensitivity effect might occur. 
5.3.4.2 Fitting Individual Probability Distributions for Parameter γ (Pre-specified 
Doses) 
The fitting of a formal probability distribution to each individual’s elicited beliefs using 
the R software that accompanies SHELF was not straightforward because the software 
enforces 10 (equally-spaced) bins to be used whereas the trial was designed to have 6 
pre-specified doses. 
Since the pre-specified doses in the planned trial were spaced according to a 
doubling-dose rule then the linear scale of bin widths could be mis-leading if the true 
dosing scale was ignored. For future elicitation sessions I recommend developing 
software that provides a user-specified number of bins and also permits bin labels 
that acknowledge unequal spacing of values (e.g. dose levels). Other recommendations 
are provided in Section 5.5.2. 
For the purposes of distribution fitting, an approximate non-uniform spacing was 
achieved by using only the virtual bins closest to the actual doses. The results of that 
fitting process are shown in Figure 12. 
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Expert 1 Expert 2 
Scaled Beta(1.47, 2.33) No satisfactory fit of the 6 available 
distributions in SHELF 
 
 
  
Figure 12 Fitted Individual Probability Distributions for Parameter γ (Pre-specified 
Doses) 
The mean value of γ for Expert 1 was estimated to be 4.95 nmol/kg using the Scaled 
Beta (1.47, 2.33). The 10th and 90th percentiles of the distribution (i.e. 1.3 and 9 
nmol/kg respectively) showed consistency with the counters for Expert 1 in Figure 11. 
The pre-planned Scaled Beta distribution could not be made to fit the elicited 
distribution for Expert 2 and this was due to the equal assignment of probabilities to 
the top two doses for a negatively skewed distribution. Similarly, none of the five other 
available distributions in SHELF (Normal, t, Beta, Log-Normal, Log-t and Gamma) could 
be made to fit the data for Expert 2. For future elicitations sessions, I recommend the 
development of software that permits fitting a mixture of distributions. For example, 
Gajewski and Mayo (2006) describe the process of eliciting a mixture of Beta 
distributions by eliciting individual Beta distributions from each of two experts and 
then forming a mixture distribution by eliciting the relative expertise of each expert as 
an additional parameter which is then used to provide relative weights of the two 
individual Beta distributions. 
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Overall, the Scaled Beta distribution appears to be a reasonable representation of the 
beliefs of the individual elicitation for Expert 1 but not Expert 2 when only the 
pre-specified doses from the protocol are considered. 
5.3.4.3 Forming Probability Distributions for γ (Unrestricted Doses) 
As described in Section 5.2, elicitation was repeated with a single change to the task 
so that before elicitation started, the experts were able to choose a range of doses that 
would span all potential values of γ (i.e. the dose highly likely to lead to a response) 
and not just those available in the protocol. Performing elicitation using two different 
approaches would permit comparison of the results. 
For the second method, the experts agreed on the doses of 0.8, 1.6, 3.2, 4, 5, 6, 8, 
12, 14 and 25 nmol/kg. The experts wrote these values under the 10 bins in a new 
template form and then, without conferring and under the guidance of the facilitator, 
placed 30 counters to form their probability distribution for γ in the same manner as 
that described previously for the case of pre-specified doses.  
As was the case with pre-specified doses, the experts were most comfortable with the 
elicitation of γ using the question “By assuming that a dose-response curve has a 
plateau at the 90% response rate then where does that plateau start?” 
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Expert 1 Expert 2 
 
 
Figure 13 Results of Individual Elicitation for Parameter γ (Unrestricted Doses) 
The differences between experts in the shape of the probability distributions was more 
pronounced in this case of unrestricted doses (see Figure 13) compared with elicitation 
when only doses pre-specified in the protocol were considered (see Figure 11). For 
Expert 1, the mode was in the bin corresponding to 6.4 nmol/kg when considering the 
doses available in the protocol and 6 nmol/kg when doses were unrestricted. This 
contrasts with Expert 2 who thought γ was equally likely to be 6.4 or 12.8 when 
considering the doses available in the protocol but equally likely to be 14 and 25 
nmol/kg when doses were unrestricted. Overall, the distribution for Expert 1 was 
nearly symmetric whereas for Expert 2 there was a high negative skew. Also shown in 
Figure 13 are the hand-annotated smoothed distribution curves although no formal 
fitting of distributions was performed by the experts. 
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As was the case when the experts discussed eliciting 𝜌0 and γ earlier, the reasons for 
the differences in beliefs between the experts was thought to be influenced by the 
dose at which a hyper-sensitivity effect might occur. 
5.3.4.4 Fitting Individual Probability Distributions for Parameter γ (Unrestricted 
Doses) 
As in Section 5.3.4.2, due to the non-uniform spacing of doses being considered, only 
approximate fitting of distributions could be produced using SHELF, though I 
recommend future elicitation sessions use software that permits unequal spacing (see 
Section 5.5.2). The results of that fitting process is shown in Figure 14. 
Expert 1 Expert 2 
Scaled Beta(3.68, 9.24) Scaled Beta(1.82, 1.37) 
  
  
Figure 14 Fitted Individual Probability Distributions for Parameter γ (Unrestricted 
Doses) 
The mean value of γ for Expert 1 was estimated to be 7.12 nmol/kg using the Scaled 
Beta (3.68, 9.24). The 10th and 90th percentiles of the distribution (i.e. 3.4 nmol/kg 
and 11 nmol/kg respectively) showed consistency with the counters for Expert 1 in 
Figure 13. If one is prepared to assume that intermediate doses were available (i.e. 
doses between the available doubling-doses) then the fitted distribution for Expert 2 
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was also a reasonable fit when compared with the counters in Figure 13. As such, the 
mean value of γ for Expert 2 was estimated to be 14.3 nmol/kg.  
Overall, If one is prepared to assume that intermediate doses were available then the 
Scaled Beta distribution appears to be a reasonable representation of the beliefs of the 
individual elicitation for both experts when the choice of doses was unrestricted. This 
contrasts with the observations from the difficulty fitting probably distributions when 
doses were confined to those pre-specified in the protocol. In retrospect, it would 
have been informative to have conducted the elicitation by transforming the doubling-
doses to a linear scale and then compared the resulting prior distributions. 
5.3.5 Results of Estimation of Parameter 𝝆𝝆 as a Consensus 
The group elicitation of the prior probability distribution for 𝜌0  (i.e. the proportion 
responding on the lowest dose) proceeded as planned using the SHELF framework that 
appears in Appendix C. The activity lasted 10 minutes and started by the facilitator 
confirming that the range of plausible probabilities should be the entire range from 0 
to 1. The fitting of a consensus distribution for 𝜌0 proceeded using the R software that 
accompanies SHELF and is shown in Figure 15 which reveals that the Beta(3.6, 8.69) 
was the best fitting distribution. 
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Fitted Beta(3.6, 8.69) 
 
Figure 15 Fitted Consensus Distribution for Parameter 𝜌0 (Unrestricted Doses) 
5.3.6 Results of Estimation of Parameter γ as a Consensus 
The group elicitation of the prior probability distribution for γ (i.e. the dose highly 
likely to lead to a response) was performed using the unrestricted dose range using 
the SHELF framework. The results are shown in Figure 16 and show that the best 
fitting distribution was Log-Normal rather than Scaled Beta, however, the mean value 
was similar from both distributions (Mean=10.1 nmol/kg from Log-Normal i.e. 𝑒2.31 
and 10.5 nmol/kg from Scaled Beta). 
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Fitted Scaled Beta(4.04, 5.54) Best Fit, Log-Normal(2.31, 0.377) 
  
Figure 16 Fitted Consensus Distribution for Parameter γ (Unrestricted Doses) 
 
5.3.7 Comparison of Fitted Priors between Individual and Group Elicitation 
Differences arose between the prior distributions elicited from individual experts 
compared with the consensus priors. Since the (scaled)-Beta distribution was chosen a 
priori the differences are summarised using (scaled)-Beta distributions in Figure 17. 
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Parameter 𝛒𝝆 
Expert 1 Expert 2 Consensus 
Fitted Beta(3.33, 7.41) Fitted Beta(5.27, 10.8) Fitted Beta(3.6, 8.69) 
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Parameter γ (Unrestricted Doses) 
Expert 1 Expert 2 Consensus 
Fitted Scaled-Beta(3.68, 9.24) Fitted Scaled-Beta(1.82, 1.37) Fitted Scaled-Beta(4.04, 5.54) 
   
   
Figure 17 Comparison of Priors from Individual and Group Elicitation 
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As can be seen from Figure 17, the consensus prior distribution for 𝜌0  was similar 
to the individual expert priors. However, for the γ parameter more noticeable 
differences were apparent. In particular, the consensus prior appeared to be a 
compromise between the two experts (Expert 1 Mean=7.12, Expert 2 Mean=14.3 
and Consensus Mean=10.5). This compromise became evident during the 
discussion that followed the individual elicitation (see Section 5.3.3.2) and the 
potential for a hyper-sensitivity effect. Under such an effect, a hyper-sensitive 
patient could have a surge in luteinising hormone at a dose much lower than for the 
majority of patients. 
To assess the suitability of the consensus priors, it is possible to simulate values 
from each of the prior distributions for 𝜌0 and γ and then derive the induced dose-
response curve. Assuming independent priors and drawing 500 samples from 
𝜌0~Beta(3.6, 8.69) and and γ~Scaled-Beta(4.04, 5.54) produces the resulting dose-
response curves over the dose range 0 to 25 in Figure 18. This type of plot can also 
be produced for the case of correlated priors and the likely impact on trial 
conclusions can be assessed using corresponding profile plots as shown in the 
simulation results from Section 7. 
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blue curves = 500 simulated dose-response curves assuming independent priors 
red curve    =  Dose-response curve using independent Prior Means 
green curve =  Dose-response curve using independent Prior Medians 
Figure 18 Induced Dose-Response Curves using Consensus Priors for the two 
parameters of the EWOC Dose Response Model 
Although such simulated dose-response plots were not generated during the 
elicitation session, I recommend that provision of such plots in real-time will 
provide an additional assessment of the anticipated variability across the whole 
dose-range. If the resulting variation is unexpected then a further revision to the 
consensus prior may be considered. 
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5.4 Comparison of Elicited Priors with Clinical Trial Results 
The objective of the kisspeptin trial”, see Section 1.4.2) was to identify the dose 
most likely to induce oocyte maturation in 80% of women and the results of the 
completed trial have recently been published (Jayasena et al., 2014). In brief, 
Jayasena et al. (2014) concluded that the trial enrolled 53 patients and identified 2 
doses that induced oocyte maturation (6.4 and 12.8 nmol/kg) but that further 
research is required to determine the optimal kisspeptin dose and also to 
demonstrate that lower doses would not induce oocyte maturation. It is thus 
possible to compare the elicited priors with the study results. Chapter 8 provides a 
more detailed evaluation of the Jayasena et al. (2014) trial and comparison with an 
alternative design (using EWOC) that allocates patients sequentially. For the 
remainder of this section, only the end of study data from all 53 patients is 
considered. 
In the final protocol for the kisspeptin trial, the sequential dose allocation 
procedure using Bayesian logistic regression was not implemented and instead the 
dose allocation procedure was amended such that only 4 of the doses were used 
(1.6, 3.2, 6.4 and 12.8 nmol/kg) because both patients randomised to 1.6 nmol/kg 
did not attain response (i.e. clinically difficult egg collection was reported 36 hours 
following study treatment) and the investigators proceeded to randomise the next 9 
patients on a 1:1:1 basis to 3.2, 6.4 and 12.8 nmol/kg. The remaining 42 patients 
were then randomised 1:1 to either 6.4 or 12.8 nmol/kg. 
It is thus not possible to compare exactly the clinical trial results with those that 
would have been obtained with a Bayesian sequential allocation procedure, 
however, an informal comparison can be made by treating the results in Table 8 
(reproduced from Jayasena et al. (2014) on an Intention-to-Treat basis) as if they 
were the final observed data from a Bayesian sequential allocation procedure. 
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Table 8 Oocyte Maturation from Jayasena et al. (2014) 
 Dose, nmol/kg 
 0.4  (n=0) 
0.8 
(n=0) 
1.6 
(n=2) 
3.2 
(n=3) 
6.4 
(n=24) 
12.8 
(n=24) 
oocyte 
maturation 0 0 2 (100%) 3 (100%) 22 (92%) 24 (100%) 
 
Using visual inspection of the data in Table 8 (i.e. not model-based) to estimate the 
dose likely to induce oocyte maturation in 80% of women would suggest a dose 
between 1.6 and 6.4 nmol/kg. Furthermore, the probability of a response on the 
lowest dose used (i.e. 1.6 nmol/kg) is fairly high (since both patients responded). 
Alternatively, fitting a Bayesian 2-parameter logistic regression with bounded 
Uniform priors (namely 𝜌0 ~ Un(0, 0.8) and γ ~ Un(0.4, 12.8) ) provides the results 
in Figure 19. 
Posterior for 𝜌0 
 
Posterior for γ 
 
Figure 19 Posterior Distributions for Data from Jayasena et al. (Uniform Priors) 
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The posterior mean (& median) for γ was 3.1 nmol/kg which is somewhat lower 
than the mean of 10.5 nmol/kg from the elicited consensus prior (Figure 17). 
However, by looking at the induced dose-response curve from these posteriors 
(shown in Figure 20) it can be seen that the curve is relatively shallow around 
response rates of 0.8 and thus much higher doses do not lead to appreciable 
increases in response rate. Furthermore, since the actual clinical trial did not 
employ a Bayesian sequential dose allocation procedure then it was not possible for 
patients recruited later in the trial to receive the lowest 3 doses (which would have 
been possible with a Bayesian sequential dose allocation trial). 
 
Key: P50 = Posterior Median (i.e. 50th percentile) 
Figure 20 Induced Dose Response Curve for Data from Jayasena et al. (Uniform 
Priors) 
Figure 21 shows the corresponding results when repeating this post hoc analysis 
using informative priors similar to the elicited Consensus priors for 𝜌0 ~ Beta(3.6, 
8.69) and  γ ~ Normal(10.5, 15.21). 
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Posterior for 𝜌0 
 
Posterior for γ 
 
Induced Dose-Response Curve 
 
Key: P50 = Posterior Median (i.e. 50th percentile) 
Figure 21 Posterior Distributions for Data from Jayasena et al. (Consensus Priors) 
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With data from 53 patients, these results from using the informative priors agree 
closely (i.e. target dose, γ, within 1 nmol/kg) with those from the Uniform priors 
which is to be expected since the trial data dominates the priors in both cases. 
Although not performed for the kisspeptin case study, it could enhance the 
performance of the experts at a future elicitation session by conducting a feedback 
session. This would include presentation of the results that combined study data 
with a range of prior distributions and also discussion of the extent to which the 
elicited prior(s) were consistent with study results. Feedback from the experts at 
this stage could also lead to improvements for the facilitator to implement at future 
elicitation sessions. The feedback session could also be used to seek the experts’ 
view on how educational/informative it was to include the schematic representation 
of the EWOC2 parameterisation (i.e. Figure 8) as compared to the mathematical 
formulation (i.e. Equation ( 2.13 )). 
5.5 Summary of Findings from the Elicitation Case Studies 
The key findings from the Kinnersley-Day and kisspeptin case studies are 
summarised below. 
5.5.1 Key Findings from the Training 
Through use of presentations and discussion immediately before the elicitation of 
expert beliefs it is feasible to familiarise clinical trial investigators in: 
• the process of elicitation 
• key features of a probability distribution (e.g. mode, tails, quantiles, area 
under the curve, representing beliefs versus long-run probability) 
• the key features of a logistic dose response curve (e.g. overall shape, 
monotonically increasing, steepness of slope, plateau) 
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• the role of the two parameters in changing the features of the logistic curve 
when using both the EWOC1 (Babb et al., 1998) and the EWOC2 (Tighiouart 
et al., 2005) parameterisations 
• the concept of non-informative and informative Bayesian priors as 
probability distributions on the two parameters of a logistic curve 
5.5.2 Key Findings from Elicitation of Parameters 
Through use of facilitation, the following findings have been observed: 
• It is feasible for clinical trial investigators to use the chips and bins method 
to provide probability distributions that represent their individual beliefs for 
the two parameters of a logistic dose-response curve when using the 
Tighiouart et al. (2005) parameterisation. 
• Despite the training, clinical trial investigators did have difficulty with 
understanding quantiles other than the mode of the probability distribution 
for the γ parameter (i.e. the dose highly likely to lead to a response). Hence, 
it is recommended that improved methods for explaining all relevant 
features of probability distributions are required for future elicitation 
sessions. 
• As non-statisticians, the experts provided feedback that they found it much 
easier to interpret the two parameters 𝜌0 and γ using the schematic 
representation of the EWOC dose response curve (see Figure 8) than the 
equations (see Equations ( 2.8 ) and ( 2.9 )) 
• Use of experts from a single academic department may have increased the 
perceived precision of elicited distributions. However, with novel therapeutic 
interventions and the inherent desire to preserve intellectual property, an 
experienced elicitation facilitator has an opportunity to identify such risks 
beforehand and to recommend avoiding an unrepresentative group of 
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experts. During the elicitation session the facilitator can also provide 
feedback on the elicited distributions such as the plots in Figure 18.  
• Since one of the planned experts was unavailable on the day of the 
elicitation I recommend that the facilitator develops a contingency plan for 
seeking additional input on the suitability of the priors specified by those 
who were present. Note that such contingency planning should also include 
training of additional experts. 
• It is feasible to elicit prior distributions using just 2 experts though this is 
considerably lower than the median number of experts (10) identified in the 
22 prospectively defined elicitation sessions for clinical trials in Table 3. The 
optimal number of experts remains an open question for which more 
research is required, and, as discussed in Table 6 ensuring coverage of the 
important domains of the planned trial is a key aspect. 
• Elicited probability distributions may differ depending on whether the 
experts are asked to provide their beliefs based on a pre-specified list of 
available doses (e.g. those planned in the clinical trial protocol) versus an 
unrestricted range of doses. Since no satisfactory distribution could be fitted 
to the beliefs of Expert 2 in this case study when the restricted set of doses 
was considered and, furthermore, the estimation during the clinical trial 
using the logistic model may not impose a restriction so I recommend 
eliciting priors on an unrestricted set of doses. If this results in elicited 
priors far removed from the planned set of doses then revision of the 
planned protocol may be warranted. 
• For future elicitations sessions, I recommend the use of software that 
permits fitting a mixture of distributions when forming the prior, as well as 
software that can accommodate non-independent priors. 
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• Non-uniform spacing of doses (even after suitable transformation) may 
occur in clinical trials so the development of new software (compared with 
SHELF and MATCH) is required in order to more easily use the Chips in Bins / 
Roulette method. 
• Including the discussion step between experts after individual elicitation can 
provide valuable information to explain differences in elicited distributions. 
For example, in this case study it revealed a potential hyper-sensitivity 
effect to kisspeptin but in a trial that includes some refractory patients it 
may highlight that no dose is likely to lead to a response. I recommend that 
the facilitator have software to assess the implication of such effects in real-
time (e.g. produce plots as in Figure 18 both with and without an important 
prognostic factor). 
• Once trial results are available, I recommend that the original elicitation 
facilitator compare the elicited distribution(s) with the trial results and, 
where feasible, to conduct a feedback session to the original experts to 
assist in calibrating their performance for future elicitation sessions. 
5.6 Conclusions 
Preparing a structured set of training materials and an elicitation protocol before 
conducting an elicitation session will increase the understanding of clinical trial 
subject matter experts in the topic of specifying uncertainty. When training non-
statistical experts in probability distributions I recommend the facilitator uses 
schematic representation of plausible dose response curves rather than equations. 
There is a need to conduct further empirical research of elicitation particularly in a 
multi-site setting to ensure probability distributions reflect a range of beliefs. 
Although I have demonstrated that structured elicitation for a 2-parameter Bayesian 
logistic model is feasible in a clinical trial setting, it is important to understand how 
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the resulting prior distribution(s) may impact conclusions from a planned clinical 
trial (particularly for the small sample sizes typically employed in early phase trials). 
Furthermore, since the EWOC design (which employs a Bayesian 2-parameter 
logistic model) can provide estimates of promising and ineffective doses with 
accumulating data, then it is also important to understand the very small sample 
properties (e.g. sample sizes between 10 and 40 patients) when both uninformative 
and informative priors are considered. Hence this thesis continues with the 
description of the simulation study created to evaluate the EWOC design with a 
range of sample sizes and other study design choices. 
  
- 129 - 
6. Design of a Simulation Study to Assess the 
Performance of the EWOC Design 
6.1 Outline of this Chapter 
There is no consensus on the exact design of a simulation study that fully 
characterises all aspects of 1- and 2-parameter Bayesian logistic dose-response 
models but more general frameworks exist (e.g. see Burton et al. (2006)). 
Nevertheless, to aid comparison with previously published simulations of dose-
response methodologies, the chapter sub-headings follow a similar structure to the 
descriptions of the simulation designs in Bornkamp et al. (2007) and Chu et al. 
(2009). 
6.2 Primary endpoint, distributional assumptions and clinically 
relevant effect 
Following common practice in a number of therapeutic areas for early phase trials, 
the primary endpoint is a binary response (“Success”/”Failure” or for a safety 
endpoint “Toxicity”/”No Toxicity”) which can be evaluated quickly (i.e. in time for 
adaptations of study design to be made). Each response is assumed independent 
and to follow a Bernoulli distribution in all simulations. Nine different values of 
clinically relevant effect have been considered, namely, target response rates {0.1, 
0.2,…, 0.9}. 
The simulation study considers the 2-parameter logistic dose-response models 
from ( 2.7 ) and ( 2.13 ) and for convenience these are referred to as EWOC1 and 
EWOC2: 
EWOC1: P(𝑌𝑗 =1 | Dose=𝑥𝑖) = �
𝑒𝛽0+𝛽1𝑥𝑖
1+ 𝑒𝛽0+𝛽1𝑥𝑖� ( 6.1 ) 
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EWOC2: 
𝑝(𝜌0, 𝛾, 𝑥[𝑖])= 𝑒�𝑙𝑚� 𝜌0(1−𝜌0)�+𝑙𝑚�𝜃(1−𝜌0)𝜌0(1−𝜃)� 𝑥[𝑖]𝛾 �
1+𝑒
�𝑙𝑚�
𝜌0(1−𝜌0)�+𝑙𝑚�𝜃(1−𝜌0)𝜌0(1−𝜃)� 𝑥[𝑖]𝛾 �   
( 6.2 )  
Per Chu et al. (2009), EWOC 1 can be reformulated to simulate the 1-parameter 
CRM by fixing the intercept parameter 𝛽0. 
Each time a new (simulated) patient is to be allocated a dose, the prior together 
with simulated data thus far will be used to re-estimate the model parameters and 
then the next patient (i.e. patient j+1) will be allocated the dose 𝑥[𝑗+1] using 
equation ( 2.14 ) or ( 2.16 ) depending on the following 2 scenarios: 
• allocate the nearest dose below the current model estimate 
• allocate the nearest dose either above or below the current model estimate 
Within a Bayesian framework of EWOC1 and EWOC2, a posterior distribution for the 
model parameters (rather than a unique value) is produced and, from this, 
estimates of the dose (termed γ) corresponding to a target response rate can be 
calculated. In practice, γ is calculated differently for EWOC1 and EWOC2. For 
EWOC1, at each iteration of the Markov chain Monte Carlo (MCMC), γ is derived 
using the current estimates of 𝛽0 and 𝛽1and inverting Equation ( 2.9 ). The posterior 
distribution of γ is taken to be the set of MCMC estimates after discarding a 
suitable number of iterations at the start of the MCMC (termed, the burn-in  
(Cowles & Carlin, 1996))  and only retaining every kth MCMC estimate (termed 
thinning (Kass et al., 1998)), where the auto-correlation between successively 
retained MCMC values is close to zero. Specific choices of burn-in and thinning 
values for the simulations are described in Section 6.6. For EWOC2, the posterior 
distribution of γ is calculated directly since it is a model parameter. 
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When point estimates are required e.g. for determining which dose to allocate to 
the next simulated patient, the median has been selected since this corresponds to 
the Bayesian Feasible Level alpha=0.5 (see Equation ( 2.14 )) and which penalises 
under-dosing and over-dosing equally (Tighiouart et al., 2005). 
6.3 Dose-level design scenarios 
Four scenarios are considered for the number and spacing of available doses in the 
clinical trial. Firstly, since it is unusual to have truly continuous doses available in 
many clinical trials simulations have been performed for the more practical situation 
of 17 equally spaced pre-determined doses {0, 1, 2,…, 16}. However, even this 
number of doses may be unrealistic in many settings so an alternative scenario is 
considered in which 5 “doubling doses” are available, namely {0, 1, 2, 4, 8, 16}. 
Doubling-doses were also considered in the simulations of Chu et al. (2009) in 
which convergence of CRM and EWOC designs were compared for response rates in 
the range 0.33 to 0.5 (whereas the present simulations consider the range 0.1 to 
0.9). 
Compared with the base case scenario of 17 dose levels, the “doubling-doses” 
scenario is changing both the number of dose levels (17 to 6) and the values of 
those dose levels, so a further scenario is considered in which the 6 approximately 
equally spaced dose levels are {0, 3, 6, 9, 13, 16}. The final scenario for varying 
dose levels has been to follow the approach of Raftery (1996) and evaluate the 
effect of standardising the dose levels. Standardising facilitates comparisons across 
simulation studies (e.g. where different values of dose could be used) and it also 
may reduce collinearity amongst regression predictors (Gelman et al., 2008). 
Standardisation could be achieved by dividing all doses by a reference dose (e.g. as 
implemented by Neuenschwander et al. (2008)) or by centering around dose=0 (e.g. 
as implemented by Bedrick et al. (1996)). An arbitrary choice was made to centre 
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around dose=0 and set the dose levels to be {-100 to 100 by 1} i.e. 201 possible 
dose levels. Future research could evaluate if conclusions are similar for the 
standardisation method of dividing by a reference dose. 
6.4 Dose-response profiles 
For target response rate, θ and dose, d, three different dose-response profiles have 
been considered: 
• Shallow: logit(θ) = -11.6 +1.4d  
• Intermediate: logit(θ) = -2.9 + 0.7d 
• Steep:  logit(θ) = -7.5 + 2.5d 
These dose-response models are shown in Figure 22 together with the dose 
corresponding to a target response rate, θ=0.9. 
 
Figure 22 The Dose-Response Models that have been Simulated 
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The shape (though not parameter values) of these dose-response curves is similar 
to the set of scenarios in Chu et al. (2009). 
6.5 Sample size, number of simulated trials and cohort size  
6.5.1 Clinical Trial Sample Size 
A fixed sample size of 40 patients has been used for each simulated trial which is 
larger than the 24 and 30 patient EWOC simulations used in Babb et al. (1998). The 
larger sample size in the current simulations was chosen to reflect the wider range 
of target response rates (i.e. between 0.1 and 0.9 in the current simulations) which 
may be appropriate in small Phase 2 studies evaluating initial signs of efficacy. 
The large sample properties for 1-parameter logistic models have been described 
by a number of authors (e.g. Cheung (2011) and Shen & O’Quigley (1996)) and so to 
enable straightforward comparison with the present simulations of the small sample 
(i.e. N=40) properties, a subset of scenarios will be generated in which the available 
dose levels are {-100 to 100 by 1} but this time allowing N=150 patients. 
6.5.2 Number of Simulated Trials  
1000 replicated clinical trials have been generated for each scenario. This number 
was chosen to balance accuracy of results with the long duration to run each 
simulated trial. The simulation accuracy, 1-δ, can be calculated by re-arranging the 
following equation (Burton et al., 2006): 
 
Number of simulations = �
𝑍
1−
𝛼
2
𝛿
𝜎�
2
 
( 6.3 ) 
where 𝑍1−𝛼
2
 is the appropriate percentage point of the Standard Normal distribution 
(e.g. 1.96 for 5% alpha) and σ is the known standard deviation. In practice, an 
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approximate simulation accuracy can be obtained using a plug-in estimate from the 
observed variance (e.g. SD=0.6822 from Figure 31), which produces an 
approximate simulation accuracy of 99%. Even if this observed estimate of variance 
was as large as 11 then 1000 simulations would still provide 95% accuracy. 
Three UNIX servers (each with 8 CPUs) were used to run the scenarios in parallel, 
the fastest of which took approximately 2 days to run the 9000 simulated trials 
required for each scenario in Table 9. The combination of scenarios tested is 
described in Table 9 and reveals that more than 500,000 trials in total have been 
simulated. 
It is possible that for a small number of simulated trials the MCMC approach may 
fail to converge and the simulation will cease before 40 simulated patients have 
been evaluated. The extent of this occurrence will be described and any limitations 
discussed. 
6.5.3 Cohort Size 
Following the findings of Goodman et al. (1995) and the subsequent 
implementation of many CRM-type designs with cohort sizes of 3, each simulated 
scenario assumes a cohort of size 3  for the first 3 cohorts (i.e. all 3 patients in 
cohorts 1 to 3 receive the same treatment). Subsequently, cohort sizes will vary 
because the estimation procedure will allocate the next patient to a specific 
dose/cohort. Hence the response-adaptive nature of EWOC will only be performed 
after 9 simulated patients. This criteria is similar in spirit to the 2-stage CRMs in 
which a Short Memory design is used until a toxicity is observed and then a Long 
Memory design takes over (Moeller, 1995; Iasonos & O’Quigley, 2012) although in 
the simulations described in Chapter 7 the initial 3 doses are used sequentially 
regardless of any responses that may be seen in those 3 cohorts. It could be argued 
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that this does not reflect clinical trial reality but conversely many early phase 
designs start with doses well below therapeutic effects and so the first 3 cohorts in 
any trial are likely to proceed as planned. This scenario also reflects the plan for the 
initial 3 cohorts in the motivating case study with kisspeptin. 
6.6 Prior Distributions 
Using the formulations in Equations ( 6.1 ) and ( 6.2 ), a range of weakly-
informative and informative priors for model parameters will be studied under each 
parameterisation of EWOC1 and EWOC2. This allows an assessment of whether a 
non-informative prior under one parameterisation is informative under an 
alternative parameterisation.  
The priors to be considered are: 
• EWOC1: 
o Independent (bounded) Uniform priors for 𝛽0 and 𝛽1 i.e. 𝛽0 
~Un(-16,16) and 𝛽1 ~Un(0.01,5) 
o Independent (vague) priors for 𝛽0 and 𝛽1  i.e. 𝛽0 ~Normal(-6,50) and 
𝛽1 ~Gamma(shape=3/10, scale=10/3), hence mean=1, var=10/3 
o Correlated multivariate Normal priors for 𝛽0 and 𝛽1 that have the same 
mean and variance as the independence scenario but also introduces 
the expected negative correlation present in 2-parameter logistic 
models i.e. 
�
𝛽0
𝛽1
� ~ MVN �−61 , � 50 −12−12 3.3 � � 
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• EWOC2: 
o Independent (bounded) Uniform priors for 𝜌0 and γ i.e. 𝜌0 ~Un(0,θ) 
where θ varies between 0.1 to 0.9 as described in Chapter 6.2 and γ 
~Un(0,16) 
o Informative priors for 𝜌0 and γ that approximate those elicited in the 
kisspeptin case study (see Section 5.3.7), namely  𝜌0 ~Beta(3.6,8.69) 
and γ ~Normal(10.5,15.21) i.e. standard deviation=3.9  
• 1-Parameter Logistic: 
o To assess if the operating characteristics are similar between 1 and 
2-parameter logistic models, a subset of scenarios will be repeated 
for the 1-parameter model described in Chu et al. (2009), in which 𝛽0 
is held fixed at -3 and the prior for 𝛽1 is Uniform(0.01,5) i.e. the same 
prior as used in one of the scenarios for EWOC1. 
A number of these Prior distributions are shown in Figure 23. 
 
Normal(Mean=-6, variance=50) 
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Gamma(Shape=3/10, Scale=10/3) 
 
Beta(3.6,8.69) 
 
Normal(Mean=10.5,Variance=15.21) 
Figure 23 Examples of Prior Distributions 
Since the Gamma density has different formulations, the form used in these 
simulations is stated explicitly: 
- 138 - 
 p(y  |a, b) = 1
𝑏𝑎𝛤(𝑎) 𝑦𝑎−1 𝑒−𝑦 𝑏�  ( 6.4 ) 
Using this formulation, implies E(Y|a, b) = ab and var(Y|a, b)=ab2. This is the 
default formulation in SAS software. 
The use of a Gamma prior for the slope parameter ensures positive values (i.e. a 
monotonically increasing dose-response curve). Although the Gamma distribution 
has theoretical appeal and thus widely described in the literature for modelling 
variances (see, for example, Spiegelhalter et al. (2004, p.238)) it’s use in 
prospectively designed clinical trials for a logistic regression slope parameter is less 
widely documented. A notable exception is the breast cancer trial described in a 
series of publications by Morita and colleagues (Morita et al., 2004; Morita et al., 
2007; Morita, 2011). In these articles, the authors considered the specific case of a 
target toxicity rate of 0.33 and elicited the prior probabilities of 5 doses then fitted 
a Gamma(5,5) as an informative prior for the slope in a 1-parameter CRM design. 
Note that although Morita et al. (2011) use an alternative formulation of the Gamma 
distribution, namely Gamma(a, 1/b), both formulations result in specifying a prior 
mean slope of 1. The variance used in the simulations described in Chapter 7 is 
larger thus representing vaguer prior knowledge in the estimate of the slope 
parameter (10/3 compared with 1/5). 
In a number of the scenarios to be considered, the priors are non-conjugate so 
Markov chain Monte Carlo (MCMC) has been used to compute the joint and marginal 
posteriors. Since it will be impractical to assess convergence of the chain within 
every simulation, an automated approach will be used such that a large number of 
burn-ins (i.e. 5000) and thinning (i.e. every 1000th iteration) from the 2000000 
iterations will be used. The values of 5000 for burn-in and 1000 for thinning was 
determined after fitting a small number of scenarios from Table 9 (i.e. Scenarios 1, 
2, 6, 7, 12 and 13) and noting that the MCMC chains had converged.  These choices 
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lead to 2000 iterations forming the marginal posterior distribution for 1 simulated 
trial; this process is repeated to produce the 1000 simulated clinical trials for each 
scenario. The performance of this automated approach is described in Section 7.5. 
6.7 Measuring Operating Characteristics 
Since there is only 1 outcome in a real dose-escalation clinical trial (i.e. where the 
true dose-response is unknown) then it is useful to be able to know: 
1. if the planned trial design produces an estimate sufficiently close to the true 
dose leading to the target response rate (i.e. after 40 patients) 
2. how quickly (i.e. after how many patients) that estimate converges to the 
true dose 
3. if (some) estimates are considered outliers to the true value 
The performance of the scenarios is assessed formally using bias and mean square 
error at 40 (simulated) patients, but is also supplemented by informal evaluation of 
outliers and the rate of convergence (from N=9 to N=40 patients) to the true value 
of the dose that predicts the response rate under consideration. 
6.7.1 Bias 
For each of the dose-response curve scenarios, the true dose leading to each of the 
specified target response rates (0.1 to 0.9) is known and this is referred to as γ. For 
each simulated clinical trial, estimates of γ (termed 𝛾�) will be calculated at N=40 
patients (the maximum number of patients in the simulated trials). Bias is then 
defined as the difference between γ and the mean 𝛾� over all simulations (Burton et 
al., 2006), namely: 
 bias = 𝛾� – γ ( 6.5 ) 
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Collins et al. (2001) define an alternative measure of bias, termed standardised 
bias,  which is expressed as: 
 standardised bias = 100�𝛾
��− 𝛾� 
SE(𝛾�)  ( 6.6 ) 
where SE(𝛾�) is the standard error of 𝛾� and calculated as the standard deviation of 𝛾� 
over all simulations. 
Collins et al. (2001) provide a rule of thumb that standardised bias values greater 
than 40% to 50% (either negative or positive) will mean that the estimate on average 
falls one-half of a standard error below the parameter i.e. approximately 1/8 of the 
width of a typical confidence interval. In the simulations of missing data in Collins 
et al. (2001) they argue that standardised bias of 40% in either direction has a 
noticeable impact on efficiency, coverage and error rates. 
6.7.2 Mean Square Error 
Using the same terminology as Burton et al. (2006), mean square error (MSE) is 
defined as: 
 MSE = ( 𝛾� – γ )2 + SE(𝛾�)2 ( 6.7 ) 
where SE(𝛾�) is the empirical standard error of 𝛾� over all simulations. As with bias, 
MSE will be calculated at N=40 simulated patients. 
6.7.3 Other Metrics 
Although other metrics such as convergence rates are available (particularly from 
the Phase 1 oncology setting, e.g. see Shen & O’Quigley (1996), Chu et al. (2009), 
Oron et al. (2011) these are less appropriate when only a finite number of doses are 
available. For example, Chu et al. (2009) define the convergence rate (at the jth 
patient) as the proportion of simulation runs for which the recommended dose level 
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is the true MTD. However, in the simulations described in Chapter 7 in which only 
discrete doses are available, the model may recommend an intermediate 
(“continuous”) dose, such that there is almost zero probability of the model 
recommending an actual “available dose”. 
To provide an informal assessment of outliers and convergence, the values of 𝛾� will 
be plotted as a profile plot from N=9 to N=40 to allow visual inspection compared 
with the true value, γ. An example profile plot from a simulated clinical trial aiming 
to identify the dose inducing a 50% response rate appears in Figure 24. The profile 
plot shows the values of 𝛾� after the EWOC model is re-estimated (i.e. after each 
patient’s response is known, N=9 to N=40). In this simulated clinical trial, the true 
value of γ is known (i.e. 4.1429) and is shown as the black dotted line in Figure 24 
to aid comparison of the estimated with the true value of the target dose that 
induces a 50% response rate. 
 
Figure 24 Example Profile Plot from 1 Simulated Trial 
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6.8 Summary of Simulation Scenarios 
A set of simulation scenarios has been described to characterise the open questions 
described in Section 2.5 and in particular to understand the small sample properties 
of designs based on Bayesian 2-parameter logistic models. The complete set of 
scenarios is summarised in Table 9 and shows a set of scenarios that are likely to 
be most relevant to the planning of a small Phase 2 dose response study i.e. a 
range of dose response models, available doses (and dose spacing), independent 
and correlated priors and two dose allocation rules.  
It should be noted that the decision to perform some of the simulation scenarios 
that are summarised in Table 9 was taken after seeing the results from the 
originally planned set of simulations. At the simulation planning stage, it had 
originally been planned to perform a set of simulations that represented all possible 
combinations of the variable factors but restricting the set of priors to independent 
priors. However, upon performing those simulations it became clear that it would 
also be useful to characterise the performance of the Bayesian 2-parameter logistic 
model with additional scenarios that were relevant to the kisspeptin trial that 
motivated the research and scenarios that would aid comparison with published 
literature. Hence, additional scenarios were added for correlated priors, the 1-
parameter Bayesian logistic model, equal dose spacing and large sample sizes 
(N=150). Future research could include performing simulations on every possible 
combination of factors in Table 9. 
To simplify referring to specific scenarios in the text, row numbering (1 to 20) has 
been included in Table 9 and abbreviations will be used for the three dose-
response scenarios as follows: shallow=W, Intermediate=I, Steep=S (see Section 
6.4). Scenarios may then be referred to as, for example, [2S] which represents 
scenario 2 for the steep dose-response curve.  
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Table 9 Simulation Scenarios Performed 
Scen
ario 
Dose 
Response 
Model 
Available Doses, d Prior(s) Dose Allocation 
Rule, 𝒅[𝒋+𝟏] 
[1] EWOC1 {0 to 16 by 1} 𝛽0~Un(-16,16) 
𝛽1~Un(0.01,5) 
less than 
[2]    nearest 
[3]   𝛽0 ~N(-6,50) 
𝛽1 ~Ga(3/10,10/3) 
less than 
[4]    nearest 
[5]   
�
𝛽0
𝛽1
� ~ MVN �−61 , � 50 −12−12 3.3 � � nearest 
[6]  {0, 1, 2, 4, 8, 16} 𝛽0~Un(-16,16) 
𝛽1~Un(0.01,5) 
less than 
[7]    nearest 
[8]   𝛽0 ~N(-6,50) 
𝛽1 ~Ga(3/10,10/3) 
less than 
[9]    nearest 
[10]  {-100 to 100 by 1} 𝛽0~Un(-16,16) 
𝛽1~Un(0.01,5) 
nearest 
[11]  {0, 3, 6, 9, 13, 16} 𝛽0~Un(-16,16) 
𝛽1~Un(0.01,5) 
nearest 
[12] EWOC2 {0 to 16 by 1} 𝜌0~Un(0,θ) 
γ~Un(0,20) less than 
[13]    nearest 
[14]   𝜌0 ~Beta(3.6,8.69) 
γ ~N(10.5,15.21) nearest 
[15]  {0, 1, 2, 4, 8, 16} 
𝜌0~Un(0,θ) 
γ~Un(0,20) less than 
[16]    nearest 
[17]   𝜌0 ~Beta(3.6,8.69) 
γ ~N(10.5,15.21) nearest 
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Scen
ario 
Dose 
Response 
Model 
Available Doses, d Prior(s) Dose Allocation 
Rule, 𝒅[𝒋+𝟏] 
[18] 1-parameter logistic {0 to 16 by 1} 
𝛽0= -3 
𝛽1~ Un(0.01,5) 
less than 
[19]    nearest 
[20] EWOC1 (N=150) 
{-100 to 100 by 1} 
for N=150 patients 
𝛽0~Un(-16,16) 
𝛽1~Un(0.01,5) 
nearest 
 
NOTE: for each dose response curve, each row represents 9000 simulated trials covering 1000 
simulated trials for each of response rates, θ = 0.1, 0.2,…,0.9 
Dose Response scenarios: 
 Shallow: logit(θ) = -11.6 +1.4*d 
 Intermediate: logit(θ) = -2.9 + 0.7*d 
 Steep: logit(θ) = -7.5 + 2.5*d 
Scenario [10] used Shallow dose response only 
Key: Scenario [2I] is 
referred to as 
“Base Case” 
scenario in 
Section 7.2 
Scenario [1I] is 
referred to as 
“Alternative Case 
1” scenario in 
Section 7.3 
 “less than” is 
 𝑎[𝑗+1]  ≤ 𝛾�  
i.e. allocate dose 
less than current 
estimate 
“nearest” is min𝑑𝑖{|𝑎𝑖 −  𝛾�|} 
i.e. allocate dose 
nearest to current 
estimate 
 
The SAS programs for producing the simulations appear in Appendix E. 
The thesis continues by describing the results of these simulations in Chapter 7, 
which, when combined with the findings from the elicitation case studies, are used 
in Chapter 8 to provide recommendations for improvements to the trial design of 
the kisspeptin case study that motivated this research. 
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7. Results of the Simulation Study 
7.1 Introduction 
Results are presented from the set of simulations to characterise the open 
questions described in Section 2.5 and in particular to understand the small sample 
properties of designs based on Bayesian 2-parameter logistic models. Since more 
than 500,000 simulated clinical trials (covering many hundreds of simulation 
scenarios) have been generated, it is helpful to provide an extended description of 
the “Base Case” and one further scenario that highlights the predominant 
characteristics. This chapter then continues by reporting the key findings from the 
wider set. 
The scenarios selected as “Base Case” and “Alternative Case”  were determined after 
seeing the simulation results but since they represent relatively realistic Phase 2 
scenarios then their use should be acceptable (and useful) to researchers planning a 
Phase 2 clinical trial. Further details of the differences between these 2 scenarios 
and justification of the “Alternative Case” are provided in Section 7.3. 
7.2 Description of Results from the Base Case Simulation 
Scenario 
Based on the simulation plan in Section 6, the scenario in Table 10 describes the 
specific simulation that is considered as the “Base Case” and thus warrants an 
extended description. This scenario has been selected since it demonstrates the 
principle features that are present in the majority of tested scenarios whilst also 
highlighting the key aspects of the simulation parameters that warrant further 
description later in this chapter (for example, impact of model-based estimates 
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outside the range of available doses in the trial). The scenario described in Table 10 
can be cross-referenced with scenario [2I] in Table 9. 
Table 10 Simulation Assumptions for Base Case 
Scenario Feature Value(s) Comments 
Target response 
rate, θ 0.5 
Target response rate higher 
than studied in majority of 
literature of early phase trials 
and key aspect of my research 
(see Section 2.5) 
Logistic model EWOC 1 (see equation ( 6.1 )) 
Frequently used 
parameterisation of 2-
parameter Bayesian logistic 
model. 
Dose-response 
profile, for  
dose, d 
Intermediate: logit(θ) = -2.9 + 0.7d 
Reflects likely clinical trial 
scenario of minimal response 
rate on lower doses but high 
effect at high doses (see 
Figure 22). 
True value of d, 
given target 
response, θ=0.5 
4.1429 
Back-transformed from 
Intermediate dose-response 
model 
Dose allocation 
rule 
Allocate the nearest dose to the current 
model estimate (where current model 
estimate referred to as γ) 
Investigates key aspect of my 
research (see Section 2.5). 
Available doses doses {0, 1, 2,…, 16} 
Investigates performance of 
non-continuous doses i.e. 
bounded and discrete values 
which is a key aspect of my 
research (see Section 2.5). 
Sample size 
First 3 cohorts (i.e. doses=0, 1, 2) have 
3 patients each then estimation process 
for γ begins for remaining patients, up 
to maximum 40 patients 
Pragmatic choice to reflect 
desire of investigators to 
learn about starting doses 
before escalating to other 
available doses. 
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Scenario Feature Value(s) Comments 
Dose escalation 
rule Any of the available doses 
Investigates performance of 
unrestricted dose escalation 
rule which is a key aspect of 
my research (see Section 2.5). 
Number of 
simulated trials 1000 
Provides 99% accuracy for 
true γ (see Section 6.5.2 for 
additional justification). 
Prior 
distributions 
Independent (bounded) Uniform priors 
for 𝛽0 and 𝛽1 i.e. 𝛽0 ~Un(-16,16) and 𝛽1 
~Un(0.01,5) 
Reflects early phase literature 
that aims to let the trial data 
(largely) determine the 
Posterior (e.g. see Chu et al. 
(2009)). 
 
Before proceeding to summarise 1000 simulations, it is useful to describe in detail 
how the model-based estimation of the target dose, γ, proceeds using the EWOC 
design (for simulated patients 9 to 40 in this Base Case scenario of an Intermediate 
dose-response curve). By considering simulation 1 (of 1000), the first row of Table 
11 shows the sequence of outcomes for the first 9 patients (3 cohorts of 3 patients 
assigned doses 0, 1 and 2) after which the first model estimation was conducted. 
Figure 25 shows the marginal posterior distributions for the two parameters 𝛽0 and 
𝛽1 as well as the marginal posteriors for the derived parameters 𝜌0 and γ (see 
Equations ( 2.8 ) and ( 2.9 )) after 9 patients. It is clear from these equations and  
Figure 25 that very small values of 𝛽1 will lead to very large values of γ, however, 
since the posterior median of γ is used as the summary measure then extreme 
values have almost no impact on the recommended dose for the next patient. 
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Figure 25(a) Posterior for 𝛽0 Figure 25 (b) Posterior for 𝛽1 
  
Figure 25(c) Posterior for  𝜌0 Figure 25 (d) Posterior for γ 
  
Figure 25 Marginal Posterior Distributions for Base Case after 9 Patients 
The posterior median after 9 patients (with no responses) was γ=5.28. Recall that 
the true value of the dose leading to a 50% response rate is 4.1429 so zero 
responses for dose=1, 2 and 3 is unsurprising. In the EWOC design with a dose 
allocation rule assigned using the nearest dose (i.e. using Equation ( 2.16 )) then 
patient 10 is allocated dose=5 (see Table 11). 
Since patient 10 also did not respond then the model provides a higher estimate of 
γ (i.e. 9.74), so patient 11 is allocated dose=10 (and responded). 
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Table 11 Model Estimation for Simulation 1 from Base Case Scenario 
Patient Dose Outcome 
(0=No Response; 
1=Response) 
Model estimate, γ 
(true value=4.1429) 
1, 2, 3 
4, 5, 6 
7, 8, 9 
0 
1 
2 
0, 0, 0 
0, 0, 0 
0, 0, 0 
N/A 
N/A 
5.28 (First estimation performed after N=9) 
10 5 0 9.74 
11 10 1 6.54 
12 7 0 8.16 
13 8 1 7.29 
14 7 1 6.77 
15 7 1 6.43 
16 6 1 6.02 
17 6 1 5.71 
18 6 1 5.52 
19 6 1 5.38 
20 5 1 5.04 
…etc    
38 5 1 4.75 
39 5 0 4.84 
40 5 0 4.90 
 
The corresponding marginal posterior distributions after 40 patients are provided in 
Figure 26 and show how the marginal posterior for γ is concentrated between 4 and 
5.5. 
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Figure 26(a) Posterior for 𝛽0 Figure 26(b) Posterior for 𝛽1 
  
Figure 26(c) Posterior for  𝜌0 Figure 26(d) Posterior for γ 
  
Figure 26 Marginal Posterior Distributions for Base Case after 40 Patients 
The estimated dose response curve for this single simulation after 40 patients using 
the posterior median values is plotted in Figure 27 alongside the true dose-
response curve and shows how (as expected) under-estimation at the lower part of 
the logistic curve is compensated by over-estimation at higher doses. A “good” 
estimator will, on average, minimise such discrepancies and later results will 
describe the properties having performed thousands of simulations. 
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Figure 27 Estimated versus True Dose Leading to Target Response Rate of 0.5 for 
Base Case after 40 Patients 
Although it is useful to obtain an estimated dose-response curve to enable 
prediction of future responses to different doses, it is also important to understand 
if (simulated) patients were allocated to doses at or near the true value. As such, the 
doses allocated and the outcomes of the 40 patients from Simulation 1 are 
summarised in Figure 28 and show that no patients were allocated to dose=4 (i.e. 
the dose closest to the true value of 4.1429), however, of the 22 patients allocated 
to dose=5, 12 did respond (i.e. response rate=0.55). Note that although the 
underlying model predicts a response rate of 0.65 for dose=5 (Figure 27), the 
observed response rate (12/22) is within sampling variability for small sample sizes 
(i.e. just 2 more responses, 14/22, would give a response rate of 0.65). 
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Figure 28 Summary of Dose Allocation and Outcomes for Simulation 1 from Base 
Case Scenario 
Comparison of Figure 27 and Figure 28 also allows us to observe that the estimated 
and true dose-response curves converge around the doses for which most patients 
were allocated, namely doses 5 to 7 (and with a mix of non-responders and 
responders). Since this is just a single simulation, generalisations would be 
premature, however, there is intuitive appeal of an estimator that has minimal bias 
near the values containing most information. 
Although 40 patients may be a suitable number to recruit for the entire trial, the 
repeated estimation in a trial with EWOC design allows a temporal inspection of the 
model estimates, hence the model estimates of γ from Table 11 have also been 
presented in graphical form as a profile plot in Figure 29 and shows that: 
• all estimates of the target dose, γ, were close but higher than the true value 
• estimates of γ stabilised after approximately 20 patients 
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Given the small changes in model estimates (beyond 20) then had this been a real 
clinical trial, the (long memory) EWOC design potentially allows the investigator to 
decide if enrolment of future patients would be worthwhile. That could be done 
either informally (e.g. by visual inspection of the data in Table 11 and noting that 
estimates of γ change by <1 after each patient response) or formally (e.g. by 
calculating the posterior predictive distribution for subsequent patient(s)). 
 
Figure 29 Example Profile Plot from 1 Simulated Trial for Base Case 
Clearly, generalisations of the small sample properties of the EWOC estimator 
cannot be made on the basis of 1 simulation so this chapter continues with the 
description of the corresponding results for 1000 simulated clinical trials. In 
particular, the profile plot of 1000 simulations is shown in Figure 30. 
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Figure 30 Profile Plot from 1000 simulated trials for Base Case 
The plot shows that: 
• Initial estimates of the target dose γ (e.g. when N<20) varied highly i.e. 
estimates ranged from 2 to 20. 
• In the majority of simulations, the estimate stabilised to its long-term value 
by the time 20 patients had been simulated (similar results in a range of 
other scenarios will be discussed later) 
• In one scenario, the estimate of γ at N=20 was more than double the true 
value (i.e. 8.6781 versus true value of 4.1429) and was still 57% higher than 
the true value at N=40 (i.e. 6.5284 versus true value of 4.1429). This 
scenario is the blue profile line in Figure 30 that is consistently higher than 
all others from N=19 patients onwards. 
A visual representation of the (small) bias at N=40 patients from the same 1000 
simulations is found by inspecting the distribution at N=40 from Figure 30 and this 
is plotted in Figure 31 along with a Kernel Density Estimate (KDE). 
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Figure 31 Example of the Distribution of Estimates of the True Dose Leading to 
Target Response Rate of 0.5 
In the example from Figure 31, the true value for γ is 4.1429 and so the mean bias 
is 0.0041 (i.e. 4.1470 – 4.1429). Furthermore, the mean bias for all of the potential 
response rates, θ=0.1 to 0.9 for the Base Case scenario from Table 10 is shown as 
the blue values in Figure 32 (Mean Square Error, MSE, is also shown by red values). 
Positive bias for values of θ<0.5 and negative bias for θ>0.5 indicates that the 
slope parameter, 𝛽1 is consistently over-estimated (i.e. greater than true value of 
0.7) when implementing the dose allocation rule of Equation ( 2.17 ) i.e. one which 
takes the nearest of the available discrete doses. Further generalisations will be 
made in Section 7.4.3 when discussing the larger set of simulation scenario results 
in Figure 41. 
The practical implication of positive bias (albeit small) for low values of θ (i.e. 0.1 to 
0.3) is very relevant in Phase 1 oncology trials, since this has been the area in which 
the EWOC design was developed and has been applied (see Section 2.4.3). In 
particular, positive bias for target toxicity rates between 0.2 and 0.35 could 
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translate to the model recommending doses higher than the true value. If such 
(higher) doses are subsequently used in later (and likely, larger) trials then the 
observed toxicity rate in those later trials might be higher than the investigators 
predicted based on the Phase 1 study. It is thus recommended that when planning 
clinical trials, simulation is used to characterise the potential for bias according to 
the expected dose-response curve (and variants thereof) as well as other study 
design parameters (see Section 7.8 for other recommendations from the 
simulations). 
 
 
Figure 32 Example of Mean Bias and MSE for various Target Response Rates 
- 157 - 
As expected, the value of MSE is minimised when the bias is close to zero (see 
Equation ( 6.7 )). The corresponding values of the mean standardised bias for θ=0.1 
to 0.9, respectively, were 162%, 126%, 73%, 31%, 1%, -13%, -36%, -54% and -59% 
thus only values of response rate, θ, between 0.4 and 0.7 were within the ±40% 
rule-of-thumb of Collins et al. (2001). 
This chapter continues by describing in detail the impact of changing one aspect of 
the Base Case that addresses one of the open questions listed in Section 2.5. 
7.3 Description of Results from the Alternative Case 1 
Simulation Scenario 
This scenario evaluates the impact of always using the dose immediately below the 
current estimate of the target dose (as opposed to using the closest dose above or 
below). This scenario has been selected since it evaluates the recommendation 
accompanying the standalone software referred to in Section 2.4.3 and Wang et al. 
(2013). For simplicity of writing, this is referred to as “Alternative Case 1” and can 
be cross-referenced with scenario [1I] in Table 9. 
The corresponding results for 1000 simulated clinical trials are shown in Figure 33 
and show similar variability as in the “Nearest Dose” rule but larger (and negative) 
mean bias (-0.6314 compared with 0.0041). 
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Figure 33(a) Profile Plot when Dose Allocation 
Rule assigns Dose Below Current Model 
Estimate 
Figure 33(b) Distribution of Estimates at 
N=40 when Dose Allocation Rule assigns 
Dose Below Current Model Estimate 
 
 
Figure 33 Distribution of Estimates for Alternative Case 1 
Furthermore, the mean bias for all of the potential response rates, θ=0.1 to 0.9 is 
shown as the blue values in Figure 34 and demonstrates that mean bias=0 now 
occurs at θ=0.25 rather than the expected θ=0.5. 
Figure 34 (a) Bias Figure 34 (b) MSE 
 
 
Figure 34 Mean Bias and MSE for various Target Response Rates for Alternative 
Case 1 
The reason for the minimum bias occurring below the expected θ=0.5 is not fully 
clear from this single scenario but is explored further with later simulation 
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Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 40 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_AV0_16BY1_I_LE_BUN_P50_N40_50
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True Dose-Response: logistic Intermediate: Beta0=-2.9, Beta1=0.7       Implies True Gamma=4.1429 at Theta=0.5
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scenarios. One potential reason for bias is the lack of information on some doses 
below and above the true value, thus the logistic dose-response curve is poorly 
characterised. For example, Figure 35(a) shows the dose allocations for the 
equivalent simulation as that in Figure 28 and reveals that doses 3 and 4 have now 
been allocated patients. The resulting estimate of γ (shown in Figure 35(b)) is now 
much closer to the true value of 4.1429. Whitehead and Williamson (1998) 
proposed a similar explanation (i.e. lack of dose exploration) for observed bias for 
the special case of θ=0.2 and so lends further support to this explanation. 
Figure 35 (a) Dose Allocation and Outcome 
 
Figure 35 (b) Estimated versus True Dose Leading to Target Response Rate 
 
Figure 35 Summary of Dose Allocation and Outcomes for Simulation 1 for 
Alternative Case 1 
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Another potential reason for bias is model parameterisation (i.e. EWOC1 vs EWOC2) 
and this is explored further in Section 7.4.3. 
In summary, when the number of available doses is high (i.e. placebo plus 16 
discrete doses) these two scenarios (Base Case and Alternative 1) show that: 
• In the majority of simulations, the estimate stabilised to its long-term value 
by the time 20 patients had been simulated. 
• Even with 17 dose levels, simulated trials can produce estimates of γ at 
N=20 patients that are more than double the true value and still more than 
50% higher than the true value at N=40. 
• Mean bias is zero at the expected response rate θ=0.5 when the estimator 
from Equation ( 2.17 ) is used but mean bias is non-zero otherwise (bias>0 
when θ<0.25 and bias>0 when θ>0.25). 
• Bias is zero at approximately θ=0.25 i.e. away from expected value of θ=0.5 
when the dose allocation rule is amended to always allocate the dose below 
the current model estimate. 
• Approximately linear slope for the bias from 0.1 to 0.9 
In subsequent sections, the results from the full set of simulation scenarios are 
compared and contrasted with the above scenarios; firstly by considering 
convergence properties and secondly by bias and MSE. Generalisations and 
recommendations are also provided. Since the focus of this thesis is the small 
sample properties of EWOC then those results are considered first. To aid 
comparison with the literature on CRM (which is based on a 1-parameter model and 
has had more widespread implementation than EWOC), summaries of the 1-
parameter logistic model are provided in Section 7.5. Finally, so that comparisons 
can be made with the (theoretical) asymptotic results, the simulation findings for 
much larger sample sizes are described in Section  7.6. 
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7.4 Small Sample Properties of the EWOC Estimator 
The simulation results from Scenarios [1] to [17] of Table 9 produced 441 profile 
plots of the EWOC estimator from Equation ( 2.17 ) and these are available in a 
Supplementary File to this thesis. In order to make meaningful conclusions and 
generalisations, a method of classifying the convergence characteristics of the plots 
and their potential impact on clinical trial conduct is required. There appears to be 
no published criteria for such classification and so a novel classification criterion is 
required. For the current simulations, the classification criterion was determined 
using visual inspection into 1 of 5 categories. The number (i.e. 5) and plot 
characteristics were determined after seeing the results so it is recognised that 
there is an element of subjectivity to this classification scheme. Further research 
could assess if this classification scheme is robust to other simulation assumptions 
for the EWOC estimator in Equation ( 2.17 ).  
7.4.1 Classification of Convergence Properties 
The classification scheme and assignment appears in Figure 36 together with the 
frequency with which they occur. The complete set of profile plots appears in the 
Supplementary File to this thesis and may be cross-referenced using the 
identification code in final column of Figure 36.
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Category Characteristics Occurrences (Out of 441 
simulation scenarios) 
Profile Plots Assigned* 
Category (a) Realistic initial estimates, rapid convergence and low variability 
 
• Of the 5 categories, this has the most 
desirable operating characteristics 
• At first estimation (at N=9), initial 
estimates in close agreement with true 
value 
• Convergence attained by N=20 
• Example taken from scenario [5S] of 
Table 9 
43 (10%) AV0_16BY1_S_LE_BUN_10 to _90, 
AV0_16BY1_S_NR_BMVN_10 to _40, 
AV0_16BY1_S_NR_BUN_10, 
AV0_16D_S_LE_BUN_10 to _90, 
AV0_16D_S_NR_BUN_10 to _90, 
AV6_ESD_I_NR_BUN_20 to _40, 
AV6_ESD_S_NR_BUN_10 to _80 
 
Category (b): Initial divergence followed by slow convergence 
 
• At first estimation (at N=9), procedure 
recommends either escalating many 
dose levels (e.g. ≥5 in example) or 
reducing (e.g. by 2 in example) 
• Procedure starts to converge around 
N=15 but still larger variability than 
Category (a) at N=40 
• Example taken from scenario [2I] of 
Table 9 
95 (22%) AV0_16BY1_I_LE_BUN_10 to _90, 
AV0_16BY1_I_NR_BUN_10 to _90, 
AV0_16BY1_S_NR_BUN_20 to _90, 
AV0_16BY1_W_LE_BUN_10 to _90, 
AV0_16BY1_W_NR_BUN_10 to _90, 
AV0_16D_I_LE_BUN_10 to _90, 
AV0_16D_I_NR_BUN_10 to _90, 
AV0_16D_I_NR_TKIS_10, 
AV0_16D_W_LE_BUN_10 to _90, 
AV0_16D_W_NR_BUN_10 to _90, 
AV6_ESD_W_NR_BUN_10 to _50, 
AVMH_HBY1_C_NR_BUN_10 to _90 
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Category Characteristics Occurrences (Out of 441 
simulation scenarios) 
Profile Plots Assigned* 
Category (c): Approximate monotonic (slow) convergence 
 
• At first estimation (at N=9), procedure 
recommends doses considerably higher 
than true value but slowly converges by 
N=20  
• Above N=20, similar variability as 
Category (b) 
• Example taken from scenario [13I] of 
Table 9 
144 (33%) AV0_16BY1_I_LE_TUN_20 to _90, 
AV0_16BY1_I_NR_BMVN_40 to _90 
AV0_16BY1_I_NR_TKIS_10 to _80, 
AV0_16BY1_I_NR_TUN_20 to _90, 
AV0_16BY1_S_LE_TUN_50 to _90, 
AV0_16BY1_S_NR_BMVN_50 to _90, 
AV0_16BY1_S_NR_TKIS_40 to _80 
AV0_16BY1_S_NR_TUN_50 to _80, 
AV0_16BY1_W_LE_TUN_10 to _90, 
AV0_16BY1_W_NR_BMVN_10 to _90, 
AV0_16BY1_W_NR_TKIS_10 to _90, 
AV0_16BY1_W_NR_TUN_10 to _90, 
AV0_16D_I_LE_TUN_10 to _90, 
AV0_16D_I_NR_TKIS_20 to _90, 
AV0_16D_I_NR_TUN_10 to _90, 
AV0_16D_S_LE_TUN_50 to _90, 
AV0_16D_S_NR_TKIS_40 to _90, 
AV0_16D_S_NR_TUN_40 to _90, 
AV0_16D_W_NR_BVNG_10 to _90, 
AV0_16D_W_NR_TUN_70 to _90, 
AV6_ESD_W_NR_BUN_60 to _90 
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Category Characteristics Occurrences (Out of 441 
simulation scenarios) 
Profile Plots Assigned* 
Category (d): Extreme initial estimate but very rapid convergence 
 
• At first estimation (at N=9), strong 
influence of Prior that is distant from 
true value 
• Convergence to long-term value by 
N=20 with low variability 
• Example taken from scenario [4S] of 
Table 9 
111 (25%) AV0_16BY1_I_LE_BVNG_10 to _90, 
AV0_16BY1_I_NR_BVNG_10 to _90, 
AV0_16BY1_S_LE_BVNG_10 to _90, 
AV0_16BY1_S_LE_TUN_10 to _40, 
AV0_16BY1_S_NR_BVNG_10 to _90, 
AV0_16BY1_S_NR_TKIS_10 to _30 
AV0_16BY1_S_NR_TUN_10 to _40, 
AV0_16BY1_W_LE_BVNG_10 to _90, 
AV0_16BY1_W_NR_BVNG_10 to _90, 
AV0_16D_I_LE_BVNG_10 to _90, 
AV0_16D_I_NR_BVNG_10 to _90, 
AV0_16D_S_LE_BVNG_10 to _90, 
AV0_16D_S_LE_TUN_10 to _40, 
AV0_16D_S_NR_BVNG_10 to _90, 
AV0_16D_S_NR_TKIS_10 to _30, 
AV0_16D_S_NR_TUN_10 to _30 
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Category Characteristics Occurrences (Out of 441 
simulation scenarios) 
Profile Plots Assigned* 
Category (e): Non-convergence by N=40 
 
• High variability at N=20 and majority 
of estimates still above true value at 
N=40 (i.e. positive bias) 
• Example taken from scenario [15W] of 
Table 9 
48 (11%) AV0_16BY1_I_NR_BMVN_10 to _30 
AV0_16BY1_I_LE_TUN_10, 
AV0_16BY1_I_NR_TKIS_90, 
AV0_16BY1_I_NR_TUN_10, 
AV0_16BY1_S_NR_TKIS_90, 
AV0_16BY1_S_NR_TUN_90, 
AV0_16D_W_LE_BVNG_10 to _90, 
AV0_16D_W_LE_TUN_10 to _90, 
AV0_16D_W_NR_TKIS_10 to _90, 
AV0_16D_W_NR_TUN_10 to _60, 
AV6_ESD_I_NR_BUN_10 & _50 to _90, 
AV6_ESD_S_NR_BUN_90 
* KEY (See Supplementary File for 441 profile plots with footnotes containing following codes):   
 AV0_16BY1 = Available doses {0 to 16 by 1} _I_ = Intermediate dose-response 
 AV0_16D = Available doses {0, 1, 2, 4, 8, 16} _S_= Steep dose-response 
 AV6_ESD = Available doses {0, 3, 6, 9, 13, 16} _W_ = shallow dose-response 
 AVMH_H = Available doses {-100 to 100} 
 
 _LE_ = Dose allocation rule “less than” _BMVN_ = EWOC1, Multivariate Normal  Priors 
 _NR_ = Dose allocation rule “nearest” _BUN_ = EWOC1, Uniform Priors 
  _BVNG = EWOC1, Normal-Gamma Priors 
  _TKIS = EWOC2, Beta-Normal Priors 
  _TUN_ = EWOC2, Uniform Priors 
 _10_90 = Target θ (e.g. 10 to 90) 
Figure 36 Small Sample Convergence Properties of the EWOC Estimator 
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In addition to the general observations made in Figure 36, it is possible to also use 
the full results in the Supplementary File to make some further observations and 
recommendations for the design and conduct of clinical trials: 
• The 43 scenarios classified as Category (a) (which has the desirable 
properties of accurate estimation and small variation) tended to occur when 
the first 9 patients (upon which the initial estimation was based) agreed 
closely with the true value. The implication being that if a trial assigns 
starting doses close to the expected target dose then the EWOC design will 
rapidly converge to the true value. It is recognised that this is not always 
possible, for example, in entry-into-human trials when starting doses are 
often the lowest possible doses for reasons of patient safety. However, in the 
situation of the kisspeptin trial in which volunteers had already been dosed, 
it may be possible to start the trial with doses closer to the expected target. 
• The 48 scenarios with non-convergence at N=40 patients (i.e. in Category 
(e)) were associated with flat sections of the dose-response curve (e.g. θ=0.1 
or 0.9) and/or in parts of the dose-response curve where the available doses 
had poor coverage. This highlights the importance of making realistic 
assessments of the dose response curve before the trial starts and using 
doses that span the target response rates. 
• None of the 162 EWOC2 parameterisation scenarios was classified into 
Category (a) and just 1 into Category (b). Furthermore, EWOC2 with Uniform 
Priors was classified as Category (d) (i.e. high initial estimates) 15 times but 
not once for EWOC1 with Uniform Priors. This suggests that the EWOC2 
parameterisation may induce increased variability for the first dose escalation 
but rapidly converges to the true value, whereas the EWOC1 parameterisation 
may induce highly variable dose escalations for approximately the first 5 
dose escalation decisions before starting to converge to the true value. With 
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more informative priors (i.e. Normal-Gamma) the EWOC1 parameterisation  
converges quicker than with Uniform Priors (see Supplementary File, 
Category (d)). Hence for the design of future clinical trials with little prior 
information, if it is acceptable to assign very high doses at the first dose 
escalation on the understanding that subsequent convergence will be quick 
then use of the EWOC2 parameterisation may be attractive. 
• Since 89% of the simulation scenarios attained convergence by N=40 then 
the EWOC design (with either EWOC1 or EWOC2 parameterisation) is an 
attractive design to identify a dose with a target response rate across the 
range 0.1 to 0.9. Furthermore, 69% of the simulation scenarios had 
converged to the true value by N=20. 
7.4.2 Other Notable Convergence Features  
In addition to the general groupings shown in Figure 36, a number of other features 
were identified from the profile plots that warrant discussion. 
• Outlying estimates 
• Multi-modal distribution of estimates 
• Estimates Beyond the Range of Available Doses 
• Dose Spacing 
A number of these features were seen when the target response rate, θ, was low 
(e.g. θ=0.1 or θ=0.9) suggesting that behaviour of the estimator could be 
unpredictable on the flat section of the dose-response curve. Specific examples of 
these occurrences appear in the following sections. 
7.4.2.1 Outlying Estimates 
The term outlying is used here to refer to the phenomenon whereby the estimates 
were largely stable with increasing sample size but occasional examples of a 
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simulated trial in which the estimate diverges before returning to its long-term 
value. An example of this behaviour occurred in the EWOC2 scenario (see Table 9 
scenario [17I]) with strongly informative priors that were distant from the true value 
of γ. In this scenario, the response rate was θ=0.1 which meant a true value of 
γ=1.004 but the highly informative priors were centred at γ=10.5.  This scenario 
appears in Figure 37(a) and, to aid comparison, the results from the equivalent 
scenario with independent Uniform priors (i.e. Table 9 scenario [16I]) are shown in 
Figure 37(b). 
Figure 37(a) Profile Plot for Informative Priors Figure 37(b) Profile Plot for Independent Uniform Priors 
  
Figure 37 Profile Plot Demonstrating Outlying Estimates 
Further investigation of the SAS output files that contained listings of every MCMC 
simulation (available upon request but not included as an appendix due to 
containing more than 5 million pages), revealed that these outlying estimates 
corresponded to situations in which MCMC convergence was not attained. This is 
discussed further in Section 7.7 but in brief, had this occurred during the conduct 
of a real clinical trial it would have been possible to tune the MCMC parameters to 
obtain convergence to the stationary distribution. As an aside, tuning is the process 
whereby parameters of the proposal distribution for the MCMC algorithm are 
adjusted to improve the efficiency of the convergence to the target (stationary) 
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distribution (Chib & Greenberg, 1995). In the above specific situation, the general 
performance of the EWOC estimator can be observed by ignoring the outlying 
estimates that occur in only 1 in 1000 iterations for each dose escalation decision. 
7.4.2.2 Multi-modal Distribution of Estimates 
The profile plot in Figure 38(a) and (b) shows an example where the mean and 
median estimates of γ at N=40 are close to the true value (i.e. small bias) but it is 
evident that the distribution is not unimodal. Hence, for any specific real clinical 
trial, the investigator will not know if the obtained estimate is close to the real 
value. These results were generated from scenario [6W] in Table 9 for which doses 
available were the doubling-doses {0, 1, 2, 4, 8, 16} so to aid comparison with the 
situation when many more doses are available, Figure 38(c) and (d) show the 
unimodal distribution for the scenario when available doses are {0 to 16 by 1} i.e. 
scenario [1W] in Table 9. 
 Figure 38(a) Profile Plot for 6 Doubling 
Doses when Dose Allocation Rule assigns 
Dose Below Current Model Estimate 
Figure 38(b) Distribution of Esimates at N=40 
for 6 Doubling Doses when Dose Allocation 
Rule assigns Dose Below Current Model 
Estimate  
  
  
P50 Posterior Estimates of Target Dose for Response Rate Theta=0.9
1000 Simulated Trials (using doses {0,1,2,4,8,16} Maximum N=40 each trial)
Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 40 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_AV0_16D_W_LE_BUN_P50_N40_90
Dose Allocation rule: Gamma >= DOSE
True Dose-Response: logistic Shallow: Beta0=-11.6, Beta1=1.4           Implies True Gamma=9.8552 at Theta=0.9
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 Figure 38(c) Profile Plot for Available 
Doses {0 to 16 by 1} when Dose Allocation 
Rule assigns Dose Below Current Model 
Estimate  
Figure 38(d) Distribution of Esimates at 
N=40 for Available Doses {0 to 16 by 1} when 
Dose Allocation Rule assigns Dose Below 
Current Model Estimate  
  
Figure 38 Profile Plot showing Multi-modal Estimates 
The explanation for the multi-model/outlying profiles is a (simulated) early 
response on a dose considerably below the true value, which then leads to very slow 
convergence to the true value because subsequent patients are rarely allocated 
much higher doses (since there are large gaps between the available doses). This 
phenomenon is most easily illustrated by focussing on the profile in Figure 38(a) in 
which the estimates of γ are approximately 4 for patients 10 to 18; this 
corresponds to simulation number 556 (of 1000). In this simulation (data not 
shown), there were no responses in the first 9 patients (allocated doses 0, 1 and 2) 
so the model provided an estimate of γ=6.3881 and thus patient=10 was allocated 
dose=4 (since the allocation rule always allocated the next lowest available dose). 
Patient=10 had a response so the new model estimate was γ=3.8576 and thus 
patient=11 was allocated dose=2 (considerably below the true dose=9.8552). At 
this point, the Likelihood for the model consisted of data from 11 patients and thus 
each additional patient contributed relatively little to the posterior and the next six 
patients all received dose=2 (since the six estimates of γ were all below 4). By N=40 
patients there were no further responders and the estimate of γ was 7.4561, still 
P50 Posterior Estimates of Target Dose for Response Rate Theta=0.9
1000 Simulated Trials (using doses {0 to 16 by 1} Maximum N=40 each trial)
Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 40 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_AV0_16BY1_W_LE_BUN_P50_N40_90
Dose Allocation rule: Gamma >= DOSE
True Dose-Response: logistic Shallow: Beta0=-11.6, Beta1=1.4           Implies True Gamma=9.8552 at Theta=0.9
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considerably below the true dose=9.8552. This behaviour can be extended to other 
profiles in Figure 38(a) in which a response occurred for N<15 and convergence 
was slow thereafter. 
The choice of dose levels and number of doses is thus a key aspect at the study 
design stage so simulations should be performed to evaluate the impact of the true 
(but unknown) target dose lying between doses to be tested in the clinical trial. In 
general, when designing a new trial it may not be practical to inspect distributions 
of parameter estimates from a large number of simulated study designs, however, it 
would be more practical to compare Mean Square Errors (MSE) from the simulated 
designs and those with large MSE may have a multi-modal distribution. Further 
discussion of bias and MSE appears in Section 7.4.3. 
7.4.2.3 Estimates Beyond the Range of Available Doses 
With the EWOC1 and 1-parameter formulation of the logistic model, the target 
dose, γ, is estimated by deriving it from the model parameters 𝛽0 and 𝛽1 (or just 𝛽1 
for the 1-parameter model) so it is possible to obtain values of γ outside the 
available dose range and the profile plot for one such scenario appears in Figure 39 
and relates to the scenario from Table 9 scenario [2I] at response rate, θ=0.1. 
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Figure 39 Profile Plot showing estimates outside available Dose Range 
Although it may appear counter-intuitive to have negative estimates of γ from the 
model fit (i.e. doses<0 predicted to lead to a response rate of 0.1), it occurs 
because the EWOC1 model parameterisation is fitting 𝛽0 and 𝛽1 as the 2 model 
parameters [with independent (bounded) Uniform priors 𝛽0 ~Un(-16,16) and 𝛽1 
~Un(0.01,5)] and then estimating γ from the (unbounded) posterior joint 
distribution. Within an MCMC approach, γ is calculated during each iteration by 
taking current estimates of 𝛽0 and 𝛽1 and then inverting Equation ( 2.9 ). Negative 
values of γ can occur under two circumstances: 
if β1>0 then β0 > -{logit (θ)} 
or if β1<0 then β0 < logit (θ) 
Although this may be rare in a general dose-response situation (in which the slope 
parameter β1 is positive), there may be situations when estimating low response 
rates (e.g. θ=0.1) the posterior median is negative. Whitehead and Williamson 
(1998) provide guidance on what investigators could do if negative estimates of the 
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slope parameter were produced in a real trial, for example, implement an ad hoc 
rule for defining the next dose until the procedure produced positive estimates 
again. 
Note that in the current simulations, the dose to be allocated to the next patient 
would be zero. If further responses are observed on the lowest available dose (e.g. 
0 in the above scenario) then the model may again recommend allocating a negative 
dose to the subsequent patient. However, since there is no lower dose available 
then the next patient will be allocated zero dose (again). If that patient responds on 
zero dose then the model will continue to recommend negative doses as being the 
Target Dose. If this phenomenon occurs when the likelihood dominates the prior 
(e.g. 20 patients in previous scenarios) then it would require a further set of non-
responders for EWOC1 to recommend positive doses again. 
Although negative estimates of γ were rare (data not shown), an advantage of the 
EWOC2 parameterisation over EWOC1 is that γ (and the other parameter, 𝜌0) are 
modelled directly in EWOC2 and so bounds can be placed on their distributions.  
7.4.2.4 Effects of Dose Spacing 
As described in Section 6.3, it may be more usual to have a small number of 
available doses in a clinical trial (e.g. 6 doses) so it is important to know if the 
earlier findings using doubling doses {0, 1, 2, 4, 8, 16} are consistent for alternative 
dose values and so the scenario with 6 approximately equally spaced dose levels of 
{0, 3, 6, 9, 13, 16} were performed (see Table 9 row [11]). Although the dose 
spacing made little difference for the Steep dose-response curve (i.e. when both 
sets of dose spacing covered the target dose range) there was much higher 
variability for the doubling dose scenarios for the Shallow and Intermediate dose-
response curves (i.e. where the doubling doses had poor coverage of the upper part 
of the dose response curve, Figure 22). For example, when response rate, θ=0.5 
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and the Intermediate dose-response curve was simulated, the distribution of 
estimates of γ at N=40 had s.d.=0.5404 for the doubling-doses scenario compared 
with s.d.=0.1294 for the equally-spaced scenario (reproduced in Figure 40 below). 
However, mean bias was smaller for the doubling-doses scenario (mean 
bias= -0.078 versus -0.8553 for the equally spaced scenario), which represents the 
potential trade-offs that need to be made at trial design stage (smaller bias and 
larger variability versus larger bias but smaller variability). 
Figure 40(a) Profile Plot for 6 Doubling Doses  
{0,1,2,4,8,16} when Response Rate, θ=0.5 
Figure 40 (b) Distribution of Esimates at 
N=40 for 6 Doubling Doses {0,1,2,4,8,16} 
when Response Rate, θ=0.5 
  
  
Figure 40(c) Profile Plot for 6 Equally Spaced 
Doses  {0,3,6,9,13,16} when Response Rate, 
θ=0.5 
Figure 40 (d) Distribution of Esimates at 
N=40 for 6 Equally Spaced Doses 
{0,3,6,9,13,16} when Response Rate, θ=0.5 
 
 
Figure 40 Profile Plots to Compare Performance with Different Dose Values  
P50 Posterior Estimates of Target Dose for Response Rate Theta=0.5
1000 Simulated Trials (using doses {0,1,2,4,8,16} Maximum N=40 each trial)
Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 40 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_AV0_16D_I_NR_BUN_P50_N40_50
Dose Allocation rule: Gamma Nearest DOSE
True Dose-Response: logistic Intermediate: Beta0=-2.9, Beta1=0.7       Implies True Gamma=4.1429 at Theta=0.5
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P50 Posterior Estimates of Target Dose for Response Rate Theta=0.5
1000 Simulated Trials (using doses {0,3,6,9,13,16} Maximum N=40 each trial)
Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 40 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_AV6_ESD_I_NR_BUN_P50_N40_50
Dose Allocation rule: Gamma Nearest DOSE
True Dose-Response: logistic Intermediate: Beta0=-2.9, Beta1=0.7       Implies True Gamma=4.1429 at Theta=0.5
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Although the rate of convergence to the true value is an important study design 
characteristic, it is also relevant to quantify how accurate are the estimates at the 
end of the trial since these are the estimates likely to be quoted in study reports 
and publications. The accuracy of the estimates from the simulations has been 
quantified in terms of bias and MSE and N=40 patients which are typical of Phase 1 
and 2 trial sizes. 
7.4.3 Small Sample Accuracy Properties of the EWOC Estimator 
As discussed in Section 6.7.1, bias and MSE are frequently used to assess 
performance of estimators from simulations and Figure 41 provides a summary of 
bias in graphical form for the scenarios in Table 9 (the full numerical results appear 
in Appendix D). As an aid to interpretation of Figure 41, row numbers correspond 
to the same row numbers as in Table 9, so for example, row 2 with the Intermediate 
column represents the Base Case scenario [2I] in which the EWOC1 parameterisation 
was used with Uniform priors and doses {0 to 16 by 1} to estimate the Intermediate 
dose-response curve for which the next patient was allocated the dose nearest to 
the current model estimate. 
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NOTE: See Table 9 for explanation of scenarios 
Figure 41 Bias of the EWOC Estimator 
By comparing the scenarios represented by Row=1 to 11 with Row=12 to 17 in 
Figure 41 reveals a key finding from these simulations that the EWOC model 
formulation plays an important role in minimising bias. For example, decreasing 
bias (positive to negative) with increasing θ, is most evident in the Intermediate 
dose-response curves for Row=1 to 11 (which corresponds to EWOC1 
parameterisation) but such bias is heavily reduced in the corresponding scenarios in 
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Row=12 to 17 (which corresponds to EWOC2 parameterisation). For example, the 
difference between Row=2 and Row=13 is purely EWOC1 versus EWOC2 
parameterisation, respectively. That this applies across a range of response rates 
(i.e. θ=0.1 to 0.9) appears to be a novel finding. Chu et al. (2009) had previously 
only documented this finding for the specific case of θ=0.33 in relation to 
simulations analogous to Phase 1 oncology trials. 
Taking this simulation accuracy finding with the intuitive understanding of the 
EWOC2 parameters (e.g. from the findings in the kisspeptin elicitation, Section 5.5.2 
and Figure 8), I recommend that the EWOC2 parameterisation is the initial 
parameterisation to use when designing a trial with informative priors and the 
EWOC design. Once priors have been elicited with the EWOC2 parameterisation, 
simulations could also be performed using the EWOC1 parameterisation to assess 
the impact of re-parameterisation. 
In general, (and extending the initial findings from Section 7.3), scenarios in which 
the dose allocation rule always uses the dose immediately below the current 
estimate of the target dose (as opposed to using the closest dose above or below) 
produces mean bias of zero away from the expected response rate θ=0.5. Although 
small in absolute size, the bias was largest for the Intermediate dose-response 
curve (see Intermediate dose-response scenarios for rows [1], [3], [6], and [8] in 
Figure 41). An obvious exception to this is the mean bias from the equally spaced 
scenario in row [11] which corresponds to the scenario already discussed in Figure 
40(c) and (d). In this scenario, precise estimates are obtained but they are biased 
downwards for values of θ>0.3. It can be seen from Figure 22 that for values of θ 
between 0.4 and 0.7 the Intermediate dose-response curve has no available dose 
levels to allocate and this may be a reason for the observed bias. 
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The importance of choosing the dose levels to evaluate in a trial is further 
demonstrated for the EWOC2 parameterisation when doubling-doses are used (i.e. 
Shallow dose-response curve, rows [15], [16] and [17] in Table 9). Compared with 
the Intermediate and Steep dose-response curves, there is larger mean bias for the 
Shallow dose-response curve for θ>0.3 and, again by inspecting Figure 22, this 
corresponds to the region of the dose-response curve with at most 1 dose level. 
Estimators that produce unbiased estimates may be of little value if they are 
produced with large variability (Burton et al., 2006) so evaluation of both 
standardised bias and MSE may provide additional insights into the performance of 
the EWOC estimator from Equation ( 2.17 ). Figure 42 shows the standardised bias 
in graphical form and may be compared with the equivalent (unstandardised) bias 
from Figure 41 (the full numerical results appear in Appendix D, together with plots 
of MSE that support the findings from bias and standardised bias measures). 
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NOTE: See Table 9 for explanation of scenarios 
Figure 42 Standardised Bias of the EWOC Estimator 
In many of the scenarios, the standardised bias measure more easily reveals the 
larger variability compared with (unstandardised) bias. For example, inspecting the 
three scenarios in row [11] of Figure 41 and Figure 42 the variability for the 
Intermediate and Steep dose-response scenarios is more easily seen with the 
standardised bias. Furthermore, for the specific case of θ=0.6 for the Intermediate 
dose-response curve (i.e. scenario [11I] of Table 9), the large negative standardised 
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bias is more evident in Figure 42 (since it is below the y-axis range, standardised 
bias=-661) than the unstandardised bias in Figure 41. Moreover, this is the same 
scenario that was already presented in Figure 40(c) and (d) where, arguably, the 
lower variability was evident but the bias was less easy to identify. The use of 
standardised bias thus provides a valuable metric to identify study design scenarios 
with low variability but larger absolute bias. 
The same data as shown in Figure 42 are provided in tabular form in Table 12 such 
that values outside the ±40% rule-of-thumb of Collins et al. (2001) appear in red 
cells.
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Table 12 Standardised Bias of the EWOC Estimator for Small Simulated Trials (N=40) 
 Shallow Intermediate Steep 
 Response rate, θ Response rate, θ Response rate, θ 
Scenario* 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[1] -26 -23 -17 -13 -8 3 7 2 12 94 30 -29 -61 -87 -106 -128 -138 -143 18 14 -12 -40 -71 -73 -67 -80 -130 
[2] -20 -14 -7 -10 3 0 2 4 11 162 126 73 31 1 -13 -36 -54 -59 40 26 30 31 7 -8 -13 -12 -18 
[3] -18 -9 8 3 21 21 23 27 26 60 35 -7 -47 -64 -81 -89 -86 -93 21 27 24 -8 -38 -41 -33 -23 -30 
[4] -24 -12 -8 -4 9 9 9 13 19 91 92 67 41 21 8 -8 -16 -30 17 3 0 7 12 10 7 8 6 
[5] -47 -10 -8 -4 -1 0 4 17 14 137 149 132 98 53 2 -28 -47 -72 30 22 21 29 33 48 60 77 52 
[6] -38 -52 -70 -73 -73 -66 -57 -49 -40 73 20 -54 -91 -121 -167 -198 -233 -294 21 23 18 6 -13 -17 -44 -65 -126 
[7] -98 -87 -40 -5 13 30 50 63 83 159 89 40 22 -14 -66 -126 -122 -107 39 21 -3 2 10 19 22 14 -22 
[8] -17 -36 -52 -63 -50 -20 -5 11 65 -3 30 -16 -65 -109 -130 -151 -160 -195 25 58 84 102 116 142 160 56 -32 
[9] -171 -71 -25 13 52 78 116 147 215 101 92 49 26 4 -22 -54 -50 -64 44 43 26 -7 -12 -15 -7 -5 -14 
[10] 39 29 12 10 1 -2 -11 -21 -28 73 57 39 19 3 -13 -31 -55 -72 8 6 9 -1 -2 -2 12 -1 -6 
[11] 27 -19 -37 -32 -26 -15 -3 6 28 1187 510 45 -338 -661 -1024 -1310 -1640 -356 315 291 249 240 221 199 186 104 50 
[12] -9 29 55 73 79 91 96 93 87 130 55 31 23 18 19 21 19 28 27 97 124 86 64 88 129 185 103 
[13] -45 -32 -20 -9 -4 8 10 22 39 123 56 34 22 26 29 19 19 32 -11 -29 -51 -26 7 42 51 34 55 
[14] -203 -25 -12 -1 -3 7 18 28 49 35 44 30 25 35 35 45 43 58 -33 -38 -57 -33 4 40 59 68 1771 
[15] 11 23 40 62 107 183 279 404 818 130 87 87 53 39 48 60 77 39 51 166 313 330 548 489 459 466 83 
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 Shallow Intermediate Steep 
 Response rate, θ Response rate, θ Response rate, θ 
Scenario* 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[16] 
-183 -148 -37 46 122 214 341 460 650 120 56 21 31 43 43 33 17 17 39 106 132 105 -13 
-
106 -84 -22 58 
[17] 
-207 7 39 114 202 323 541 766 967 37 54 29 41 72 85 88 46 42 13 109 154 100 -33 
-
135 -82 25 413 
[18] -159 15 40 65 76 94 106 94 89 83 19 -2 -3 -3 -1 4 -2 1 12 53 109 104 78 94 140 189 122 
[19] -47 -43 -19 -18 3 2 19 23 44 63 18 8 7 5 4 4 -2 6 -70 -42 -67 -39 -3 40 54 21 27 
 * See Table 9 
NOTE: each cell shows mean standardised bias (%) generated from 1000 simulated trials of size N=40 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
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Of the three dose-response models considered in this extensive simulation study, 
the application of colour coding to the scenarios in Table 12 elegantly reveals that 
one can always find study design assumptions leading to large mean standardised 
bias for trials of 40 patients. Thus, for researchers designing new trials, it is vitally 
important to use simulation to study specific trial design parameters that are likely 
to reflect the conditions of the planned trial. 
Furthermore, by comparing the results for row [10] of Table 12 (based on N=40) 
with those in Table 17 (based on N=150) reveals very similar qualitative conclusions 
and further supports the evidence that the EWOC estimator has reached its 
asymptotic properties by the time 40 patients have been recruited. That this applies 
across a wide range of response probabilities (θ=0.1 to 0.9) appears not to have 
been published previously. 
To assess if these estimates had stabilised before 40 patients, a subset of Table 12 
for the first 5 scenarios was considered for N=10, 20, 30 and 40 patients and is 
presented in Table 13. In nearly every scenario, the standardised bias at N=20 was 
similar to that at N=40 (i.e. standardised bias within ±40% at N=20 remained within 
±40% and vice-versa).
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Table 13 Standardised Bias of the EWOC Estimator for Very Small Sample Sizes 
 Shallow Intermediate Steep 
 Response rate, θ Response rate, θ Response rate, θ 
Scen
ario* 
N 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[1] 10 -138 -198 -62 92 219 245 219 170 216 190 135 102 72 52 39 24 7 -20 69 55 49 63 89 96 65 104 1295 
 20 -30 -21 -18 -18 -15 -6 3 4 11 159 80 20 -13 -42 -67 -89 -105 -121 52 53 15 -9 -25 -31 -40 -41 -60 
 30 -24 -25 -12 -14 -12 -1 4 4 15 117 49 -9 -44 -72 -93 -115 -128 -138 30 22 -1 -29 -53 -60 -57 -68 -103 
 40 -26 -23 -17 -13 -8 3 7 2 12 94 30 -29 -61 -87 -106 -128 -138 -143 18 14 -12 -40 -71 -73 -67 -80 -130 
[2] 10 -235 47 227 240 196 143 215 252 145 181 111 78 67 52 33 11 -5 -19 64 69 89 89 93 122 1011 1445 556 
 20 -22 -17 -15 -9 3 -1 5 7 12 220 136 81 44 13 -1 -31 -53 -69 61 35 26 26 16 12 8 -4 -12 
 30 -27 -15 -7 -12 -1 1 6 7 13 188 136 78 36 5 -8 -36 -55 -65 50 28 26 28 9 -1 -4 -9 -17 
 40 -20 -14 -7 -10 3 0 2 4 11 162 126 73 31 1 -13 -36 -54 -59 40 26 30 31 7 -8 -13 -12 -18 
[3] 10 -
1716 -1314 -1085 -935 -808 -708 -615 -517 -395 3648 3002 2616 2339 2071 1845 1622 1365 1020 2599 2764 2827 2875 2865 2878 2895 2899 2890 
 20 -29 -12 -6 6 14 12 22 27 32 121 87 42 4 -17 -38 -46 -49 -71 47 29 32 22 5 -2 -3 -1 -2 
 30 -24 -8 3 5 19 11 22 29 28 79 54 11 -29 -48 -67 -73 -74 -88 30 24 27 6 -20 -29 -24 -19 -21 
 40 -18 -9 8 3 21 21 23 27 26 60 35 -7 -47 -64 -81 -89 -86 -93 21 27 24 -8 -38 -41 -33 -23 -30 
[4] 10 -
1716 -1314 -1085 -935 -808 -708 -615 -517 -395 3648 86 2616 68 2071 1845 1622 1365 1020 2599 2764 2827 2875 2865 2878 2895 2899 2890 
 20 -28 -12 -9 -4 9 13 17 19 40 167 123 88 56 36 21 -2 -10 -39 32 20 15 23 26 28 21 22 -3 
 30 -29 -11 -13 -6 8 11 11 17 23 117 105 75 46 26 13 -5 -13 -32 24 5 8 12 17 15 12 14 11 
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 Shallow Intermediate Steep 
 Response rate, θ Response rate, θ Response rate, θ 
Scen
ario* 
N 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
 40 -24 -12 -8 -4 9 9 9 13 19 91 92 67 41 21 8 -8 -16 -30 17 3 0 7 12 10 7 8 6 
[5] 10 -
3469 -3835 -752 
-
1588 
-
1178 
-
1177 -968 -207 -164 435 285 196 139 85 43 -4 -30 -88 292 291 405 1279 806 631 901 1358 4743 
 20 -249 -44 -12 -10 -4 4 10 13 18 222 187 144 103 58 10 -19 -41 -81 50 50 59 71 74 95 103 113 208 
 30 -104 -17 -10 -5 -3 -1 8 12 16 165 168 141 101 55 6 -24 -43 -74 32 29 31 42 46 60 72 79 68 
 40 -47 -10 -8 -4 -1 0 4 17 14 137 149 132 98 53 2 -28 -47 -72 30 22 21 29 33 48 60 77 52 
 
* See Table 9 
NOTE: each cell shows mean standardised bias (%) generated from 1000 simulated trials of size N=40 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
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To assist future researchers reducing the number of design parameters to vary, it is 
possible to compare specific subsets of scenarios from Table 12 and assess the 
impact of the differences within the subset. This section continues by describing 
the following changes in trial design parameters: 
• Impact of choice of prior distributions 
• Impact of number of doses and dose levels 
• Impact of dose allocation rule (allocate lowest or nearest dose) 
7.4.4 Impact of Prior Distributions 
By considering only those scenarios from Table 12 in which the available doses 
were {0 to 16 by 1} and the dose allocation rule was to allocate the dose nearest to 
the current model estimate then the impact of the prior distributions can be 
compared between the EWOC1 and EWOC2 parameterisations of the 2-parameter 
Bayesian logistic model and the 1-parameter logistic. These results are shown in 
Table 14. 
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Table 14 Impact of Priors on the EWOC Estimator for Small Simulated Trials (N=40) 
 
Standardised Bias (%) 
Shallow Intermediate Steep 
Response rate, θ Response rate, θ Response rate, θ 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Scen
ario* 
Paramete
risation 
Prior distribution(s) 
-20 -14 -7 -10 3 0 2 4 11 162 126 73 31 1 -13 -36 -54 -59 40 26 30 31 7 -8 -13 -12 -18 [2] EWOC1 Prior for 𝛽0 ~Un(-16,16), 𝛽1 ~Un(0.01,5) 
[4] EWOC1 
Prior for 𝛽0 ~Normal(-6,var=50), 
𝛽1 ~Gamma(shape=3/10,scale=10/3) 
-24 -12 -8 -4 9 9 9 13 19 91 92 67 41 21 8 -8 -16 -30 17 3 0 7 12 10 7 8 6 
[5] EWOC1 
Prior for 𝛽0, 𝛽1 ~MVNormal(-6 1, var=50 
-12 -12 3.3) 
-47 -10 -8 -4 -1 0 4 17 14 137 149 132 98 53 2 -28 -47 -72 30 22 21 29 33 48 60 77 52 
[13] EWOC2 
Prior for 𝜌0 ~Un(0,Response Rate), 
 γ ~Un(0,20) 
-45 -32 -20 -9 -4 8 10 22 39 123 56 34 22 26 29 19 19 32 -11 -29 -51 -26 7 42 51 34 55 
[14] EWOC2 
Prior for 𝜌0 ~Beta(3.6,8.69), 
 γ ~Normal(10.5,sd=3.9) 
-203 -25 -12 -1 -3 7 18 28 49 35 44 30 25 35 35 45 43 58 -33 -38 -57 -33 4 40 59 68 1771 
[19] 
1-
parameter 
logistic 
𝛽0=-3, Prior for 𝛽1 ~Un(0.01,5) -47 -43 -19 -18 3 2 19 23 44 63 18 8 7 5 4 4 -2 6 -70 -42 -67 -39 -3 40 54 21 27 
 * See Table 9 
NOTE: each cell shows mean standardised bias (%) generated from 1000 simulated trials of size N=40 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
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When considering response rates, θ=0.5 and 0.6, mean standardised bias was 
always less than 55% thus providing evidence that the impact of the choice of priors 
was negligible by the time 40 patients had been recruited. For responses rates on 
or near the plateau of the dose-response curve (e.g. θ=0.1 for the Intermediate 
dose-response curves, see Figure 22) the standardised bias was generally 
unacceptably high (>60% for 5 of the 6 scenarios) suggesting that study design 
factors other than solely choice of prior should be considered to improve estimation 
for response rates on or near the plateau. 
Although the qualitative conclusions were similar when treating the 2 parameters as 
independent (scenario [4]) versus correlated (scenario [5]) for N=40 (Table 14), 
there were some qualitative differences with smaller sample sizes (Table 13). For 
example, for both the Intermediate and Steep dose-response scenario when 
response rates ≥0.8, the standardised bias remained >40% for N=10, 20, 30 and 
40 for the correlated priors scenario but dropped below 40% for the independent 
priors scenario by N=20. The exact reason for this is unclear since negative 
correlation of the two parameters of a logistic model is expected (Bedrick et al., 
1996) so one might have expected more accurate results with smaller sample sizes 
when this negative correlation was incorporated. A potential reason is that the 
correlation used in this simulation study (i.e. -0.9) was incorrectly specified (i.e. too 
strongly negative) and there is some evidence for this explanation based on the 
following example scenario. By considering scenario [2] of Table 14 (i.e. Uniform 
priors), the scatterplot of posterior estimates of  𝛽0 versus 𝛽1 in Figure 43 shows the 
negative correlation across the range of response rates, θ, at N=40 with Pearson 
correlation coefficients for these 9 scenarios ranging from -0.66 to -0.91. 
Furthermore, the standardised bias was minimised for the Multivariate Normal prior 
scenario when θ=0.6 (Table 14) for which the observed Pearson correlation 
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was -0.69 and so further simulations with alternative correlation structures would 
be useful. 
 
Figure 43 Scatterplot of Posterior Estimates for the Intermediate Dose Response 
Scenario 
The highest mean standardised bias (1771%) occurred in the scenario with a highly 
informative prior which was well away from the true value (scenario [14], the Steep 
dose-response curve when estimating θ=0.9, see also Figure 22). The true value of 
dose, γ=3.8789, but the informative prior was centred on dose=10.5 (which is 
closer to the Shallow scenario). The profile plot corresponding to this highly biased 
scenario is shown in Figure 44 and clearly shows that the prior is having a strong 
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influence and convergence to the true value is slow. Simulations for a much larger 
number of patients could be performed but are likely to show that the impact of the 
incorrectly specified informative prior would be minimal beyond 60 patients. 
 
Figure 44 Profile Plot Showing Impact of Incorrectly Specified Informative Prior 
7.4.5 Impact of Number of Doses and Dose Levels 
By considering only those scenarios from Table 12 in which the available doses 
were {0 to 16 by 1}, {0, 1, 2, 4, 8, 16} or {0, 3, 6, 9, 13, 16} and the dose allocation 
rule was to allocate the dose nearest to the current model estimate then the impact 
of the number of dose levels and values of dose can be compared between the 
EWOC1 and EWOC2 parameterisations of the 2-parameter Bayesian logistic model. 
These results are shown in Table 15. 
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Table 15 Impact of Dose Levels on the EWOC Estimator for Small Simulated Trials (N=40) 
 
Standardised Bias (%) 
Shallow Intermediate Steep 
Response rate, θ Response rate, θ Response rate, θ 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Scen
ario* 
Paramete
risation 
Prior distribution(s) Available 
Doses 
-20 -14 -7 -10 3 0 2 4 11 162 126 73 31 1 -13 -36 -54 -59 40 26 30 31 7 -8 -13 -12 -18 
[2] EWOC1 
Prior for 𝛽0 ~Un(-16,16), 
 𝛽1 ~Un(0.01,5) 
{0 to 16 
by 1} 
[7] EWOC1 Prior for 𝛽0 ~Un(-16,16),  
𝛽1 ~Un(0.01,5) 
{0, 1, 2, 4, 
8, 16} -98 -87 -40 -5 13 30 50 63 83 159 89 40 22 -14 -66 -126 -122 -107 39 21 -3 2 10 19 22 14 -22 
[11] EWOC1 Prior for 𝛽0 ~Un(-16,16),  
𝛽1 ~Un(0.01,5) 
{0, 3, 6, 9, 
13, 16} 27 -19 -37 -32 -26 -15 -3 6 28 
118
7 510 45 -338 -661 
-
102
4 
-
131
0 
-
164
0 
-356 315 291 249 240 221 199 186 104 50 
[4] EWOC1 
Prior for 𝛽0 ~Normal(-6,var=50), 
𝛽1 ~Gamma(shape=3/10, 
scale=10/3) 
{0 to 16 
by 1} -24 -12 -8 -4 9 9 9 13 19 91 92 67 41 21 8 -8 -16 -30 17 3 0 7 12 10 7 8 6 
[9] EWOC1 
Prior for 𝛽0 ~Normal(-6,var=50), 
𝛽1 ~Gamma(shape=3/10, 
scale=10/3) 
{0, 1, 2, 4, 
8, 16} 
-171 -71 -25 13 52 78 116 147 215 101 92 49 26 4 -22 -54 -50 -64 44 43 26 -7 -12 -15 -7 -5 -14 
[13] EWOC2 
Prior for 𝜌0 ~Un(0,Response 
Rate), γ ~Un(0,20) 
{0 to 16 
by 1} 
-45 -32 -20 -9 -4 8 10 22 39 123 56 34 22 26 29 19 19 32 -11 -29 -51 -26 7 42 51 34 55 
[16] EWOC2 
Prior for 𝜌0 ~Un(0,Response 
Rate), γ ~Un(0,20) 
{0, 1, 2, 4, 
8, 16} 
-183 -148 -37 46 122 214 341 460 650 120 56 21 31 43 43 33 17 17 39 106 132 105 -13 -106 -84 -22 58 
[14] EWOC2 
Prior for 𝜌0 ~Beta(3.6,8.69),  
γ ~Normal(10.5,sd=3.9) 
{0 to 16 
by 1} 
-203 -25 -12 -1 -3 7 18 28 49 35 44 30 25 35 35 45 43 58 -33 -38 -57 -33 4 40 59 68 
177
1 
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Standardised Bias (%) 
Shallow Intermediate Steep 
Response rate, θ Response rate, θ Response rate, θ 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[17] EWOC2 Prior for 𝜌0 ~Beta(3.6,8.69),  γ ~Normal(10.5,sd=3.9) 
{0, 1, 2, 4, 
8, 16} -207 7 39 114 202 323 541 766 967 37 54 29 41 72 85 88 46 42 13 109 154 100 -33 -135 -82 25 413 
 * See Table 9 
NOTE: each cell shows mean standardised bias (%) generated from 1000 simulated trials of size N=40 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
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As with the evaluation of the impact of priors, for responses rates on or near the 
plateau of the dose-response curve (e.g. θ=0.1 for the Intermediate dose-response 
curves, see Figure 22) the standardised bias was generally unacceptably high (>90% 
for 7 of the 9 scenarios) suggesting that, in isolation, study design choices other 
than merely the dose levels or spacing should be considered to improve estimation 
for response rates on or near the plateau. In other words, it is a combination of 
study design parameters that should be simulated when designing a new trial. 
Another notable finding from Table 15 was the poor performance for the equally-
spaced scenario for Intermediate and Steep dose response curves (row [11] of Table 
9) in which mean standardised bias was greater than ±45% for all response rates, 
θ=0.1 to 0.9. The potential reason has already been noted in Section 7.4.3 and 
concerns the very low variability but high absolute bias thus resulting in very large 
standardised bias. 
7.4.6 Impact of Dose Allocation Rule 
Table 16 shows the subset of rows from Table 12 for which scenarios were repeated 
for both dose allocation rules, namely, always allocate the next patient the dose less 
than or equal to the current model estimate (< symbol) or the nearest dose (^ 
symbol). The table is most easily interpreted by comparing adjacent rows.
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Table 16 Impact of Dose Allocation Rule on the EWOC Estimator for Small Simulated Trials (N=40) 
  Shallow Intermediate Steep 
  Response rate, θ Response rate, θ Response rate, θ 
Scen
ario* Rule
# 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[1] < -26 -23 -17 -13 -8 3 7 2 12 94 30 -29 -61 -87 -106 -128 -138 -143 18 14 -12 -40 -71 -73 -67 -80 -130 
[2] ^ -20 -14 -7 -10 3 0 2 4 11 162 126 73 31 1 -13 -36 -54 -59 40 26 30 31 7 -8 -13 -12 -18 
[3] < -18 -9 8 3 21 21 23 27 26 60 35 -7 -47 -64 -81 -89 -86 -93 21 27 24 -8 -38 -41 -33 -23 -30 
[4] ^ -24 -12 -8 -4 9 9 9 13 19 91 92 67 41 21 8 -8 -16 -30 17 3 0 7 12 10 7 8 6 
[6] < -38 -52 -70 -73 -73 -66 -57 -49 -40 73 20 -54 -91 -121 -167 -198 -233 -294 21 23 18 6 -13 -17 -44 -65 -126 
[7] ^ -98 -87 -40 -5 13 30 50 63 83 159 89 40 22 -14 -66 -126 -122 -107 39 21 -3 2 10 19 22 14 -22 
[8] < -17 -36 -52 -63 -50 -20 -5 11 65 -3 30 -16 -65 -109 -130 -151 -160 -195 25 58 84 102 116 142 160 56 -32 
[9] ^ -171 -71 -25 13 52 78 116 147 215 101 92 49 26 4 -22 -54 -50 -64 44 43 26 -7 -12 -15 -7 -5 -14 
[12] < -9 29 55 73 79 91 96 93 87 130 55 31 23 18 19 21 19 28 27 97 124 86 64 88 129 185 103 
[13] ^ -45 -32 -20 -9 -4 8 10 22 39 123 56 34 22 26 29 19 19 32 -11 -29 -51 -26 7 42 51 34 55 
[15] < 11 23 40 62 107 183 279 404 818 130 87 87 53 39 48 60 77 39 51 166 313 330 548 489 459 466 83 
[16] ^ 
-183 -148 -37 46 122 214 341 460 650 120 56 21 31 43 43 33 17 17 39 106 132 105 -13 
-
106 -84 -22 58 
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  Shallow Intermediate Steep 
  Response rate, θ Response rate, θ Response rate, θ 
Scen
ario* Rule
# 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
[18] < -159 15 40 65 76 94 106 94 89 83 19 -2 -3 -3 -1 4 -2 1 12 53 109 104 78 94 140 189 122 
[19] ^ -47 -43 -19 -18 3 2 19 23 44 63 18 8 7 5 4 4 -2 6 -70 -42 -67 -39 -3 40 54 21 27 
 
 
* See Table 9 
# Rule: < indicates always allocate dose than current model estimate; ^ indicates allocate nearest dose 
NOTE: each cell shows mean standardised bias (%) generated from 1000 simulated trials of size N=40 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
 
 
- 202 - 
For the scenarios in which 17 dose levels were available in both 2-parameter and 1-
parameter logistic parameterisations (i.e. Table 16 rows [1] to [4] for EWOC1, rows 
[12] and [13] for EWOC2 and rows [18] and [19] for the 1-parameter logistic), the 
dose allocation rule assigning to the nearest dose generally performed better, 
particularly for 0.3≤θ≤0.7. For the doubling-doses scenarios (i.e. Table 16 rows [6] 
to [9] for EWOC1 parameterisation and rows [15] and [16] for EWOC2), both 
scenarios generally performed poorly indicating that the dose-spacing had a bigger 
impact than the dose allocation rule. 
As previously described in Section 2.4.2, no guidance is available in the literature 
for appropriate Tolerance values 𝑇1and 𝑇2  in Equation ( 2.16 ), but the simulation 
results in Table 16 can now be used to provide some initial evidence to guide the 
design of future trials: 
• Setting  𝑇1= “half of the dose-spacing” is equivalent to the “nearest” dose 
allocation rule 
• Setting 𝑇2 = 0.5. This is the value used in all simulations because alpha was 
set to 0.5 and 𝑇2=1-alpha. Hence the findings described above apply to the 
specific choice of 𝑇2 = 0.5 and future research for other choices would be 
useful. 
The Mean Square Error (MSE) of the EWOC estimator for the same 19 scenarios as 
considered for bias and standardised bias are shown in Appendix D and show 
similar conclusions to those from standardised bias, however, the intuitive 
understanding of standard bias (together with the ±40% rule of thumb from Collins 
et al. (2001)) makes it likely to appeal to a wider audience than does MSE. 
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7.5 One versus Two Parameter Logistic Model 
As discussed in Section 2.4.1, the CRM model can be formulated in terms of a 1-
parameter Bayesian logistic model and since there is a larger body of literature for 
implementation of CRM than EWOC, the results of the 1-parameter logistic are 
summarised separately here. The scenarios considered are [18] and [19] in Table 9. 
Convergence characteristics for the 1-parameter model were similar to the 2-
parameter model in most cases and have been classified in Figure 45 using the 
same classification scheme as in Figure 36. 
Category Example Profile Plots Assigned* 
(a) Realistic 
initial 
estimates, rapid 
convergence 
then low 
variability 
 
AV0_16BY1_S_LE_OUN__10 to _80, 
AV0_16BY1_S_NR_OUN__10  
(b) Initial 
divergence 
followed by 
convergence 
 
AV0_16BY1_I_LE_OUN__20 to _90, 
AV0_16BY1_I_NR_OUN__20 to _90, 
AV0_16BY1_S_NR_OUN__20 to _50, 
AV0_16BY1_W_LE_OUN__20 to _90, 
AV0_16BY1_W_NR_OUN__20 to _90 
(c) Approximate 
monotonic 
(slow) 
convergence 
 
AV0_16BY1_S_LE_OUN__90, 
AV0_16BY1_S_NR_OUN__60 to _90 
* KEY:  AV0_16BY1 = Available doses {0 to 16 by 1} _I_ = Intermediate dose-response 
  _S_= Steep dose-response 
 _LE_ = Dose allocation rule “less than” _W_ = shallow dose-response 
  
 _10_90 = Target θ (e.g. 10 to 90) _OUN_ = 1-parameter, Uniform Priors 
 
Figure 45 Small Sample Convergence Properties of the 1-Parameter Estimator 
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However, one additional classification for the 1-parameter results was required and 
appears in Figure 46, namely where the initial estimate is far from the true value, 
convergence is slow and then there is high variability with a self-correcting 
mechanism.  
Example Profile Plots Assigned* 
 
AV0_16BY1_I_LE_OUN__10, 
AV0_16BY1_I_NR_OUN__10, 
AV0_16BY1_W_LE_OUN__10, 
AV0_16BY1_W_NR_OUN__10 
* KEY:  AV0_16BY1 = Available doses {0 to 16 by 1} _I_ = Intermediate dose-response 
  _S_= Steep dose-response 
 _LE_ = Dose allocation rule “less than” _W_ = shallow dose-response 
  
 _10_90 = Target θ (e.g. 10 to 90) _OUN_ = 1-parameter, Uniform Priors 
 
Figure 46 Example of the Self-correcting Property of the 1-parameter EWOC 
Estimator 
The scenario shown in Figure 46 is taken from scenario [19W] in Table 9 and could 
be very problematic in real trials since investigators may wish to stop the trial by 
N=25 but the bimodal distribution of estimates means that the actual trial may still 
be well away from the true value. However, this result needs to be put into context 
because it occurred in just 4 (7%) of the simulations for the 1-parameter model. 
Furthermore, all of those occurrences were when the target response rate was 0.1 
and on the flat part of the dose-response curve Figure 22. Hence, although there 
are circumstances when this could present a problem, the situation is restricted to 
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those situations with very low response rates which is below the typical range for 
the implementation of the 1-parameter CRM in oncology trials (i.e. usually 0.2 to 
0.35). 
Since the asymptotic properties of the 1-parameter CRM were demonstrated by 
Shen and O’Quigley (1996), it is of interest to extend the profile plot from Figure 46 
to 150 dose escalation estimates (i.e. N=158 patients) and these results are shown 
in Figure 47. There is a clear “self-correcting” mechanism below N=30 and still 
some evidence of non-convergence at N=90, however, convergence is attained by 
N=120. 
 
Figure 47 Large Sample Properties of the 1-parameter Logistic Model 
In summary, for the situations in which the 1-parameter CRM is most likely to be 
used (i.e. response rates in the range 0.2 to 0.35) the small sample convergence 
properties are similar to those for EWOC. Having described the small sample 
properties of EWOC and compared them with the 1-parameter logistic model, it is 
now pertinent to assess the large sample properties of the 2-parameter EWOC to 
assess how closely the small sample and asymptotic results agree. 
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7.6 Large Sample Convergence Properties of the EWOC 
Estimator 
The assumed monotonic logistic dose response curve can be assessed by 
calculating the percentage of simulations in which the slope parameter for EWOC1 
formulation was positive. For sample sizes 10 to 150 by 10, this percentage was 
calculated for the Shallow, Intermediate and Steep dose-response curves in row 20 
of Table 9 and all were positive (data not shown) demonstrating that by using the 
Bayesian Feasible Level alpha=50% (i.e. the posterior median) then the monotonic 
assumption held for all simulations, i.e. even those with a sample size of 10. 
Long-term convergence properties were also assessed by visual inspection of 
profile plots (of 1000 simulated trials) corresponding to 150 dose-escalation 
decisions (i.e. N=158 patients). Per Section 6.3 and row 20 of Table 9, “centering” 
of doses was performed (i.e slope parameter held at 0.7 but intercept parameter 
changed from -2.9 to -0.4) such that available “centred doses” were any integer in 
the range -100 to 100. These scenarios would permit identification of any 
important differences from the remaining scenarios for which doses were 
constrained to be positive (e.g. 0 to 16). This profile plot and histogram are shown 
in Figure 48 and can be considered to be the counterparts to those from Figure 30 
and Figure 31 (albeit with simulation variability for N≤40). 
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Figure 48(a) Profile Plot for N=158 Figure 48(b) Distribution of Estimates at 
N=158 
 
 
Figure 48 Large Sample Properties of EWOC1 Estimator 
Both Figure 30 and Figure 48 show similar variability between N=40 and N=158 
(s.d.=0.6822 versus 0.6363) and also confirm that a small number of simulation 
scenarios result in outlying estimates that remain at their long-term value beyond 
N=40 and still have not converged to the true value by N=158. In particular, the 
lower and upper blue profiles in Figure 48(a) comprise 10 simulated trials with 
estimates of γ above or below 3 standard deviations of the true value {-1.3375 to 
2.4803} after 100 patients and still outside at 158 patients. If these were real 
clinical trials then such slow convergence is useful to know because it could permit 
the investigator to stop recruiting patients much earlier (e.g. after 40 or 50 
patients) on the basis that data from additional patients would be unlikely to 
significantly change the current estimate of γ (although the investigator would 
never know if such an estimate was “close” to the true value). 
The corresponding values of the mean standardised bias for N=158 across the 
range of dose-response scenarios and response rates (i.e. row [20] of Table 9) are 
presented in Table 17 using the ±40% rule-of-thumb of Collins et al. (2001). The 
same data is plotted (together with MSE) in Figure 49 .
P50 Posterior Estimates of Target Dose for Response Rate Theta=0.5
1000 Simulated Trials (using doses {-100 to 100 by 1} Maximum N=158 each trial)
Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) 
Distribution after 158 patients (with KDE superimposed)
DATASEED=12345 for Initial cohorts then DATASEED varied. Output code: P_CONV_E_NR_BUN_P50_N40_50
Dose Allocation rule: Gamma Nearest DOSE
True Dose-Response: logistic CentInterm: Beta0=-0.4, Beta1=0.7         Implies True Gamma=0.5714 at Theta=0.5
True Value
-3 -2 -1 0 1 2 3 4
0
10
20
30
40
50
60
P
er
ce
nt
Sims 1000
Mean 0.6184
Median 0.8179
SD 0.6363
Min -1.5798
Max 2.6206
Posterior Estimate of Target Dose, Gamma
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Table 17 Standardised Bias of EWOC1 Estimator for Large Simulated Trials (N=150) 
Centred Shallow: Beta0=-0.4, Beta1=1.4 Centred Intermediate: Beta0=-0.4, Beta1=0.7 Centred Steep: Beta0=-0.4, Beta1=2.5 
Response Rate, θ Response Rate, θ Response Rate, θ 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
37 35 12 12 8 -6 -18 -21 -32 52 48 34 19 8 -14 -30 -48 -60 8 16 22 2 -26 -17 3 9 -9 
NOTE: each cell generated from 1000 simulated trials of size N=150 
Red cells indicate values outside ±40% rule-of-thumb of Collins et al. (2001) 
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A potential reason why the mean standardised bias falls outside the ±40% range for 
θ≤0.2 and θ≥0.8 for the Intermediate dose-response curve (only) could be that 
these are the shallow areas of the dose-response curve (see Figure 3), whereas for 
the Shallow and Steep curves the gradient is steeper at these values of θ. Hence, for 
the Intermediate dose-response curve, a change of 1 or 2 units in the dose levels 
translates to only small incremental changes in the estimated response rate. As 
such, the point estimate (i.e. posterior median) of target dose , γ, may be less well 
estimated than elsewhere on the dose-response curve. 
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Figure 49(a) Centred Shallow: Beta0=-0.4, 
Beta1=1.4 
 Figure 49(b) Centred Intermediate: Beta0=-0.4, 
Beta1=0.7 
Figure 49(c) Centred Steep: Beta0=-0.4, Beta1=2.5 
   
NOTE: uniform vertical axes ranges chosen to aid comparison with other Figures 
Figure 49 Standardised Bias and MSE of EWOC1 Estimator for Large Simulated Trials 
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In summary, when the number of available doses is high (i.e. 201 and thus 
essentially continuous) and centred on zero, these large sample (N=150) 
simulations show that: 
• In the majority of simulations, the estimate stabilised to its long-term value 
by the time 20 patients had been simulated. 
• Even with 201 dose levels, simulated trials can produce estimates of γ at 
N=150 patients that can be considered as outliers for which these outlying 
values are very similar to the estimate at N=40 patients. 
• Mean standardised bias was between ±40% for all dose-response scenarios 
when 0.3≤θ≤0.7 but went as low as -60% when θ=0.9 for the intermediate 
dose curve. 
• The reason for the high standardised bias values may be due to the shallow 
gradient around those response rates (i.e. a large change in dose leads to 
large change in response rate) but further investigation is warranted (see 
Section 7.4.3 for discussion of other similar scenarios). 
7.7 MCMC Performance 
As discussed in Section 6.6, it was not feasible to check convergence of the chain 
within every MCMC simulation so an automated approach was used such that a 
large number of burn-ins (i.e. 5000) and thinning (i.e. every 1000th iteration) from 
the 2,000,000 iterations was used. These values were chosen by experimentation 
on a small number of scenarios (assuming independent priors) and would be 
expected to be conservative for the majority of scenarios but it is important to 
assess if this automated procedure was reliable for the 540,000 simulated trials in 
Table 9. 
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There is no consensus on a universally acceptable statistic to assess convergence of 
the MCMC to its stationary distribution (Kass et al., 1998) but the Effective Sample 
Size (ESS) is one such statistic and is defined as: 
 ESS = 
𝑚
1+2 ∑ 𝜌(𝑡)𝑇𝑡=1  ( 7.1 ) 
where n is the number of MCMC samples, ρ(t) is the autocorrelation at lag time t=1 
to T (Kass et al., 1998). As a guide, an ESS approximately equal to the number of 
posterior samples indicates likely convergence (Gelman et al., 2013, pp.286–287). 
Unfortunately, when performing the 540,000 simulations I did not retain the ESS 
values in a dataset (they were retained in the SAS output files) so it is not 
straightforward to provide this performance metric. However, it was possible to 
recreate the ESS for specific scenarios when indicated by other methods. For 
example, visual inspection of the profile plot in Figure 50(a) shows estimates of γ of 
approximately zero for N=9 to 12 and so provides an informal assessment of the 
potential for non-convergence of the MCMC chain. This is confirmed by inspecting 
the diagnostic plots in Figure 50(b) that reveal correlated samples and incomplete 
mixing. The ESS at N=9 was 31.4 (i.e. ≪2000 posterior samples). At N=13 
convergence appears to have been achieved (see Figure 50(c)) and the ESS=1840.1.  
Figure 50(a) Profile Plot 
Showing Posterior Median at 
Zero for N≤12 
Figure 50(b) MCMC 
Diagnostic Plots at N=9 
Figure 50(c) MCMC 
Diagnostic Plots at N=13 
   
Figure 50 Example of MCMC with Non-convergence 
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A further example of non-convergence was discussed in Section 7.4.2.1 and, in 
general, occurs in < 1/10000 dose escalation estimations (each profile plot in the 
Supplementary File involves 32,000 dose escalation estimations).  
In summary, of more than 1.6 million simulated dose escalation estimations, 
ignoring a small number of non-convergence would not change overall conclusions 
from these extensive simulations. Further work to re-compute the ESS and other 
convergence statistics would be useful to confirm the findings from visual 
inspection. 
7.8 Summary of Simulations into Small Sample Properties of the 
EWOC Estimator 
The key findings from the simulations with Bayesian logistic regression, the EWOC 
estimator ( 2.17 ) to estimate target doses for a range of dose-response curves and 
dose allocation scenarios are summarised below: 
• The 2-parameter Bayesian logistic model is sufficiently flexible to describe a 
range of dose-response curves that might arise (Figure 3). 
• When 2 logistic parameters were being estimated, the estimates of target 
dose, γ, stabilised to its long-term value by the time 20 patients had been 
simulated. This observation extends the findings of Oron and Hoff (2013) 
who found similar “settling” in the specific case of θ=0.3 
• EWOC model formulation plays an important role in minimising bias and 
these simulations extend the findings of Chu et al. (2009) who made similar 
findings in the specific case of θ=0.33. By combining the simulation and 
elicitation findings (i.e. the intuitive understanding of the EWOC2 
parameters, Section 5.5.2 and Figure 8), I recommend that the EWOC2 
parameterisation is the initial parameterisation to use when designing a trial 
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with informative priors and the EWOC design. Once priors have been elicited 
with the EWOC2 parameterisation, simulations could also be performed 
using the EWOC1 parameterisation to assess the impact of re-
parameterisation. 
• When a restrictive (and discrete) set of doses is available for a planned 
clinical trial, simulation studies should be performed to assess the ability of 
those doses to be differentiated with high probability. Such simulation 
studies may need to model dose on a suitably transformed scale e.g. log-
dose (see results from scenario [11] in Table 9). 
• Previous published work has focussed on measures of central tendency 
when accruing patients (e.g. mean bias) but these simulations show that it is 
also important to know the potential for outliers as judged by the profile 
plots 
• When performing simulation studies to assess operating characteristics of 
potential study designs I would recommend to not only report the 
conventional bias and Mean Square Error (MSE) statistics but also report 
standardised bias and the potential for outliers. Reporting of standardised 
bias will enable easy identification of study designs for which variability of 
the estimate is low relative to the absolute bias (e.g. see Table 12). 
• For trials targeting response rates around 0.5 to 0.6, using an incorrectly 
specified informative prior will have minimal influence by the time 40 
patients have been accrued (see Section 7.4.4). For much higher target 
response rates (e.g. 0.9) then minimal impact is unlikely until approximately 
60 patients have been accrued. 
• A number of scenarios generated dose recommendations at N=9 that were 
very much higher than the true target dose, so the recommendations of 
Goodman et al. (1995) to impose a restriction on the maximal dose 
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increment should be applied. These dose escalation restrictions have 
become increasingly common practice in EWOC implementations when the 
probability of overdosing is usually more conservative than the current 
simulations (e.g. Bayesian-feasible level alpha=0.1 or 0.25 provides only 
10% (25%) probability of overdosing, respectively) but even in these more 
liberal simulations where BFL alpha=0.5, consideration for relaxing that 
criteria (i.e. skipping doses) could be considered beyond N=20 
• Although negative estimates of γ were rare when using the EWOC1 
parameterisation, an advantage of the EWOC2 parameterisation over EWOC1 
is that γ (and the other parameter, 𝜌0) are modelled directly in EWOC2 and 
so bounds can be placed on their distribution.  
• The large sample properties of EWOC (to converge to true estimates of the 
target dose) were generally realistic in the typically modest trial sizes used 
in early phase studies (N≤40) but mis-specification of the priors could still 
have an influence at N=40 patients. That this applies across a wide range of 
response probabilities (θ=0.1 to 0.9) appears not to have been published 
previously. 
• The use of EWOC to estimate target doses outside the previously widely 
studied safety setting (where response rates typically range from 0.2 to 
0.35) is feasible, but a statistician designing such a trial is strongly advised 
to simulate a range of scenarios with a number of dose levels likely to span 
the expected dose-response curve. 
• Choosing a conservative dose allocation rule (i.e. always selecting a dose 
below the current model estimate) leads to non-symmetric bias properties 
and generally increased bias compared with allocating the nearest dose to 
the current model estimate. I would thus advise against using the dose 
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allocation rule recommended by Wang et al. (2013) but instead use a rule 
which allocates the nearest dose to that recommended by the model. 
• The dose allocation rule of assigning the nearest dose can be interpreted as 
setting specific Tolerance values 𝑇1 = {half of the dose spacing} and 𝑇2 =0.5 
in Equation ( 2.16 ), and it would be useful to have further research on 
performance of EWOC for other values of 𝑇1 and 𝑇2 . 
• The effects of bias can be ameliorated by increasing the number of available 
doses (e.g. 17 doses compared with 6 doubling or equally-spaced doses in 
these simulations). 
• The use of an informative prior may improve the rate of convergence if 
specified correctly, however, an incorrectly specified prior (e.g. a prior 
centred well away from the true value) may still result in appreciable bias 
even after 40 patients have been recruited. I recommend that the statistician 
performing simulations for a new trial should provide the other team 
members with an impact assessment for an informative prior having 
considerable mass well away from the estimates that could arise from the 
study data. If the impact is minimal then the team may decide that the 
potential gain is worthwhile. 
• In any particular clinical trial setting, e.g. when response rates are likely to 
be in a narrow range (such as 0.5 to 0.7) the choice of parameterisation may 
not be so important thus it may be useful to implement the rule-of-thumb 
for Standardised Bias to select an appropriate parameterisation. 
• The monotonicity assumption held for a range of sample sizes from 10 to 
150 across the 3 dose-response scenarios evaluated. This compares with 
the rare scenario identified by Shen and O’Quigley (1996) who described a 
specific scenario in which monotonicity did not hold. A key difference 
- 217 - 
between the current simulations and those of Shen and O’Quigley is the 
choice of estimator (those authors used the estimator in Equation ( 2.4 )).  
• The standardised bias provides a valuable metric to identify study design 
scenarios with low variability and but larger absolute bias and should be 
routinely reported in simulation studies.  
• The standardised bias metric revealed that it was possible to identify study 
designs assumptions leading to large bias for studies of 40 patients so when 
designing a new trial, it is important to use simulation to study specific trial 
design parameters that are likely to reflect the conditions of the planned 
trial  
• Visual inspection of MCMC convergence indicated that the automated 
approach produced reliable posterior estimates in the overwhelming 
majority of simulation scenarios but further work to calculate the Effective 
Sample Size (ESS) and other convergence statistics would be useful to 
confirm the findings from visual inspection. 
7.9 Conclusions from Simulations 
In a clinical trial, the true dose that predicts a pre-specified response rate is 
unknown so in early phase trials, practitioners generally rely on the large sample 
(theoretical) properties of available study designs to give assurance that the 
observed results are likely to represent the true effects of the drug. Through 
simulation, I have demonstrated that some of the large sample properties of the 
EWOC design may not hold in any particular (i.e. single) clinical trial. I have provided 
recommendations on how to mitigate some of these risks and these should be 
disseminated wider so that statisticians and other clinical researchers can consider 
if the well documented benefits of long memory designs are applicable to the early 
phase trials they are designing. 
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In most early phase clinical trials it is important to learn about the potential benefits 
and risks of the drug and so pre-specifying (and adhering to) a single target 
response rate throughout the trial will not produce a full understanding of the 
trade-offs of lowering (or raising) the target response rate during the trial. Since all 
of the scenarios considered in these simulations maintained the same target 
response rate throughout the trial, future research could establish the operating 
characteristics of long memory designs (such as EWOC) when the target response 
rate is allowed to vary. To consider all possible adaptions would be prohibitive so 
selecting a subset on the basis of reasonably likely scenarios would be appropriate. 
For example, simulate scenarios in which a target response rate of, say, 0.8 for the 
first 15 patients but then reduce the target to 0.7 for the rest of the trial. This 
would simulate the situation when standard-of-care may produce response rates of 
say, 0.4 and the original target for a promising agent is reduced slightly (e.g. θ=0.8 
to θ=0.7 in above scenario) on the basis of non-life threatening adverse events 
emerging during the trial (e.g. pre-trial expected adverse event incidence had been 
15% but only 5% observed in early cohorts, so it might become desirable to retain 
an experimental drug with θ=0.7). 
Through simulation, I have also shown that the properties of the EWOC estimator 
with correctly specified informative priors can improve the rate of convergence to 
the true value. For a real clinical trial, this may permit fewer patients to be enrolled 
and/or fewer patients to be allocated ill-tolerated, sub- or supra-therapeutic 
doses. These findings may now be applied to recommending improvements to the 
design of the kisspeptin trial and for generalisations to other settings. 
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8. Evaluation of the Kisspeptin Trial Design and 
Further Generalisations 
8.1 Open Questions from the Kisspeptin Trial 
As described in Section 1.4, the objective of the kisspeptin trial was to “Investigate 
whether kisspeptin could stimulate oocyte maturation in IVF therapy for infertility” 
for which the published design included a requirement to test up to 6 doubling 
doses {0.4 to 12.8 nmol/kg} in no more than 90 patients while minimising the 
chance of inducing ovarian hyperstimulation e.g. through over-dosing (Jayasena et 
al., 2014). Further trials would also be conducted to confirm any findings from the 
planned Phase 2 trial, and so, doses other than the 6 doubling doses may be 
feasible in such confirmatory trials. Now that the trial has completed, it is possible 
to evaluate how closely the selected trial design met the study objectives, and, 
where relevant to offer suggestions for improvements if the study were to be run 
again. 
Jayasena et al. (2014) acknowledge that despite testing 6 doses of kisspeptin in 53 
women, they were not able to identify one dose to take forward to confirmatory 
studies but rather one of two doses (6.4 and 12.8 nmol/kg), as such, there is still 
some uncertainty as to which dose of kisspeptin would induce oocyte maturation 
with a high probability. Furthermore, since 49/51 (96%) patients responded on 
these 2 doses and 3/3 (100%) of those on 3.2 nmol/kg responded then there is still 
some uncertainty as to the minimally effective dose.  
Although no description of further clinical trials of kisspeptin is currently available 
in the public domain, it is likely that at least 3 doses of kisspeptin would be needed 
in a trial to answer these dose-response questions. A further trial may also be 
needed to serve as a confirmatory study to permit a submission for licensing 
- 220 - 
consideration. As such, it would be useful to determine if a single dose-response 
trial based on the EWOC design could have identified the optimal dose with the 
same (or fewer) patients than two trials. The data from Jayasena et al. (2014) can be 
used to simulate the outcome of a trial using the EWOC design by re-analysing the 
accruing data in a sequential manner using a Bayesian 2-parameter logistic model. 
The response data from Jayasena et al. (2014) are plotted in Figure 51 in the order 
in which the patients were allocated to treatment. 
 
Key: open circle=Responder; red cross=Non-responder 
Figure 51 Plot of Outcome Data from Jayasena et al. (2014) 
As can be seen from Figure 51, the 2 non-responses (i.e. failure to achieve oocyte 
maturation) occurred on a dose of 6.4 nmol/kg and occurred for the 6th and 36th 
patient. Figure 51 also demonstrates how the treatment allocation procedure 
allocates only 1 of 2 doses from patient 6 onwards (6.4 and 12.8 nmol/kg). There 
are some limitations when attempting to re-create how the EWOC design would 
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have performed using the actual data from Jayasena et al. (2014) and these are 
described in Section 8.2 together with other assumptions that had to be made. 
8.2 Simulation Assumptions for a Kisspeptin Trial Using The 
EWOC Design 
At any point during a trial, the Bayesian 2-parameter logistic model underlying the 
EWOC design produces a recommended dose for the next patient conditional on the 
data observed thus far (see Section 2.4.2). As such, it could be applied to the 
Jayasena et al (2014) data from the first patient onwards, however, it is highly likely 
that at some point (e.g. after patient k) that the dose recommended by the model 
for patient k+1 would differ from the dose actually given to patient k+1. For 
example, if the EWOC model recommended dose=3.2 nmol/kg for any patients 
after patient=5 then it would not be possible to use a response/non-response 
outcome from dose=3.2 (Figure 51). Furthermore, had that lower dose been used in 
an EWOC design for patient k+1 and the resulting outcome incorporated into the 
next model update then further divergence of actual versus EWOC doses may have 
occurred. 
Hence, in the simulations described below, the decision was made to fit the 
Bayesian 2-parameter logistic model using the observed dose and outcome data 
regardless of what dose the model actually recommended for the next patient. This 
is likely to produce a more conservative estimate of how quickly the EWOC design 
would converge to the (unknown) true value because the simulation cannot explore 
the outcome of allocating patients to low doses. In practice, a more conservative 
estimate may be appealing when planning a trial since recruitment and other costs 
are likely to be sufficiently covered. A decision could then be taken by the Principal 
Investigator whether to allocate the additional patients to promising doses and/or 
to start subsequent trials sooner. 
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In Jayasena et al. (2014) the first dose escalation occurred after 2 patients had been 
allocated dose=1.6, thus the EWOC simulation has been implemented from patient 
2 onwards (i.e. resulting in 52 sequential estimates, denoted 𝛾2� to  𝛾53� ). 
Since the EWOC design uses a Bayesian approach, prior distributions are required 
for the 2 parameters of the logistic model and two sets of priors have been 
implemented, namely those already considered for the EWOC2 parameterisation in 
Section 6.6: 
1. Independent (bounded) Uniform priors for 𝜌0 and γ i.e. 𝜌0 ~Un(0,0.8) and γ 
~Un(0.4,12.8). These represent vague prior information and would be 
suitable when the researcher wants the trial data to dominate inferences.  
2. Informative priors for 𝜌0 and γ that approximate those elicited in the 
kisspeptin case study (see Section 5.3.7), namely  𝜌0 ~Beta(3.6,8.69) and γ 
~Normal(10.5,15.21) i.e. standard deviation=3.9. These would be 
appropriate when the researcher has more confidence in prior beliefs 
(and/or external information). 
8.3 Results of a Simulation of a Kisspeptin Trial Using the EWOC 
Design 
8.3.1 Uniform Priors 
The estimates of the dose leading to an 80% chance of oocyte maturation are shown 
in Figure 52 (blue diamond symbols) for the scenario with Uniform priors.  
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Key: open circle=Responder; red cross=Non-responder; blue diamond=EWOC model estimates 
Figure 52 Estimates of Target Dose using EWOC Design and data from Jayasena et 
al. (2014) with Uniform Priors 
The first estimate (4.4 nmol/kg, exact value not shown) was higher than the dose 
allocated to patient 3 (3.2 nmol/kg) and is likely to be due to great uncertainty from 
the vague prior (i.e. equally likely to be anywhere between 0.4 and 12.8) and having 
a model estimate that uses trial data from only 2 patients. Thereafter, the estimates 
decrease until the first non-responder (patient 6) at which point the EWOC model 
recommends a dose of 7.4 nmol/kg be allocated to patient 7, whereas patient 7 
was actually allocated dose=12.8 nmol/kg. In fact, of the remaining 46 patients, 45 
(98%) were allocated a dose higher than that recommended by the model (patient 
10 was allocated 6.4 nmol/kg whereas the model recommended 6.8 nmol/kg). 
It is also worth noting that the theoretical coherence properties (Cheung, 2005) of 
the EWOC design are also demonstrated by the results in Figure 52, i.e. the model 
recommends increasing the dose after a non-response and decreasing the dose 
after a response. Furthermore, the estimate after 53 patients was 3.1 nmol/kg 
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which agrees (as expected) with the end of study results already described in 
Section 5.4 and Figure 20. Interestingly, the EWOC model estimate after patient=31 
was also 3.1 nmol/kg and (in purely mathematical terms) the remaining 22 patients 
served to improve the precision of this estimate. 
8.3.2 Informative Priors 
The equivalent scenario with the informative priors from Section 8.2 is shown in 
Figure 53 as green asterisk symbols (the blue diamond symbols are for Uniform 
priors).  
 
Key: open circle=Responder; red cross=Non-responder;  
EWOC model estimates: blue diamonds=Uniform priors, green asterisk=Informative priors 
Figure 53 Estimates of Target Dose using EWOC Design and data from Jayasena et 
al. (2014) with Uniform and Informative Priors 
The model estimates using informative priors are consistently higher than those 
with Uniform priors with a difference still present after 53 patients (4.2 nmol/kg 
using informative priors compared with 3.1 nmol/kg for Uniform priors).  The EWOC 
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model estimate after patient=33 was also 4.2 nmol/kg and, as with the Uniform 
priors, the remaining (20) patients served to improve the precision of this estimate. 
Since the model estimates from the two sets of priors do not agree after 53 patients 
then these simulation results demonstrate that the informative prior is still having 
an influence on model estimates after 53 patients. However, it should be 
remembered that these sequential Bayesian estimates used the results from the 
actual trial and not a complete EWOC design in which the dose for subsequent 
patients may be doses other than the 2 doses used after patient 7. As such, the full 
EWOC design can characterise many parts of the dose response curve. 
However, even if the complete EWOC design had been followed and still resulted in 
these differences after 53 patients then, in practice, a difference of 1.1 nmol/kg 
may be minimal since the dose response curve is relatively flat between dose=3 and 
4 nmol/kg (see Figure 20). After patient 17 (i.e. 7 more than with Uniform priors) all 
subsequent patients would be allocated a lower dose using EWOC than in the actual 
trial. 
8.4 Recommendations for Improved Clinical Trial Design of the 
Kisspeptin Case Study 
For both sets of prior distributions considered, the EWOC design met the original 
trial objective (i.e. investigate whether kisspeptin could stimulate oocyte 
maturation) and the secondary objectives to identify a subset of 2 or 3 promising 
doses for subsequent confirmatory trials. Furthermore, if one considers the more 
conservative situation of Uniform priors then potentially just a single dose (3.1 
nmol/kg) could be identified for subsequent trials. Since the EWOC model estimate 
stabilised after approximately 30 patients then the trial objective was attained with 
fewer patients than the 53 enrolled in Jayasena et al. (2014). 
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By combining the findings from the structured elicitation sessions and the 
simulation results, I would make the following recommendations to improve on the 
design of the original kisspeptin Phase 2 study so that subsequent confirmatory 
studies were more efficient: 
1. Implement a long memory trial design such as the EWOC design so that a 
small number of doses (i.e. 1 or 2) can be identified for subsequent trials. 
2. At the design stage, I would recommend planning and conducting a 
structured elicitation session. Even if use of an informative and subjective 
prior was highly unlikely to be used at the design or analysis stage, there is 
still value in educating experts in the models and methods that will underlie 
the planned trial (see Section 5.6). Since Phase 2 trials may take months or 
even years to plan and execute then conducting a structured elicitation 
session is unlikely to introduce noticeable delays. 
3. To minimise the chance of incorrectly using prior distributions that conflict 
with the accruing data, I recommend that for each dose escalation 
recommendation, the statistician should provide the Principal Investigator 
with model estimates using a range of priors. Where those estimates provide 
markedly different recommendations, the Principal Investigator can use the 
totality of the accruing data to make the actual dose decision. 
4. Assuming an EWOC design will be used, I recommend to define a stopping 
rule such that as few patients as possible are enrolled. For example, define a 
stopping rule based on the precision of the EWOC estimate (e.g. an 
appropriate width of the 95% credible interval for 𝛾� might be defined as the 
width that excludes 2 of the available doses). Further research to guide the 
choice of credible interval width could also be undertaken. 
5. Use the EWOC2 parameterisation (see Equation ( 6.2 )) of the Bayesian 
logistic model since: 
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o it has intuitive interpretation for non-statisticians 
o it is feasible to elicit expert beliefs and form prior distributions 
o it is straightforward to apply bounded (prior) probability distributions 
to its parameters such that the monotonicity assumption of dose 
response can be incorporated directly. 
Implementing the above recommendations could produce a trial that would 
identify a single dose to take forward to confirmatory trials with fewer than 40 
patients (i.e. less than half of the original planned sample size) and, potentially 
20 fewer than the number of women (53) in the actual Phase 2 trial that was 
conducted (Jayasena et al., 2014)). Additionally, since the simulations showed 
that once 20 patients had been enrolled, the EWOC design resulted in estimates 
below the actual doses allocated in the trial, then implementing an EWOC design 
may result in fewer women being exposed to doses that may lead to ovarian 
hyperstimulation. 
Although the previously described recommendations could assist the design of a 
future trial of kisspeptin, the work in this thesis can also be generalised to other 
clinical settings and this is now provided in the form of a series of steps for the 
interested researcher to consider. 
8.5 Generalisations to Other Settings 
When information external to a planned dose-response trial is available in the form 
of expert beliefs, the interested researcher would have to consolidate 
recommendations from across multiple sources in the clinical trial and statistical 
literature so a possible workflow is provided below to facilitate the study design and 
study conduct choices that would need to be considered. 
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In order to make the workflow manageable within the scope of this thesis, some 
assumptions have to be made: 
• The study objective is to identify a subset of 1 or 2 doses from a set of 4 or 
more discrete doses that will lead to a target response rate, θ. 
• One or more subsequent trials would be planned, using the identified 
dose(s), to demonstrate confirmatory evidence sufficient for a Regulatory 
Health Authority assessment. 
• Information external to the planned trial is available in the form of expert 
beliefs. 
• It is feasible to conduct the (Bayesian) model updates required for dose 
escalation/de-escalation during the conduct of the EWOC trial 
On the basis of these assumptions the workflow in Figure 54 could be used to plan 
and conduct a trial using the EWOC design. 
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Figure 54 Design and Conduct of a Dose Response Trial using an EWOC Design and Incorporating Expert Beliefs 
- 230 - 
9. Discussion and Conclusions 
9.1 Summary 
This thesis set out to improve the design and analysis of clinical trials within a drug 
development programme with particular emphasis on the application of Bayesian 
methods in early phase clinical trials to enable better design of confirmatory (Phase 
3) trials. In particular, the specific aims were to: 
• Characterise the performance of 2-parameter Bayesian logistic dose-
response models across a range of experimental design choices when 
sample sizes are small 
• Assess the impact of the choice of a range of prior distributions (weakly and 
more informative distributions) on posterior conclusions 
• Evaluate methods for extracting beliefs from experts (i.e. elicitation) 
• Evaluate methods for incorporating expert beliefs into informative priors for 
the 2-parameter Bayesian logistic dose-response model 
The outcome of the research was to propose recommendations for the 
incorporation of external information into the prior distributions for the 2-
parameter Bayesian logistic dose-response model across a range of experimental 
design choices. The range of response rates considered could thus be applied to 
future studies with safety and tolerability objectives (e.g. Phase 1 oncology trials in 
patients) and/or to Phase 2 trials with efficacy objectives. Through better 
understanding of the operating characteristics of the EWOC design with informative 
priors, it would also be possible to recommend the total number of patients to 
allocate to the most promising dose (e.g. to the expansion cohort of a Phase 1 
oncology study in which a Recommended Phase 2 Dose, RP2D, has been identified 
earlier in the study). 
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Recommendations would also be given on how to improve the study design and 
statistical analysis for the (kisspeptin) case study that motivated this research. 
9.2 Original Contributions 
The following original contributions have been made: 
1. When using the Bayesian 2-parameter logistic model on accruing data from a 
clinical trial with discrete doses, I have evaluated the recommendation by 
Wang et al. (2013) to always allocate a dose lower than recommended by the 
model. Through extensive simulations, my research is not supportive of their 
recommendation and I recommend always to use the closest available dose 
even if that is higher than that recommended by the model. This dose 
allocation rule is more likely to lead to an unbiased estimate of the dose that 
attains a pre-specified target response rate. 
2. Two case studies were performed of elicitation of expert beliefs in the clinical 
trial domain using a structured format. I have been the lead author on a peer 
reviewed publication for one of the case studies that demonstrates that 
elicitation is feasible in the clinical trial domain. 
3. Furthermore, through these elicitation case studies, I have identified that 
improved methods for explaining all relevant features of probability 
distributions are required for the training section of elicitation sessions. This 
will enable expert beliefs to be elicited with improved reliability. 
4. Additional insights from one elicitation case study revealed that when 
designing a future study, experts may try to incorporate information that is 
not yet published. Using a structured format to elicit such information would 
increase the transparency of study design choices (even if such information 
is not incorporated at the data analysis stage).  
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5. The operating characteristics of the EWOC design have been studied across a 
range of response rates far in excess of those in published literature. In 
particular, the EWOC study design has previously largely been studied and 
implemented in the oncology early phase trial setting in which target 
response rates,θ, between 0.2 and 0.33 are typical, whereas the simulations 
in this thesis consider response rates,θ, between 0.1 to 0.9 thus extending 
its potential use in other scenarios that evaluate both efficacy and safety. 
Through this work I have demonstrated that the EWOC model formulation 
plays an important role in minimising bias and I recommend that the EWOC2 
parameterisation (see Equation ( 6.2 )) is the initial parameterisation to use 
when designing a trial with informative priors and the EWOC design. Once 
priors have been elicited with the EWOC2 parameterisation, simulations could 
also be performed using the EWOC1 parameterisation to assess the impact of 
re-parameterisation. This observation extends the findings of Chu et al. 
(2009) who made similar findings in the specific case of θ=0.33 
6. Previous published work to evaluate the operating characteristics of the 
EWOC design with informative priors has generally employed conjugate 
priors for the two parameters. While this often results in mathematical 
convenience in constructing the resulting posteriors (e.g. prior and likelihood 
belong to the Normal family of distributions) the advent of MCMC methods 
allows incorporation of arbitrary priors that may result from expert beliefs. 
Through a structured elicitation case study and clinical trial simulations, this 
thesis has evaluated the operating characteristics of the EWOC design for a 
range of conjugate and non-conjugate priors. Through simulation, I have 
shown that the properties of the EWOC estimator with correctly specified 
informative priors can improve the rate of convergence to the true value. For 
a real clinical trial, this may permit fewer patients to be enrolled and/or 
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fewer patients to be allocated ill-tolerated, sub- or supra-therapeutic doses. 
Furthermore, the impact of mis-specified priors has also been studied and 
reveals that substantial bias may still be present even after 40 patients have 
been recruited into a trial. Hence, during the trial planning stage, the 
simulations produced by the statistician should include scenarios of mis-
specified priors so that the team developing the protocol can assess the 
impact of mis-specifying the prior. Additionally, during the data analysis 
stage, the statistician should perform analyses using more than one prior 
and evaluate if the resulting conclusions are robust to (potentially) mis-
specified priors. As the simulations show, this check of robustness is 
particularly important when N<20 (e.g. for ongoing dose escalation decisions 
and/or very small trials) since convergence to the long-term value may not 
have been attained. 
7. SAS/STAT® software (SAS Institute Inc, 2008) has been written to implement 
the EWOC design and is sufficiently flexible to incorporate a wide range of 
clinical trial design scenarios that include discrete doses, conjugate and non-
conjugate priors and trials with a range of sample sizes from 10 to 40 that 
are typical of early phase designs. Other available software has either been 
written in proprietary format (e.g. (Wang et al., 2013)) or in the R language (R 
Development Core Team, 2014). Making the SAS/STAT® software version 
freely available as part of this thesis will potentially enable a larger user base 
to implement the EWOC design, particularly in the pharmaceutical industry 
where use of SAS/STAT® software is widespread. The code is sufficiently 
modular to permit use at both the trial design and data analysis stages. 
8. The use of the metric standardised bias is not routinely reported in the 
published literature that summarises simulation studies and through 
extensive use in simulations as part of this thesis, I would recommend more 
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widespread adoption. In particular, using a combination of the ±40% rule-of-
thumb of Collins et al. (2001) it would be straightforward to identify potential 
study designs at the planning stage that may lead to high bias and 
variability. 
9. The findings from the elicitation case studies and the simulations have also 
been used to make recommendations for improvements to the design of the 
kisspeptin trial that motivated this research. It should be possible to design a 
more efficient Phase 2 trial that would identify a single dose to take forward 
to confirmatory trials with fewer than 40 patients (i.e. less than half of the 
original planned sample size) and, potentially 20 fewer patients than the 53 
women in the actual Phase 2 trial that was conducted (Jayasena et al., 2014)). 
Furthermore, since such a Phase 2 trial is highly likely to identify a single 
dose to take forward to confirmatory trials then the time and cost of such a 
confirmatory trial would be less. Additionally, fewer women may also be 
exposed to doses that may lead to ovarian hyperstimulation. 
10. The simulations show that there is no single set of priors that always 
produce unbiased estimates with minimum variance across a full range of 
target response rates, so simulations specific to the planned trial must be 
conducted beforehand. The statistician can then adjust the assumptions to 
test for robustness of the conclusions. For example, on the basis of pre-
clinical information it may be more likely that the molecule could lead to 
responses in the range 0.6 to 0.8 than, say, 0.1 to 0.4. Likewise, the 
simulations may suggest that more robust conclusions could occur if a 
specific set of doses or priors are used. 
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9.3 Limitations and Future Research 
As discussed in Section 5.5.2, more empirical research is needed to confirm the 
initial finding that the two experts found it much easier to interpret the two 
parameters 𝜌0 and γ using the schematic representation of the EWOC dose response 
curve (see Figure 8) than the equations (see Equations ( 2.8 ) and ( 2.9 )). 
During early phase trials that include a number of pre-specified doses (e.g. dose 
levels may be restricted to formulations that can be manufactured) then it is 
important to clearly specify in a structured elicitation session if the experts are to 
provide their beliefs based on the available pre-specified list of doses versus an 
unrestricted range of doses. Based on the preliminary findings from Section 5.5.2, 
further empirical research is warranted to see if the elicited probability distributions 
are consistent across those two scenarios (i.e. restricted versus unrestricted doses). 
Non-uniform spacing of doses (even after suitable transformation) may occur in 
clinical trials so the development of new software (compared with SHELF and 
MATCH) is required in order to more easily use the Chips in Bins / Roulette method. 
I recommend that software be developed (e.g. extend the SAS/STAT® software in 
this thesis) so that the facilitator in the elicitation session could create plots of the 
induced dose-response curve in real-time (e.g. produce plots such as those in 
Figure 18). Such plots could provide the experts with a check of the dose-response 
shape and possible variability to be observed in the planned trial. 
Since the simulations to evaluate the large sample properties of the EWOC design 
employed an arbitrary choice in how to standardise the dose levels (see Section 6.3 
for centering around dose=0, as per Bedrick et al. (1996)) it would be useful to 
perform additional simulations that employ an alternative rule, for example, to 
divide by a reference dose as implemented by Neuenschwander et al. (2008)). 
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Further limitations of the work undertaken in this thesis include the restriction to 
only three dose-response models and so further models could be considered. It 
would also be beneficial to evaluate alternative automated methods to conduct 
extensive MCMC simulations to minimise the number of simulated trials in which 
the target distribution may not have been reached. 
With the advent of targeted biologic agents, early stage drug development is less 
reliant on estimating a single dose with pre-specified toxicity but is increasingly 
about evaluation of benefit and risk of proceeding to later stage trials. It may also 
be about the speed at which to progress promising molecules. For example, if there 
is no standard of care in a disease setting then a promising efficacy signal of a 20% 
response rate may be sufficient benefit to outweigh a 40% toxicity rate, whereas in a 
disease setting with a standard of care attaining 40% response rates then a 
response rate of 70% may be needed to even outweigh a toxicity rate of (the 
traditional) 30%. As such, it would be useful to characterise the performance of the 
Bayesian 2-parameter logistic model under the scenario when an initial target 
efficacy is set (e.g. 80%) but due to emerging safety data the target efficacy is 
changed (e.g. to 70%). 
In many disease settings, a biomarker may be available that correlates with the 
clinical endpoint and if such a biomarker is available sooner than the clinical 
endpoint, then it could provide a quicker evaluation of efficacy. As such, it would be 
useful to conduct research into how to conduct a two-step elicitation process for 
the biomarker and the clinical endpoint (i.e. assess the effect of the drug on the 
biomarker then assess the change on clinical endpoint conditional on the biomarker 
change). Such research could evaluate if the resulting priors from 2-step elicitation 
is similar to the one-step elicitation process for the effect of drug on the clinical 
endpoint. 
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9.4 Conclusions 
When planning an early phase trial to evaluate preliminary efficacy and/or safety 
(i.e. response rates between 0.1 and 0.9), the 2-parameter Bayesian logistic model 
with the EWOC design provides a flexible method to incorporate emerging data to 
estimate the dose leading to a target response rate. In this thesis I have 
demonstrated that the EWOC model formulation plays an important role in 
minimising bias and I recommend that the EWOC2 parameterisation (see Equation   
( 6.2 )) is the initial parameterisation to use when designing a trial with informative 
priors and the EWOC design. Once priors have been elicited with the EWOC2 
parameterisation, simulations could also be performed using the EWOC1 
parameterisation to assess the impact of re-parameterisation. This observation 
extends the findings of Chu et al. (2009) who made similar findings in the specific 
case of θ=0.33. For trials targeting response rates around 0.5 to 0.6, the model 
estimates have been shown to be reliable once at least 40 patients have been 
accrued even if a mis-specified prior had been used. For much higher target 
response rates (e.g. 0.9) then bias may still be present until approximately 60 
patients have been accrued. For trials with a discrete set of doses available, using a 
dose allocation rule that always assigns a dose lower than the model estimate 
should be avoided; instead the nearest dose should be allocated to the next patient. 
The simulations in this thesis have shown that it is possible to conduct trials with as 
few as 20 patients to obtain reliable estimates of the dose leading to a pre-
specified target toxicity but these generally require more informative (and correctly 
specified) prior distributions for the model parameters. Using a structured approach 
to elicit expert beliefs is a viable method to form such prior distributions, however, 
the statistician designing a future trial should use clinical trial simulation to 
evaluate the impact of using a mis-specified prior. 
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Obtaining efficient estimates of dose-response in early phase trials will lead to 
fewer patients being exposed to ill-tolerated, sub- or supra-therapeutic doses and, 
furthermore, obtaining more reliable estimates of dose-response in early phase 
trials will lead to more efficient confirmatory (Phase 3) trials. 
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Structured approach to the elicitation of
expert beliefs for a Bayesian-designed
clinical trial: a case study
Nelson Kinnersley* and Simon Day
To quantify uncertainty in a formal manner, statisticians play a vital role in identifying a prior distribution for a Bayesian-
designed clinical trial. However, when expert beliefs are to be used to form the prior, the literature is sparse on how feasible
and how reliable it is to elicit beliefs from experts. For late-stage clinical trials, high importance is placed on reliability;
however, feasibility may be equally important in early-stage trials.
This article describes a case study to assess how feasible it is to conduct an elicitation session in a structured manner and to
form a probability distribution that would be used in a hypothetical early-stage trial. The case study revealed that by using a
structured approach to planning, training and conduct, it is feasible to elicit expert beliefs and form a probability distribution
in a timely manner. We argue that by further increasing the published accounts of elicitation of expert beliefs in drug devel-
opment, there will be increased confidence in the feasibility of conducting elicitation sessions. Furthermore, this will lead to
wider dissemination of the pertinent issues on how to quantify uncertainty to both practicing statisticians and others involved
with designing trials in a Bayesian manner. Copyright © 2013 John Wiley & Sons, Ltd.
Keywords: Bayesian; elicitation; beliefs; expert opinion; feasibility
1. INTRODUCTION
In the design and analysis of clinical trials that implement
Bayesian methods, a prior distribution is required for the param-
eters of interest, which is then combined with the collected data
(through the likelihood) to form a posterior distribution for those
parameters. Inferences and decisions are then made using the
posterior. The choice of which prior has been the subject of much
debate in the literature [1–6], and it is not the intention of this
article to repeat that debate but instead to focus on the scenario
where expert opinion may be available from which to form a prior
distribution that may be used in the design and analysis of a trial.
The literature reveals two general approaches to forming
prior probability distributions using beliefs elicited from multiple
experts, generally referred to as mechanical (or mathematical) and
behavioural or (group) aggregation [7]. A Bayesian approach to
combining expert opinion has also been proposed recently [8].
Whichever approach is selected, it should be noted that multiple
prior distributions could be formed to assess the characteristics
and impact of those priors. Ultimately, prespecifying which prior
has been selected for combining with trial data will increase the
integrity of the study. For example, Spiegelhalter et al. [9] used
the terms sceptical and enthusiastic priors to advocate forming of
priors at either end of plausible beliefs so that those interpreting
the trial results would have a vehicle against which to judge their
own priors (note that the authors acknowledged that Cornfield
[10] introduced the term ‘sceptical’).
Regardless of the number of available experts, uncertainty will
be present in the precise value of the treatment effect, and so,
statisticians can play a vital role in the process of identifying and
quantifying uncertainty in a formal manner. The use of historical
data in clinical trial design has been extensively described in the
literature (see, e.g. [5, 11–13]). Similarly, the use of pseudo-data
(also called data augmented) priors has also received increased
attention, in part, due to the simplicity of implementation [14].
Using a loss function approach, Etzioni and Kadane [15] studied
the optimal allocation of patients when those designing the trial
are different from those analysing and interpreting the trial.
However, when expert beliefs are to be used to form the prior,
the clinical trial literature is sparse on how feasible and how reli-
able it is to elicit beliefs from experts [16–18]. For late-stage trials,
high importance is placed on reliability; however, feasibility may
be equally important in early-stage trials. This article describes a
case study to assess how feasible it is to conduct an elicitation ses-
sion in a structured manner and to form a probability distribution
that would be used in a hypothetical early-stage trial.
Before providing details of the case study, we provide an
overview of the available methods for eliciting expert beliefs. This
permits description of the issues faced and decisions made when
conducting the elicitation session in practice.
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2. OVERVIEW OF METHODS OF ELICITATION
A full treatment of the available methods is beyond the scope of
this article, but the interested reader is referred to the compre-
hensive texts by O’Hagan et al. [7] and Kynn [19].
2.1. Definition of an expert
In a key paper by Morris [20] that used the Bayesian framework
for decision analysis, he describes an expert as ‘a person who
provides a judgment concerning uncertain matters’. In a medical
context with public health implications, Kadane [21] argues that
who qualifies as an expert contains political components ‘While
the politics involved rarely includes Congress, it usually does have
to do with the pecking order among physicians and scientists’.
In a rather unusually open approach, Blanck et al. [22] describe
a trial in which they list the actual names, job titles and previ-
ous relevant experience for each of the five experts who took
part in an elicitation for a clinical trial. In a contrasting approach,
Myung et al. [23] introduce a mathematical definition of expert
competence as ‘a function of the deviation between the observed
outcome and the predicted outcome’. Garthwaite et al. [24] recog-
nise that bias can be introduced if an expert has a personal
interest in the result. Although definitions of an expert may vary
amongst different authors, it is abundantly clear that the credi-
bility of inferences from the resulting trials relies heavily on the
transparency of the process to identify and incorporate expert
beliefs. Ensuring a formal method is available for increasing trans-
parency is thus an important step in the elicitation process.
2.2. Frameworks for conducting the elicitation session
Some authors [25–27] have recognised that it is impractical for
the typical researcher to distill the critical pieces of information
into a set of working practices (or elicitation protocol) that can be
used to inform the design of a new experiment. In the ecology
setting, Kuhnert et al. [28] argue that without such a framework,
the researcher can be tempted to start the elicitation process
directly without due consideration for the subsequent inferences
that need to be made.
Several features are present in a number of the frameworks,
and these have been elegantly described in six key steps by
Choy et al. [27] as follows:
 determining the purpose and motivation for using prior
information
 specifying the relevant expert knowledge available
 formulating the statistical model
 designing effective and efficient numerical encoding
 managing uncertainty
 designing a practical elicitation protocol
These six steps are further divided into 18 substeps described
by Choy et al. and, as with Cook and Goossens [25], the major-
ity could apply to the drug development domain. It is worth
noting the increasing use of technology supporting the pro-
cess of elicitation, for example, by Choy et al. who developed
the software application Elicitor as a chargeable add-on for
WinBUGS [29]. Another general purpose framework that incor-
porates (open-source) software is Sheffield Elicitation Framework
(SHELF) as developed by Oakley and O’Hagan [30].
2.3. Limitations of elicitation methods
Although the frameworks described earlier unite the essential
elements for elicitation, none currently responds directly to the
key observation of Kynn [19] in which she fervently advocated
the use of more prescriptive questioning on the basis of her
assessment of the recent advances in the psychology and cog-
nitive models literature. A thorough treatment of the psycholog-
ical aspects of assessing uncertainty is provided by Kahneman
[31]. By performing a systematic review of 33 observational stud-
ies and randomised controlled trials, Johnson et al. [17] criticise
much of the statistical literature on elicitation because of its fail-
ure to apply the criteria of measurement science. The authors
extend the earlier work of Kadane and Wolfson [32] to describe
the currently accepted measurement science criteria of validity,
reliability, responsiveness and feasibility [33]. The focus of our case
study is feasibility and, specifically, feasibility of conducting an
elicitation session in a drug development setting.
3. THE CASE STUDY
3.1. Background
In 2011, a group of four statisticians from the UK office of a
global pharmaceutical company had been formed to plan and
conduct a series of seminars on theoretical and practical aspects
of Bayesian methodology for other statisticians from the UK office.
The purpose of the series was to ensure all statisticians could
share existing expertise and identify the opportunities and chal-
lenges of implementing Bayesian approaches to drug develop-
ment. Following three seminars and practicals in other areas of
the application of Bayesian methods, the fourth seminar was
designed to introduce the audience to the literature and practi-
cal aspects of elicitation and the creation of an informative prior
using expert beliefs. This case study describes the preparation
and conduct of that session for the purpose of identifying the fea-
sibility of conducting an elicitation session. The following descrip-
tion of the case study is divided into the planning and execution
of the elicitation session before the presentation of conclusions.
3.2. Planning the elicitation session
Feedback from previous seminars in the series indicated that the
audience benefitted more when the format included a mix of
lecture and practical elements. As such, the session was planned
to include presentations on the following:
 the relevant literature on the use of informative priors
(i.e. use of historical data and/or expert opinion)
 published methods to elicit expert opinion, together with
any open problems
 description of at least one case study from the clinical trial
literature
After the presentations, a mock elicitation session would be con-
ducted that aimed to
 show a clinical trial design scenario that could benefit from
the use of a subjective prior
 identify the appropriate questions to ask the experts during
the elicitation session
 highlight the issues with identifying the attributes of an
expert who would participate in the elicitation session
 show how to conduct an elicitation session for a specific
clinical trial design objective
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 show how to convert the elicited beliefs into a (subjective)
prior
 provide a forum to discuss how an expert makes choices
about probability distributions
 provide a forum to discuss issues raised during the session
to aid future elicitation sessions
Performing an elicitation session for a real trial that was under-
going protocol development was considered but ruled out for a
number of reasons, most notably that the required project team
members (and also experts) were not all available in the time
frame required to plan the seminar. The consequences of this
decision are described later in this article. However, it was felt
that very similar issues could be highlighted by using a hypo-
thetical trial for the elicitation session. Furthermore, we included
a plan to involve the audience in discussion after the mock elic-
itation, which would highlight the issues they perceived would
occur when working on a real trial.
Once the decision was made to create a realistic, but hypothet-
ical, trial scenario, it became clear that we would need to choose a
therapeutic area known to the majority of the audience of statis-
ticians. This is not always practical in a global pharmaceutical
company in which statisticians at one site may work on a variety
of different therapeutic areas; however, in our case, inflamma-
tory diseases was chosen because a number of statisticians and
potential experts were available.
Over the following 3 weeks, the organising team together with
a physician outlined a hypothetical trial in ankylosing spondylitis
(AS) for which it would be hypothesised that an existing inflam-
matory disease medicine would be tested in this new disease
setting of AS. Decisions of which endpoint to elicit were made
(i.e. 20% improvement in ASessment of Ankylosing Spondylitis
(ASAS20), [34]). ASAS20 was assumed to follow a binomial distri-
bution (n, p/ where n corresponds to the sample size and p is the
probability of achieving ASAS20. The objective was, therefore, to
form a prior distribution for p using expert opinion as input.
Typically, one aspect of the planning of a trial involves deter-
mining the sample size accounting for expected variability of the
endpoints; however, for the purposes of the hypothetical trial,
there would be insufficient time during the session to iteratively
determine the operating characteristics of a chosen prior for vari-
ous sample sizes, and so, the organising team fixed the size of the
two treatment groups to be 20 patients each (experimental and
control groups). In setting this sample size, the organising team
discussed if the experts should be informed of this fixing before
providing their beliefs on the prior distribution of p. It was consid-
ered useful to do so, and using the work of Morita et al. [35], we
would be able to feed back to the experts the effective sample size
implied by the prior that they had formed.
To ensure the audience were familiar with the relevant termi-
nology, it was felt useful to inform the audience about the two
types of uncertainties as described by O’Hagan [36]. These were
aleatory uncertainty (i.e. induced by randomness) and epistemic
uncertainty (i.e. due to lack of knowledge). Thus, in our case
study, the response rate p represents the epistemic uncertainty
(i.e. the true value of the response rate). Had we been considering
a very large trial (e.g. 10 000 patients), then elicitation would be
essentially of the epistemic uncertainty, but for trials of much
smaller sample sizes, both aleatory and epistemic uncertainties
are present. The statistical literature is unclear as to whether
experts can accurately separate aleatory and epistemic uncertain-
ties when providing their beliefs [7].
Other features of the hypothetical molecule and trial design
included the following:
 the mechanism of action
 current stage of drug development
 the specific trial objective for the planned trial
 comparison(s) of interest to enable evaluation of the trial
objective
 likely size of a such a trial (to mimic time and budget
constraints)
 any relevant supporting (medical) publications for the
experts to read
During the practical element of the seminar, it was decided that
the team of experts would be asked to plan a future Phase 2 study
with study size as small as possible to establish the likely effects
of the drug. To ensure a manageable set of literature from which
the experts would draw knowledge, five articles relating to AS
were distributed to six scientists with expertise in clinical science,
drug safety (two people), biomarkers, clinical pharmacology and
medical statistics.
There was a need for the organising team to determine
which of the available methods from the literature would be
used to elicit expert beliefs for proportions, and because the
Roulette method (also known as chips in bins method), origi-
nally introduced by Gore [37], had been validated and imple-
mented by Johnson et al. [38, 39] in another inflammatory disease
(scleroderma), it was selected for the seminar.
Previous research on transparency of assumptions for elicita-
tion (e.g. see Kuhnert et al. [28]) has shown that it is necessary
to document the most important features of the session before
conducting it. The SHELF version 2 [30] was selected because of
previous familiarity with the framework and because it included
an open-source R package [40] to display the resulting prior
probability distribution(s).
The final decision to be made before the rehearsal concerned
the room configuration for the experts. The SHELF framework
permits each expert to provide their own assessment of the prob-
ability distribution before going on to form the distribution as a
group of experts. Hence, it was decided to use the individual elic-
itation step to reveal the thought process of each expert to the
audience by assigning a single expert to a table in the room and
to have audience members sit alongside the expert. During the
individual elicitation task, the audience would be encouraged to
ask the expert to justify their choice at each step. For example, to
prompt the expert for what evidence they used in order to form
their opinion about the shape and location of the distribution.
In summary, the following materials were created for a
rehearsal performed two working days before the planned
seminar:
 description of the elicitation protocol to be used by the
facilitators during the elicitation session using the SHELF
framework
 (card) sheets to be used by the experts to place stickers
representing their individual opinion of the probability dis-
tribution for p
 code to run the R package accompanying SHELF to enable
visualisation of the distribution(s) elicited during the group
expert elicitation step
The rehearsal revealed the issues described in Table I:
Following the rehearsal, amendments to address issues
identified in Table I were made to the elicitation protocol, and the10
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Table I. Issues identified during rehearsal of training in expert elicitation.
Learning Solution Reason(s)
Using five articles as the reference
material introduced substantial room
for debate that caused longer duration
to conduct elicitation
Use only two articles as the standard
reference material in the seminar
Reducing to two articles permitted
reasonable debate within allotted
timescale without losing significant
impact on seminar objectives. Note
that for a real trial, all relevant articles
should be included.
Restricting range of allowable proba-
bilities (i.e. narrower than range 0–1)
would not improve elicitation
Keep range 0–1 In some situations (e.g. very rare
events), restricting to a narrow range
such as 0–0.01 permits bin widths
that are wide enough to differenti-
ate expert opinion; however, for the
ASAS20 endpoint, experts believed
restriction of range could adversely
affect their choices.
Number of bins for experts to place
chips was felt to be too low by some
experts and therefore not accurately
reflect their beliefs
Keep at 10 R package accompanying Sheffield
Elicitation Framework version 2 does
not support changing the number
of bins.
Elicitation of beliefs based on likely
response rates observed in a small trial
is different from elicitation of beliefs for
true (but unknown) response rate in
infinite population
Retain questioning focussing on
smaller trial size but ask audience at
each table to pose questions to the
expert at their table about likely effects
in infinite population
Theoretically desirable to ask for
epistemic uncertainty (i.e. infinite
population) but wanted to be able to
feedback equivalent sample size esti-
mates to experts following elicitation
in real time.
Clinical trial group size of 20 patients
was too low to permit experts to differ-
entiate between 1 and 2 responders
Amend target trial size to 60 patients
with 2:1 randomisation (experimental :
control)
Greater ability to differentiate beliefs
for 40 patients in the experimental
group when using 30 chips.
resulting final document appears in the Appendix. The elicita-
tion protocol thus contained all of the features of the planned
session, and the interested reader is strongly encouraged to read
the protocol in the Appendix before proceeding further. In brief,
the objective of the session was to elicit the proportion of respon-
ders in the experimental group in a planned trial of 60 AS patients
randomised in a 2:1 ratio (experimental : control).
The need for flexibility over available personnel was also under-
lined by an assignment of a different expert statistician at the
rehearsal compared with the expert statistician at the seminar.
3.3. Executing the elicitation session
At the start of the seminar, a short presentation was given that
described relevant terminology, the available published elicita-
tion methods (with recommendations for usage) and a published
clinical trial case study using the article by Tan et al. [41] in hepato-
cellular carcinoma. Next, the description of the hypothetical trial
was provided together with the structure of the 1-h elicitation ses-
sion. The audience then separated into groups at five tables such
that each table had an expert and four (or five) audience members
(i.e. statisticians). The facilitator proceeded to conduct the elicita-
tion session according to the protocol in the Appendix, starting
with individual elicitation, then group elicitation.
3.4. Summary of the results from the elicitation session
Although space does not permit a detailed description of the
elicited quantities and fitted prior distribution resulting from
the elicitation, the interested reader is encouraged to review the
results in this section in tandem with the elicitation protocol in
the Appendix.
The experts reported that it was more straightforward to spec-
ify their most likely value for ASAS20 response than it was to spec-
ify other aspects of the distribution, for example, the tails. This
finding is consistent with the literature [32, 42]. Throughout the
individual elicitation task, the experts were prompted to justify
their choices by the statisticians sitting at their table. At the com-
pletion of the individual elicitation, the experts were brought
together as a group and asked to comment on the variety of distri-
butions from their fellow experts before proceeding to the group
elicitation stage.
As per the elicitation protocol, the accompanying R package
for SHELF was used to visualise the construction of the consensus
prior. As with the individual elicitation, the facilitator prompted
the experts to place their first electronic chip (most likely value for
ASAS20) before proceeding to ask them to form the full consensus
distribution.
The agreed placing of 30 electronic chips to represent the prior
beliefs of ASAS20 at week 14 for the experimental group is shown
in Figure 1.
Pharmaceut. Statist. 2013, 12 104–113 Copyright © 2013 John Wiley & Sons, Ltd.
1
0
7
N. Kinnersley and S. Day
Figure 1. Final screenshot of chips in bins from group elicitation.
Figure 2. Final screenshot of fitted beta distribution from data generated by chips
in bins from group elicitation.
When planning and writing the elicitation protocol, it was
anticipated that a beta distribution would be fitted to the elec-
tronic chips and feedback quantities provided to the experts
to check that the fitted distribution reflected their beliefs. It is
acknowledged that other distributions could have been fitted
and sensitivity analyses performed; however, because of time
constraints, only the preplanned beta distribution was fitted dur-
ing the elicitation session.
Figure 2 shows the final fitted consensus distribution that the
experts agreed to represent their prior beliefs of ASAS20 endpoint
at week 14 of a planned hypothetical trial in 40 patients treated
with the experimental drug.
This consensus distribution was reached by checking that the
experts confirmed their acceptance of the following five features
that derived from specific characteristics of a two-parameter beta
distribution with parameters 3.23 and 4.71, namely:
 10% chance that the ASAS20 at week 14 for the experi-
mental group would lie at or below 0.19 (i.e. 19% response
rate).
 10% chance that the ASAS20 at week 14 for the experimen-
tal group would lie at or above 0.63.
 The expected value of the ASAS20 at week 14 for the
40 patients treated with the experimental drug would be
0.407 (i.e. 40.7% response rate).
 The equivalent sample size of the expert opinion was 7.94
patients (found by summing the parameters of the beta
distribution).
 The expert opinion was equivalent to 3.23 of the 7.94
patients achieving ASAS20 at week 14 for the experimental
group.
If more time had been available, a comparison of the consen-
sus distribution with the five distributions formed from the first
part of the practical (with card and stickers) would have been per-
formed to see how changes had occurred moving from individual
to group elicitation. Such an exercise would also have permitted
discussion by the experts about their reasons for making such
changes. It has been hypothesised that such changes can be due
to a variety of reasons such as the dictator effect or due to the
effects of hearing alternative interpretations of the literature by
fellow experts [7].
Lessons Learned
Implementing a structured expert elicitation session to form a
prior distribution for use in a hypothetical clinical trial requires
careful planning and making decisions on the format, content and
conduct. Some of the specific lessons learned and recommenda-
tions are described in Table II.
4. DISCUSSION
Making use of information external to the currently planned trial
is a feature available to both frequentist and Bayesian approaches
to clinical trial design. In the Bayesian approach where a prior
distribution is combined with the likelihood (from the trial data)
to form the posterior distribution, the method of formation of a
prior is a well-documented barrier to implementation of Bayesian
designs with informative priors (see, e.g. Altman’s response to
Spiegelhalter et al. [9], in which Altman expresses concern that
informed clinicians could use the process to affect results of the
trial). To show how a prior distribution can be constructed in
a transparent manner using a systematic framework, this case
study describes how a group of statisticians at a pharmaceutical
company enlisted the help of colleagues to plan and execute a
hands-on practical designed to construct an informative prior for
a hypothetical clinical trial. The case study revealed that by using
a structured approach to planning, training and conduct, it is fea-
sible to elicit expert beliefs and form a probability distribution in a
timely manner. An elicitation protocol is an important document
to record the preplanned choices and rationale for those choices.
The case study revealed issues that require further research
before the routine use of the chips in bins methods can be relied
upon to accurately represent expert beliefs. For example, the elic-
itation questions used in this case study required the experts
to form the prior distribution for the planned study directly
(i.e. combination of both aleatory and epistemic uncertainties).
Further empirical research is required to repeat the case study
using questions that ask the experts to consider (only) the true
(but unknown) parameter value (i.e. from an infinite population)
and for the facilitator to transform the elicited quantities in real
time to the prior distribution that would be used for the much
smaller trial being planned.
Because the clinical trial scenario was entirely hypothetical, it
was not possible to ascertain the extent to which consensus was
reached amongst the experts merely to finish the exercise rather
than to truly devise a distribution that represented their beliefs.
Anecdotal feedback from the five experts involved in the practi-
cal (as well as from those additional experts who attended the
rehearsal) suggests that they completed the exercise with full
intentions. On a related issue, the hypothetical nature also meant
that it was not possible to assess if the experts behaved in the
same way as if they had a vested interested in the outcome of the
trial [21]. All of the experts found it harder to assess the tails of
the distribution than the value they felt most likely to occur, an
observation consistent with the literature [32]. In future research,
it would be useful to study what shapes for the tails have a large
impact on resulting inferences.
Whether in a frequentist or a Bayesian framework, the design
and analysis of many clinical trials relies on the assumption10
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Table II. Recommendations for the conduct of training in expert elicitation for clinical trials.
Topic Recommendation
1. Format of training Incorporating a presentation of the elicitation literature followed by conduct-
ing individual elicitation (with observers) then by group elicitation is a feasible
approach to enhance learning of the issues involved with the conduct of an
elicitation session.
2. Content of training Choosing a therapeutic area known to the audience ensures familiarity of the
clinical trial endpoints. From this single case study, it is not possible to identify
the issues that would arise if a real clinical trial was used for the training, and so,
further empirical research is required.
3. Use of an elicitation protocol Preparing a document that includes key features of the elicitation process and
that can be used as record of the elicitation session will promote transparency of
methodology.
4. Question structure Providing prescriptive questions that closely reflect the intended study design
and endpoints will minimise ambiguity of interpretation by the experts.
5. Specialism of experts At a minimum, identify those disciplines that typically contribute to clinical trial
protocol design. This is likely to include (but not be limited to) one or more
physicians, statisticians, pharmacologists, drug safety and biomarker experts.
6. Availability of experts Co-locating all experts facilitates preparation, training and discussion during the
elicitation session. Implement contingency plans for unavailability of experts
(for the rehearsal and the elicitation session).
7. Distinguishing types of uncertainty Ensure experts understand the concepts of aleatory and epistemic uncertain-
ties. Further research is required to discover optimal methods for converting
estimates of epistemic uncertainty in real time to implications on planned
study design.
8. Choice of elicitation instrument Use of the Roulette (chips in bins) instrument is feasible in the context of train-
ing; research has also shown its validity in other settings [38, 39]. Evidence of the
performance of other instruments is currently sparse [17]. Assessment of the tails
of the distribution was more difficult for our experts than elicitation of the most
likely value.
9. Use of technology Incorporating interactive visualisations of the prior distribution facilitates discus-
sion between the experts when constructing a consensus distribution.
10. Choice of prior distribution To promote transparency, the protocol should justify the prespecified choice of
prior distribution used to fit the expert beliefs together with a description of how
that choice might be affected once beliefs are elicited.
11. Feedback mechanisms Providing quantiles and the equivalent sample size [35] to the experts during
elicitation is a useful means for them to assess the elicited prior.
of a prespecified model for the responses, and so, model mis-
specification is an important consideration (see for example
McCulloch et al. [43]). In the Bayesian framework where the addi-
tional effects of a mis-specified prior could arise, it is not fully
clear how the elicitation process should proceed, although the
Bayesian model averaging techniques [44] may offer some poten-
tial. However, further research is required in this area.
The experts confirmed that the elicitation session had been
a valuable exercise in which they had learnt a great deal about
implementing a structured approach to documenting uncer-
tainty as part of the process of designing a hypothetical Phase 2
clinical trial. Furthermore, the audience of statisticians attending
the seminar provided feedback that they found the SHELF frame-
work a useful format to use for documenting the beliefs of the
experts whether they would go on to design a clinical trial in a
frequentist or Bayesian manner.
It would also be useful to evaluate the choice of fitted dis-
tribution (i.e. beta distribution in this case) to assess if it had
any substantial influence on the inferences from the clinical
trial. However, we maintain that prespecification in an elicitation
protocol promotes the transparency that permits reviewers to
evaluate such a choice after the results are known. Furthermore, it
would be interesting for future research to evaluate methods that
permit a range of models to be employed [45].
5. CONCLUSION
Involving those people designing clinical trials in the preparation
and conduct of an elicitation practical using a hypothetical clini-
cal trial is a feasible method to increase understanding on how to
document expert beliefs. We contend that by further increasing
the number of published accounts of elicitation of expert beliefs
in drug development, there will be increased confidence in con-
ducting elicitation sessions. Furthermore, this will lead to wider
dissemination of the pertinent issues on how to quantify uncer-
tainty to both practicing statisticians and others involved with
designing clinical trials in a Bayesian manner. In addition to fur-
ther empirical research on the feasibility of conducting elicitation,
more research is required to establish the measurement science
properties of the available elicitation instruments in the clinical
trial domain.
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APPENDIX A. PROTOCOL DEVELOPED FOR ELICITATION SESSION USING SHELF v2
Elicitation title Elicitation of a Proportion for the Experimental group response in a planned trial of Ankylosing Spondylitis
patients randomized to placebo or Experimental
Session 1 of 1
Date 6 Sep 2011
Quantity Proportion of patients who display at least 20% improvement in the ASsessment in AS International Working Group
criteria (ASAS20) at Week 14.
Start time 13:00
Definition ASAS20 is defined as per Anderson et al (2001) and in this Phase 2 study a patient is considered as providing valid
results if all component measures for ASAS are recorded at both baseline and Week 14.
The denominator for the proportion is the set of patients:
 meeting the protocol-defined definition of Ankylosing Spondylitis
 DMARD-Inadequate Responder
 with BASDAI (Disease Activity) score> 4
 CRP level >1.5 mg/dl and mean age 40y (range 30-50)
 and who are randomised to the Experimental treatment arm (regardless of what treatment they actually
received)[-3pt]
The numerator for the proportion is the subset of patients (from the denominator) who:
 have a CRF field completed showing evidence that they achieved an ASAS20 at Week 14
Evidence
 Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group
preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis & Rheumatism 2001; 44:
1876–86.
 Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z.,
Hsu, B., Beutler, A. and Braun, J. (2008), Efficacy and safety of golimumab in patients with ankylosing spondylitis:
Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis & Rheumatism; 58: 3402–3412
Plausible range The Facilitator will ask the experts (as a collective) to consider a planned Phase 2 trial that should enrol as few patients
as possible (target 60 total, with 40 on Experimental) and to identify range of values (between 0 and 1) in which it is
extremely unlikely that the ASAS20 will lie outside (i.e. for the proportion of the Experimental group achieving ASAS20).
Alternative way to think about this is to specify a range (for the Experimental group) outside of which the experts would
consider the trial to be questionable Expecting to keep entire 0-1 range but explain to audience that other scenariosmay
benefit from reducing scale at outset e.g. rare AEs where 1:1000 versus 1:100000may require narrower plausible range
Chips in bins One expert will be assigned to each table in the room, at which will also be seated a number of statisticians who are
mainly considered observers (since they constitute the audience being trained) butwhomay also question/interactwith
the expert during the initial elicitation step (see later). If there aremore experts than tables then groupings will bemade
such that every expert has a “group” with whom he/she may interact. Within the expert’s assigned table (and without
consulting the other experts at other tables), each expert will be given 30 chips to place in 10 bins. The bins will span the
range identified in the “Plausible Range” question above. The Facilitator will use the “Definition” field above to ask the
experts to start by considering where they think themost likely valuewill occur and place some chips in that bin. Each
expert should be willing to explain their rationale to the other people at their table. Next, the expert should consider
what is the lowest value (on Experimental) that is likely to be observed in the planned study and they should place 1
or more chips in that lowest bin. Again, the expert should be willing to explain their rationale. Repeat the process for
the largest value that might be observed; then place remaining chips to form the entire distribution representing that
expert’s beliefs. It is permitted for an expert to revise his/her choice throughout this process and the expert is encouraged
to explain their reasons for revising to the other people at his/her table.
Fitting For each expert’s placing of chips, the Session Facilitatorwill join the expert at their table and superimpose a single prob-
ability distribution thatmost closely captures the expert’s beliefs. Feedback to the expert is not expected at this stage but
may be accepted if the expert is insistent that the fitted distribution is a poor reflection of his/her beliefs.
NOTE: capturing the individual beliefs permits identification of the divergent views prior to group elicitation. The
distributions for each expert will be brought to the front of the room and revealed to everybody.
Pharmaceut. Statist. 2013, 12 104–113 Copyright © 2013 John Wiley & Sons, Ltd.
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Group elicitation After discussion of the distributions of the different experts, and sharing of knowledge and reasoning about the
differences, the facilitator will lead a session to create and record a group allocation of chips to bins. This will use
an interactive software application to represent the placing of chips into bins:
 start with a blank sheet with 10 bins
 ask for agreement on themost probable bin and allocate a chip there
 then ask for agreement on the lowest bin in to which at least 1 chip should be placed
 repeat for highest valued bin
 continue until all chips have been placed.
Before discussion, there are two components of uncertainty in the group – uncertainty that each expert has and
is expressed in that expert’s set of chips, as well as variability between the experts’ judgements. The agreed bin
probabilities should reflect the group’s overall uncertainty that remains after the discussion.
(example screenshot attached)
Fitting and feedback The facilitator first fits a distribution to the group’s elicited probabilities. This is shown to the experts, and the fitted
probabilities compared with elicited values. The experts are invited to consider whether the fit is acceptable. The
facilitator then feeds back to the experts some implied probabilities in the fitted distribution, such as the 10th and
90th percentiles, or the median and quartiles. The experts are invited to consider whether these are reasonable
reflections of the group’s knowledge.
Example screenshot attachedbut ideas in followingbulletswill beadapted in real-timeduring theactual elicitation
 shows 0.1 and 0.9 quantiles i.e. we think there’s a 10% chance that the ASAS20 response is below 0.15 and a
10% chance it will be above 0.44 with amean value of 0.29
 this assumes a Beta Distribution is a good fit to the group of experts’ beliefs
 Facilitator will feedback the Effective Sample Size that the Beta Distribution represents e.g. 4.38+10.7=
“15.08 patients worth of data”. The Facilitator will then ask the group of experts if this ESS is a reasonable
size given their preliminary thoughts on the eventual size of the planned Phase 2 study
 The Facilitator will also convey that a Statistician can then start an iterative process to compute the sample
size given this Prior. For example, by choosing trial size n such that 95% Credible Interval of the Posterior
mean is of certain width.
1
1
2
Copyright © 2013 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2013, 12 104–113
N. Kinnersley and S. Day
Chosen distribution The finally fitted distribution will be recorded here.
Discussion The facilitator should record here any difficulties that arose during the elicitation of this distribution. Also the
experts’ reactions to the process and to the finally fitted distribution.
The elicitation record should be open about any concerns with the finished distribution. The SHELF protocols are
designed to avoid many of the pitfalls of elicitation, but no process is perfect. It is important to be critical and real-
istic about the result. Nevertheless, it is important also to remember that, despite whatever deficiencies it might
have, the elicited distribution is our best attempt. It has been developed using a robust protocol, and since expert
knowledge is needed in the wider organisation there is no alternative!
End time 14:15
Attachments Facilitator will include any attachments, e.g. plots of distributions
Pharmaceut. Statist. 2013, 12 104–113 Copyright © 2013 John Wiley & Sons, Ltd.
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Appendix C Elicitation Protocol for Kisspeptin Case Study 
Appendix C.1 Roulette (Chips in Bins) Method for Proportion 
 
Elicitation title Elicitation of the Proportion of patients administered 0.4nmol/kg who 
produce oocyte maturation in a planned trial of kisspeptin  
Session 1 of 1 
Date 19 April 2012 
Quantity Proportion of patients on the lowest dose (0.4nmol/kg) of kisspeptin 
who display oocyte maturation within 36 hours of kisspeptin 
administration.  
Start time 11:00 
 
Definition Oocyte maturation is defined as presence of a polar body (which 
indicates they are in  metaphase 2 stage). 
The denominator for the proportion is the set of patients: 
• meeting the protocol inclusion and exclusion criteria 
• and who have been administered 0.4nmol/kg of kisspeptin 
• and who have measurements of plasma LH, FSH, oestradiol 
and kisspeptin at the baseline administration of kisspeptin 
The numerator for the proportion is the subset of patients (from the 
denominator) who: 
• show evidence that they achieved oocyte maturation within 
36 hours of kisspeptin administration 
Relevant 
Evidence for 
elicitation 
• Dhillo, W.S. (2008) Kisspeptin: A novel regulator of reproductive 
function. Journal of Neuroendocrinology, 20 (8), pp.963–970. 
• Dhillo W.S., Chaudhri, O.B., Patterson, M., Thompson, E.L., 
Murphy, K.G., Badman, M.K., McGowan, B.M., Amber, V., Patel, 
S., Ghatei, M.A. & Bloom, S.R. (2005) Kisspeptin-54 stimulates the 
hypothalamic-pituitary gonadal axis in human males. Journal of 
Clinical Endocrinology & Metabolism, 90 (12), pp.6609–6615. 
• Dhillo, Waljit S., Chaudhri, O.B., Thompson, E.L., Murphy, K.G., 
Patterson, M., Ramachandran, R., Nijher, G.K., Amber, V., 
Kokkinos, A., Donaldson, M., Ghatei, M.A. & Bloom, S.R. (2007) 
Kisspeptin-54 stimulates gonadotropin release most potently during 
the preovulatory phase of the menstrual cycle in women. Journal of 
Clinical Endocrinology & Metabolism, 92 (10), pp.3958–3966. 
• Hameed, S., Jayasena, C.N. & Dhillo, W.S. (2010) Kisspeptin and 
fertility. Journal of Endocrinology, 208 (2), pp.97–105. 
• Hameed, S. & Dhillo, W.S. (2010) Biology of Kisspeptins. In: R. 
Quinton ed. Frontiers of Hormone Research. Basel, KARGER, 
pp.25–36. Available from: 
<http://www.karger.com/doi/10.1159/000312691>. 
• Jayasena, C.N., Comninos, A.N., Misra, S., Ali, A., Aniket, T., 
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Donaldson, M., Ghatei, M.A., Bloom, S.R. & Dhillo, W.S. (2011) 
kisspeptin-54 injection stimulates activity of the human GnRH pulse 
generator in healthy women. In: Society for Endocrinology BES 
2011. Birmingham, UK, p.P269. Available from: 
<http://www.endocrine-abstracts.org/ea/0025/default.htm>. 
• Jayasena, C.N., Nijher, G.M.K, Abbara, A., Murphy, K.G., Lim, A., 
Patel, D., Mehta, A., Todd, C., Donaldson, M., Trew, G.H., Ghatei, 
M.A, Bloom, S.R. & Dhillo, W.S. (2010) Twice-weekly 
administration of kisspeptin-54 for 8 weeks stimulates release of 
reproductive hormones in women with hypothalamic amenorrhea. 
Clin Pharmacol Ther, 88 (6), pp.840–847. 
• Jayasena, C.N., Nijher, G.M.K., Comninos, A.N., Abbara, A., 
Januszewki, A., Vaal, M.L., Sriskandarajah, L., Murphy, K.G., 
Farzad, Z., Ghatei, M.A., Bloom, S.R. & Dhillo, W.S. (2011) The 
effects of kisspeptin-10 on reproductive hormone release show 
sexual dimorphism in humans. Journal of Clinical Endocrinology & 
Metabolism, 96 (12), p.E1963-E1972. 
• Kol, S. (2004) Luteolysis induced by a gonadotropin-releasing 
hormone agonist is the key to prevention of ovarian 
hyperstimulation syndrome. Fertility and Sterility, 81 (1), pp.1–5. 
• Nijher, G.M.K., Chaudhri, O.B., Ramachandran, R., Murphy, K.G., 
Zac-Varghese, S.E.K., Fowler, A., Chinthapalli, K., Patterson, M., 
Thompson, E.L., Williamson, C., Kumar, S., Ghatei, M.A., Bloom, 
S.R. & Dhillo, W.S. (2010) The effects of kisspeptin-54 on blood 
pressure in humans and plasma kisspeptin concentrations in 
hypertensive diseases of pregnancy. British Journal of Clinical 
Pharmacology, 70 (5), pp.674–681. 
• Rienzi, L., Ubaldi, F.M., Iacobelli, M., Minasi, M.G., Romano, S., 
Ferrero, S., Sapienza, F., Baroni, E., Litwicka, K. & Greco, E. 
(2008) Significance of metaphase II human oocyte morphology on 
ICSI outcome. Fertility and Sterility, 90 (5), pp.1692–1700. 
• Sam, A. & Dhillo, W.S. (2010) Kisspeptin: A critical regulator of 
puberty and reproductive function. Current Drug Targets, 11 (8), 
pp.971–977. 
Plausible range In this part of the elicitation session, the experts (as a collective)  
should identify the range of plausible values (between 0 and 1) for the 
proportion of patients who respond on the lowest dose. This task is 
designed to determine if the experts can determine a set of values in 
which it is extremely unlikely that the proportion responding on the 
lowest dose will lie outside. In many situations, restricting the range is 
not required but in some instances (e.g. extremely rare events, such as 
1 in 1000000) performing elicitation on the full range loses the 
required granularity. 
Given the assumptions above, the Facilitator will firstly ask the 
experts (as a collective) to consider the hypothetical situation where a 
very large number of patients (e.g. 1,000,000 patients) would be given 
the lowest dose (i.e. 0.4nmol/kg) and the experts will need to estimate 
the proportion of those patients in whom oocyte maturation will be 
achieved. Secondly, the Facilitator will ask the experts if they can 
identify a reduced range. 
An alternative way to think about this is to specify a range (for the 
response rate on the  lowest dose group) outside of which the trial’s 
C-3 
credibility would be questioned. 
The Facilitator will record the decision from the collective here: 
• Given that the possible response rates on lowest dose lie 
between 0 and 1, is it necessary to change this range? 
Yes / No   (delete as applicable) 
If Yes, please specify the new range: ______________ 
 
Solitary 
elicitation using 
Chips in bins 
Each expert will perform the following task without consulting the 
other experts. 
Each expert will be given a form containing the schematic 
representation of an empty histogram with 10 bins. The bins will span 
the range identified in the “Plausible Range” question above. Each 
expert will also be provided with 30 chips to place in the bins. A 
screenshot of the template appears below. 
 
 
With reference to the hypothetical situation where a very large 
number of patients (e.g. 1,000,000 patients) would be given the lowest 
dose (i.e. 0.4nmol/kg), the Facilitator will use the “Definition” field 
above to ask the experts to start by considering where they think the 
most likely value will occur and place some chips in that bin. Each 
expert should be willing to explain their rationale to the Facilitator if 
prompted. 
Next, the expert should consider what is the lowest (response rate) 
value (on 0.4nmol/kg dose) that is likely to be observed in the 
hypothetical scenario and they should place 1 or more chips in that 
lowest bin. Again, the expert should be willing to explain their 
rationale. 
Repeat the process for the largest value that might be observed; then 
place remaining chips to form the entire distribution representing 
that expert’s beliefs. 
It is permitted for an expert to revise his/her choice throughout this 
process and the expert is encouraged to explain their reasons for 
revising if prompted by the Facilitator.  
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Distribution 
Fitting for 
Individual 
elicitation 
The Facilitator will ask each expert to draw (i.e. superimpose) a single 
probability distribution that most closely captures the expert’s beliefs. 
Wherever possible, the expert should attempt to create a smooth 
curve. 
NOTE: capturing the individual beliefs permits identification of the 
divergent views prior to group elicitation. 
The Facilitator will collect the elicitation forms (including 
superimposed distributions) without revealing the completed forms to 
all of the experts (yet). 
Group elicitation For this task, the Facilitator will all experts to act as a group since the 
aim is to form a distribution as a consensus. 
The Facilitator will start by revealing the output from the solitary 
elicitation session and invite each expert to justify his/her choices. 
Discussion and questioning by the other experts is encouraged at this 
stage but changes to the output from the solitary elicitation session are 
not permitted at this stage. 
After discussion of the distributions of the different experts, and 
sharing of knowledge and reasoning about the differences, the 
Facilitator will lead a session to create and record a group allocation 
of chips to bins. This will use an interactive software application to 
represent the placing of chips into bins: 
• start with a blank sheet with 10 bins 
• ask for agreement on the most probable bin and allocate a 
chip there 
• then ask for agreement on the lowest bin in to which at least 1 
chip should be placed 
• repeat for highest valued bin 
• ask for agreement on where to place all remaining chips. 
Before discussion, there are two components of uncertainty in the 
group – uncertainty that each expert has and is expressed in that 
expert’s set of chips, as well as variability between the experts’ 
judgements. The agreed bin probabilities should reflect the group’s 
overall uncertainty that remains after the discussion. 
(example screenshot attached) 
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Fitting and 
feedback 
The facilitator first fits a distribution to the group’s elicited 
probabilities. This is shown to the experts, and the fitted probabilities 
compared with elicited values. The experts are invited to consider 
whether the fit is acceptable. The facilitator then feeds back to the 
experts some implied probabilities in the fitted distribution, such as 
the 10th and 90th percentiles, or the median and quartiles. The experts 
are invited to consider whether these are reasonable reflections of the 
group’s knowledge. 
Example screenshot attached but ideas in following bullets will be 
adapted in real-time during the actual elicitation 
• shows 0.1 and 0.9 quantiles i.e. we think there’s a 10% 
chance that the response on 0.4nmol/kg is below 0.1 and a 
10% chance it will be above 0.31 with a mean value of 0.205 
• this assumes a Beta Distribution is a good fit to the group of 
experts’ beliefs 
• Facilitator will feedback the Effective Sample Size that the 
Beta Distribution represents e.g. 4+7.68= “11.68 patients 
worth of data”. The Facilitator will then ask the group of 
experts if this ESS is a reasonable size given their preliminary 
thoughts on the eventual size of the planned study 
• The Facilitator will also convey that once elicitation of the 
required 2 points on the dose-response curve has been 
completed then a Statistician can start an iterative process to 
compute the sample size given this Prior. For example, by 
choosing trial size n such that 95% Credible Interval of the 
Posterior mean is of certain width. 
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Chosen 
distribution 
The finally fitted distribution will be recorded here. Since the 
statistical modelling of dose-response requires elicitation of 2 points 
on the dose-response curve it is acceptable to revisit the elicitation of 
each point and iterate until the experts are content with the 
distributions of both points on the dose-response curve. Only the final 
distributions are required to be recorded here. 
Discussion The Facilitator will record here any difficulties that arose during the 
elicitation of this distribution. Also the experts’ reactions to the 
process and to the finally fitted distribution.  
The elicitation record should be open about any concerns with the 
finished distribution. The SHELF protocols are designed to avoid 
many of the pitfalls of elicitation, but no process is perfect. It is 
important to be critical and realistic about the result. Nevertheless, it 
is important also to remember that, despite whatever deficiencies it 
might have, the elicited distribution is our best attempt. It has been 
developed using a robust protocol, and since expert knowledge is 
needed in the wider organisation there is no alternative! 
 
End time 12:30 
Attachments Facilitator will include any attachments, e.g. plots of distributions 
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Appendix C.2 Roulette (Chips in Bins) Method for Dose 
 
Elicitation title Elicitation of the Lowest Dose that will lead to at least 90% chance 
of oocyte maturation in a planned trial of kisspeptin  
Session 1 of 1 
Date 19 April 2012 
Quantity We wish to elicit from the experts the dose of kisspeptin (in nmol/kg) 
that will lead to a 90% chance of oocyte maturation.  
Start time 11:00 
 
Definition Oocyte maturation is defined as presence of a polar body (which 
indicates they are in  metaphase 2 stage).  
To estimate the probability of oocyte maturation on various doses of 
kisspeptin, a dose-response curve will be calculated during the trial 
and revised with the emerging data. It will also be calculated at the 
end of the trial with final study data. An illustrative dose response 
curve is shown in the schematic below (blue curve). 
 
For the purposes of this elicitation session we confine ourselves to the 
final dose response curve available at the end of the trial. 
It is possible to use the dotted arrows in the above schematic to read-
off that dose which would lead to 90% chance of oocyte maturation. 
Using the terminology of Babb et al. (1998), this dose is referred to as 
Gamma. It should be noted that a dose other than one of the pre-
selected 6 doses available for the trial may be predicted by the dose 
response model. 
However, by selecting only one value for Gamma does not provide 
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any reflection of the uncertainty that exists with such a prediction. To 
reflect the uncertainty that exists, a Bayesian posterior distribution 
will be computed for Gamma (i.e. for the dose leading to >90% 
chance of oocyte maturation). 
As an illustration, if the posterior distribution of Gamma looked like 
the blue curve below then we can see that the most likely value (i.e. 
the “peak” or mode) is approximately 10nmol/kg but other likely 
values for Gamma are in the range 8 to 14nmol/kg (i.e. by visual 
inspection of the schematic below).  
 
 
For the purposes of elicitation, we require the experts to provide 
their (prior) beliefs about the likely values of Gamma (i.e. beliefs 
about the dose leading to >90% chance of oocyte maturation). 
At the end of the trial, the parameters of the dose response curve will 
be estimated using the combination of prior distributions and the 
collected data. 
Relevant 
Evidence for 
elicitation 
• Dhillo, W.S. (2008) Kisspeptin: A novel regulator of reproductive 
function. Journal of Neuroendocrinology, 20 (8), pp.963–970. 
• Dhillo W.S., Chaudhri, O.B., Patterson, M., Thompson, E.L., 
Murphy, K.G., Badman, M.K., McGowan, B.M., Amber, V., Patel, 
S., Ghatei, M.A. & Bloom, S.R. (2005) Kisspeptin-54 stimulates the 
hypothalamic-pituitary gonadal axis in human males. Journal of 
Clinical Endocrinology & Metabolism, 90 (12), pp.6609–6615. 
• Dhillo, Waljit S., Chaudhri, O.B., Thompson, E.L., Murphy, K.G., 
Patterson, M., Ramachandran, R., Nijher, G.K., Amber, V., 
Kokkinos, A., Donaldson, M., Ghatei, M.A. & Bloom, S.R. (2007) 
Kisspeptin-54 stimulates gonadotropin release most potently during 
the preovulatory phase of the menstrual cycle in women. Journal of 
Clinical Endocrinology & Metabolism, 92 (10), pp.3958–3966. 
• Hameed, S., Jayasena, C.N. & Dhillo, W.S. (2010) Kisspeptin and 
fertility. Journal of Endocrinology, 208 (2), pp.97–105. 
• Hameed, S. & Dhillo, W.S. (2010) Biology of Kisspeptins. In: R. 
Quinton ed. Frontiers of Hormone Research. Basel, KARGER, 
pp.25–36. Available from: 
<http://www.karger.com/doi/10.1159/000312691>. 
• Jayasena, C.N., Comninos, A.N., Misra, S., Ali, A., Aniket, T., 
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Donaldson, M., Ghatei, M.A., Bloom, S.R. & Dhillo, W.S. (2011) 
kisspeptin-54 injection stimulates activity of the human GnRH pulse 
generator in healthy women. In: Society for Endocrinology BES 
2011. Birmingham, UK, p.P269. Available from: 
<http://www.endocrine-abstracts.org/ea/0025/default.htm>. 
• Jayasena, C.N., Nijher, G.M.K, Abbara, A., Murphy, K.G., Lim, A., 
Patel, D., Mehta, A., Todd, C., Donaldson, M., Trew, G.H., Ghatei, 
M.A, Bloom, S.R. & Dhillo, W.S. (2010) Twice-weekly 
administration of kisspeptin-54 for 8 weeks stimulates release of 
reproductive hormones in women with hypothalamic amenorrhea. 
Clin Pharmacol Ther, 88 (6), pp.840–847. 
• Jayasena, C.N., Nijher, G.M.K., Comninos, A.N., Abbara, A., 
Januszewki, A., Vaal, M.L., Sriskandarajah, L., Murphy, K.G., 
Farzad, Z., Ghatei, M.A., Bloom, S.R. & Dhillo, W.S. (2011) The 
effects of kisspeptin-10 on reproductive hormone release show 
sexual dimorphism in humans. Journal of Clinical Endocrinology & 
Metabolism, 96 (12), p.E1963-E1972. 
• Kol, S. (2004) Luteolysis induced by a gonadotropin-releasing 
hormone agonist is the key to prevention of ovarian 
hyperstimulation syndrome. Fertility and Sterility, 81 (1), pp.1–5. 
• Nijher, G.M.K., Chaudhri, O.B., Ramachandran, R., Murphy, K.G., 
Zac-Varghese, S.E.K., Fowler, A., Chinthapalli, K., Patterson, M., 
Thompson, E.L., Williamson, C., Kumar, S., Ghatei, M.A., Bloom, 
S.R. & Dhillo, W.S. (2010) The effects of kisspeptin-54 on blood 
pressure in humans and plasma kisspeptin concentrations in 
hypertensive diseases of pregnancy. British Journal of Clinical 
Pharmacology, 70 (5), pp.674–681. 
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Ferrero, S., Sapienza, F., Baroni, E., Litwicka, K. & Greco, E. 
(2008) Significance of metaphase II human oocyte morphology on 
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Sam, A. & Dhillo, W.S. (2010) Kisspeptin: A critical regulator of 
puberty and reproductive function. Current Drug Targets, 11 (8), 
pp.971–977. 
Solitary 
elicitation using 
Chips in bins – 
Template 1 
Each expert will perform the following task without consulting the 
other experts. 
Each expert will be given a form containing the schematic 
representation of an empty histogram with 6 bins (each bin represents 
one of the available doses for the trial). Each expert will also be 
provided with 30 chips to place in the bins. A screenshot of the 
template appears below. 
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With reference to the hypothetical situation where a very large 
number of patients (e.g. 1,000,000 patients) would be given one of the 
available doses, the Facilitator will use the “Definition” field above to 
ask the experts to start by considering what they think the most likely 
dose for Gamma and place some chips in that bin. Each expert 
should be willing to explain their rationale to the Facilitator if 
prompted. 
Next, the expert should consider what is the lowest dose for Gamma 
that is likely to be observed in the hypothetical scenario and they 
should place 1 or more chips in that lowest bin. Again, the expert 
should be willing to explain their rationale. 
Repeat the process for the largest dose that might be observed; then 
place remaining chips to form the entire distribution representing 
that expert’s beliefs. 
It is permitted for an expert to revise his/her choice throughout this 
process and the expert is encouraged to explain their reasons for 
revising if prompted by the Facilitator. 
Distribution 
Fitting for 
Individual 
elicitation – 
The Facilitator will ask each expert to draw (i.e. superimpose) a single 
probability distribution that most closely captures the expert’s beliefs. 
Wherever possible, the expert should attempt to create a smooth 
curve. 
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Template 1 NOTE: capturing the individual beliefs permits identification of the 
divergent views prior to group elicitation. 
The Facilitator will collect the elicitation forms (including 
superimposed distributions) without revealing the completed forms to 
all of the experts (yet). 
Individual 
elicitation using 
Chips in bins – 
Template 2 
This task is similar to the earlier task but uses a slightly modified 
template that permits doses other than those available for the trial. 
Each expert will be given a form containing the schematic 
representation of an empty histogram with 10 bins but without dose 
values pre-printed. Each expert will also be provided with 30 chips to 
place in the bins. A screenshot of the template appears below. 
 
 
In this part of the elicitation session, the experts (as a collective)  
should identify the range of plausible doses (>0 nmol/kg) for the dose  
leading to ≥90% chance of oocyte maturation (i.e. Gamma). This task 
is designed to determine if the experts can determine a set of doses in 
which it is extremely unlikely that the dose will lead to ≥90% chance 
of oocyte maturation. In this approach the experts are free to consider 
doses other than those available in the trial. 
The Facilitator should be alert for experts who try to confine the range 
based on manufacturing, cost or other issues unrelated to the 
probability of response. In other words, it is entirely possible that a 
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dose much higher than the 6 available could be the lowest dose to 
achieve ≥90% chance of response. Similarly, there is no requirement 
to use 0.4nmol/kg in the first “bin”. 
The Facilitator should ask the experts to reach a consensus on the 10 
doses within that dose range and then each expert should annotate 
those doses in the bins on their own form. 
Each expert will perform the following task without consulting the 
other experts.  
With reference to the hypothetical situation where a very large 
number of patients (e.g. 1,000,000 patients) would be given one of the 
available doses, the Facilitator will use the “Definition” field above to 
ask the experts to start by considering what they think the most likely 
dose for Gamma and place some chips in that bin. Each expert 
should be willing to explain their rationale to the Facilitator if 
prompted. 
Next, the expert should consider what is the lowest dose for Gamma 
that is likely to be observed in the hypothetical scenario and they 
should place 1 or more chips in that lowest bin. Again, the expert 
should be willing to explain their rationale. 
Repeat the process for the largest dose for Gamma that might be 
observed; then place remaining chips to form the entire distribution 
representing that expert’s beliefs. 
It is permitted for an expert to revise his/her choice throughout this 
process and the expert is encouraged to explain their reasons for 
revising if prompted by the Facilitator.  
Distribution 
Fitting for 
Individual 
elicitation – 
Template 2 
The Facilitator will ask each expert to draw (i.e. superimpose) a single 
probability distribution that most closely captures the expert’s beliefs. 
Wherever possible, the expert should attempt to create a smooth 
curve. 
NOTE: capturing the individual beliefs permits identification of the 
divergent views prior to group elicitation. 
The Facilitator will collect the elicitation forms (including 
superimposed distributions) without revealing the completed forms to 
all of the experts (yet). 
Group elicitation For this task, the Facilitator will all experts to act as a group since the 
aim is to form a distribution as a consensus. 
The Facilitator will start by revealing the output from the solitary 
elicitation session and invite each expert to justify his/her choices. 
Discussion and questioning by the other experts is encouraged at this 
stage but changes to the output from the solitary elicitation session are 
not permitted at this stage. 
After discussion of the distributions of the different experts, and 
sharing of knowledge and reasoning about the differences, the 
Facilitator will lead a session to create and record a group allocation 
of chips to bins. This will use an interactive software application to 
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represent the placing of chips into bins: 
• Load SHELF using source(shelf2.R) and then 
invoking command roulette.single(Lo=0, Up=20) 
• start with a blank sheet with 10 bins 
• ask for agreement on the most probable bin and allocate a 
chip there 
• then ask for agreement on the lowest bin in to which at least 1 
chip should be placed 
• repeat for highest valued bin 
• ask for agreement on where to place all remaining chips. 
Before discussion, there are two components of uncertainty in the 
group – uncertainty that each expert has and is expressed in that 
expert’s set of chips, as well as variability between the experts’ 
judgements. The agreed bin probabilities should reflect the group’s 
overall uncertainty that remains after the discussion. 
(example screenshot attached) 
 
Fitting and 
feedback 
The facilitator first fits a distribution to the group’s elicited 
probabilities. This is shown to the experts, and the fitted probabilities 
compared with elicited values. The experts are invited to consider 
whether the fit is acceptable. The facilitator then feeds back to the 
experts some implied probabilities in the fitted distribution, such as 
the 10th and 90th percentiles, or the median and quartiles. The experts 
are invited to consider whether these are reasonable reflections of the 
group’s knowledge. 
Example screenshot attached but ideas in following bullets will be 
adapted in real-time during the actual elicitation 
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• shows 0.1 and 0.9 quantiles i.e. we think there’s a 10% 
chance that Gamma (i.e. dose with ≥90% chance to achieve 
oocyte maturation) is below 6.7nmol/kg and a 10% chance it 
will be above 14nmol/kg with a mean value of 10.2nmol/kg 
• this assumes a Scaled Beta Distribution is a good fit to the 
group of experts’ beliefs; however, other distributions will 
also be fitted to assess goodness of fit e.g. Normal, log-
Normal and Gamma 
• The Facilitator will also convey that once elicitation of the 
required 2 points on the dose-response curve has been 
completed (i.e. Rho0 and Gamma) then a Statistician can 
reveal the implied dose-response curve. 
 
Chosen 
distribution 
The finally fitted distribution will be recorded here. Since the 
statistical modelling of dose-response requires elicitation of 2 points 
on the dose-response curve it is acceptable to revisit the elicitation of 
each point and iterate until the experts are content with the 
distributions of both points on the dose-response curve. Only the final 
distributions are required to be recorded here. 
Discussion The Facilitator will record here any difficulties that arose during the 
elicitation of this distribution. Also the experts’ reactions to the 
process and to the finally fitted distribution.  
The elicitation record should be open about any concerns with the 
finished distribution. The SHELF protocols are designed to avoid 
many of the pitfalls of elicitation, but no process is perfect. It is 
important to be critical and realistic about the result. Nevertheless, it 
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is important also to remember that, despite whatever deficiencies it 
might have, the elicited distribution is our best attempt. It has been 
developed using a robust protocol, and since expert knowledge is 
needed in the wider organisation there is no alternative! 
 
End time 12:30 
Attachments Facilitator will include any attachments, e.g. plots of distributions 
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Appendix D Accuracy of the EWOC Estimator 
  
D-2 
Summary Statistics in Tabular Form 
Bias, Standardised Bias & MSE of Median Posterior Estimates of Target Dose for various Response Rates, Theta 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[01W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 6.7163 6.54 -0.18 -25.7 0.5198 0.70 
      0.2 7.2955 7.17 -0.12 -23.3 0.3002 0.53 
      0.3 7.6805 7.61 -0.07 -16.5 0.1904 0.43 
      0.4 7.9961 7.94 -0.05 -13.4 0.1561 0.39 
      0.5 8.2857 8.26 -0.03 -8.1 0.1272 0.36 
      0.6 8.5753 8.59 0.01 3.2 0.1022 0.32 
      0.7 8.8909 8.91 0.02 6.5 0.0958 0.31 
      0.8 9.2759 9.28 0.01 2.0 0.1179 0.34 
      0.9 9.8552 9.91 0.05 12.4 0.1645 0.40 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[01I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 1.0040 1.56 0.56 93.8 0.6622 0.59 
      0.2 2.1624 2.32 0.15 29.8 0.2863 0.51 
      0.3 2.9324 2.77 -0.16 -28.8 0.3332 0.55 
      0.4 3.5636 3.18 -0.38 -61.0 0.5402 0.63 
      0.5 4.1429 3.51 -0.63 -86.9 0.9272 0.73 
      0.6 4.7221 3.86 -0.87 -105.6 1.4224 0.82 
      0.7 5.3533 4.23 -1.12 -127.6 2.0220 0.88 
      0.8 6.1233 4.78 -1.34 -137.9 2.7423 0.97 
      0.9 7.2817 5.74 -1.54 -142.5 3.5387 1.08 
 
 
  
D-3 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[01S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 2.1211 2.18 0.06 18.3 0.1051 0.32 
      0.2 2.4455 2.48 0.03 13.6 0.0611 0.24 
      0.3 2.6611 2.64 -0.03 -12.3 0.0426 0.20 
      0.4 2.8378 2.76 -0.08 -39.5 0.0419 0.19 
      0.5 3.0000 2.87 -0.13 -70.7 0.0544 0.19 
      0.6 3.1622 3.01 -0.15 -73.4 0.0680 0.21 
      0.7 3.3389 3.19 -0.15 -66.7 0.0738 0.23 
      0.8 3.5545 3.40 -0.16 -80.4 0.0621 0.19 
      0.9 3.8789 3.67 -0.21 -129.7 0.0705 0.16 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[02W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 6.62 -0.09 -19.5 0.2417 0.48 
      0.2 7.2955 7.25 -0.05 -13.7 0.1374 0.37 
      0.3 7.6805 7.66 -0.02 -6.9 0.1154 0.34 
      0.4 7.9961 7.97 -0.03 -9.7 0.0916 0.30 
      0.5 8.2857 8.29 0.01 2.9 0.0887 0.30 
      0.6 8.5753 8.58 0.00 0.3 0.0793 0.28 
      0.7 8.8909 8.90 0.01 1.6 0.1011 0.32 
      0.8 9.2759 9.29 0.02 4.2 0.1319 0.36 
      0.9 9.8552 9.90 0.05 10.9 0.2099 0.46 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[02I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.97 0.96 161.5 1.2880 0.60 
      0.2 2.1624 2.79 0.63 126.2 0.6480 0.50 
      0.3 2.9324 3.31 0.38 73.0 0.4164 0.52 
      0.4 3.5636 3.76 0.19 31.0 0.4216 0.62 
      0.5 4.1429 4.15 0.00 0.6 0.4654 0.68 
      0.6 4.7221 4.63 -0.09 -12.5 0.4954 0.70 
      0.7 5.3533 5.08 -0.28 -35.8 0.6741 0.77 
      0.8 6.1233 5.71 -0.41 -54.4 0.7533 0.76 
      0.9 7.2817 6.76 -0.53 -58.7 1.0786 0.90 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[02S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 2.21 0.08 39.8 0.0518 0.21 
      0.2 2.4455 2.50 0.05 26.1 0.0417 0.20 
      0.3 2.6611 2.71 0.05 29.9 0.0319 0.17 
      0.4 2.8378 2.88 0.05 31.1 0.0238 0.15 
      0.5 3.0000 3.01 0.01 6.7 0.0188 0.14 
      0.6 3.1622 3.15 -0.01 -7.7 0.0245 0.16 
      0.7 3.3389 3.32 -0.02 -12.5 0.0358 0.19 
      0.8 3.5545 3.53 -0.03 -12.4 0.0477 0.22 
      0.9 3.8789 3.83 -0.04 -17.9 0.0632 0.25 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[03W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma >= DOSE 0 to 16 by 1 0.1 6.7163 6.59 -0.13 -17.9 0.5366 0.72 
      0.2 7.2955 7.26 -0.04 -8.5 0.2263 0.47 
      0.3 7.6805 7.71 0.03 7.6 0.1557 0.39 
      0.4 7.9961 8.01 0.01 2.9 0.1327 0.36 
      0.5 8.2857 8.36 0.07 20.8 0.1333 0.36 
      0.6 8.5753 8.64 0.07 20.7 0.1083 0.32 
      0.7 8.8909 8.96 0.07 22.6 0.1045 0.32 
      0.8 9.2759 9.37 0.10 26.5 0.1413 0.36 
      0.9 9.8552 9.97 0.11 25.5 0.2052 0.44 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[03I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma >= DOSE 0 to 16 by 1 0.1 1.0040 1.43 0.43 60.0 0.7009 0.72 
      0.2 2.1624 2.34 0.18 34.7 0.3099 0.53 
      0.3 2.9324 2.90 -0.04 -6.5 0.3181 0.56 
      0.4 3.5636 3.26 -0.30 -47.2 0.4900 0.63 
      0.5 4.1429 3.71 -0.43 -64.1 0.6456 0.68 
      0.6 4.7221 4.09 -0.63 -81.1 1.0079 0.78 
      0.7 5.3533 4.63 -0.72 -88.6 1.1914 0.82 
      0.8 6.1233 5.34 -0.78 -86.3 1.4242 0.90 
      0.9 7.2817 6.38 -0.90 -93.0 1.7527 0.97 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[03S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma >= DOSE 0 to 16 by 1 0.1 2.1211 2.19 0.07 21.4 0.1218 0.34 
      0.2 2.4455 2.51 0.07 26.5 0.0709 0.26 
      0.3 2.6611 2.71 0.05 24.3 0.0385 0.19 
      0.4 2.8378 2.82 -0.01 -8.1 0.0262 0.16 
      0.5 3.0000 2.93 -0.07 -38.1 0.0405 0.19 
      0.6 3.1622 3.06 -0.10 -40.9 0.0680 0.24 
      0.7 3.3389 3.25 -0.09 -33.2 0.0816 0.27 
      0.8 3.5545 3.49 -0.06 -23.1 0.0775 0.27 
      0.9 3.8789 3.81 -0.07 -29.8 0.0576 0.23 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[04W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 6.59 -0.12 -24.4 0.2779 0.51 
      0.2 7.2955 7.25 -0.04 -12.1 0.1402 0.37 
      0.3 7.6805 7.66 -0.03 -7.6 0.1099 0.33 
      0.4 7.9961 7.98 -0.01 -3.6 0.0990 0.31 
      0.5 8.2857 8.31 0.02 8.5 0.0807 0.28 
      0.6 8.5753 8.60 0.03 8.8 0.0903 0.30 
      0.7 8.8909 8.92 0.03 9.0 0.1270 0.35 
      0.8 9.2759 9.32 0.05 12.8 0.1483 0.38 
      0.9 9.8552 9.95 0.10 18.6 0.2823 0.52 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[04I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.66 0.65 91.4 0.9310 0.71 
      0.2 2.1624 2.63 0.47 92.2 0.4822 0.51 
      0.3 2.9324 3.28 0.35 67.1 0.3951 0.52 
      0.4 3.5636 3.79 0.23 41.0 0.3629 0.56 
      0.5 4.1429 4.27 0.13 20.8 0.3880 0.61 
      0.6 4.7221 4.77 0.05 7.7 0.4319 0.66 
      0.7 5.3533 5.30 -0.06 -7.7 0.5313 0.73 
      0.8 6.1233 6.00 -0.12 -15.9 0.5761 0.75 
      0.9 7.2817 7.01 -0.28 -29.8 0.9355 0.93 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[04S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 2.16 0.04 17.3 0.0522 0.23 
      0.2 2.4455 2.45 0.01 3.3 0.0353 0.19 
      0.3 2.6611 2.66 0.00 0.1 0.0308 0.18 
      0.4 2.8378 2.85 0.01 6.8 0.0295 0.17 
      0.5 3.0000 3.02 0.02 12.2 0.0250 0.16 
      0.6 3.1622 3.18 0.02 9.7 0.0282 0.17 
      0.7 3.3389 3.35 0.01 6.5 0.0348 0.19 
      0.8 3.5545 3.57 0.02 8.2 0.0469 0.22 
      0.9 3.8789 3.90 0.02 5.6 0.0971 0.31 
  
D-8 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[05W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0,Beta1 ~MVNormal(-6 1,var=50 -12 -12 3.3) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 6.13 -0.59 -47.2 1.8902 1.24 
      0.2 7.2955 7.24 -0.06 -9.6 0.3509 0.59 
      0.3 7.6805 7.65 -0.03 -7.7 0.1386 0.37 
      0.4 7.9961 7.98 -0.01 -4.3 0.1065 0.33 
      0.5 8.2857 8.28 -0.00 -0.6 0.0919 0.30 
      0.6 8.5753 8.58 0.00 0.2 0.0929 0.30 
      0.7 8.8909 8.91 0.02 4.4 0.1152 0.34 
      0.8 9.2759 9.34 0.06 17.2 0.1351 0.36 
      0.9 9.8552 9.92 0.07 13.9 0.2352 0.48 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[05I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0,Beta1 ~MVNormal(-6 1,var=50 -12 -12 3.3) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.88 0.88 136.7 1.1889 0.64 
      0.2 2.1624 2.93 0.76 149.0 0.8465 0.51 
      0.3 2.9324 3.53 0.60 132.3 0.5580 0.45 
      0.4 3.5636 4.02 0.45 97.5 0.4196 0.46 
      0.5 4.1429 4.39 0.25 52.6 0.2841 0.47 
      0.6 4.7221 4.73 0.01 2.2 0.2705 0.52 
      0.7 5.3533 5.19 -0.16 -27.7 0.3776 0.59 
      0.8 6.1233 5.81 -0.31 -47.4 0.5339 0.66 
      0.9 7.2817 6.74 -0.55 -71.7 0.8757 0.76 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[05S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0,Beta1 ~MVNormal(-6 1,var=50 -12 -12 3.3) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 2.19 0.07 30.4 0.0626 0.24 
      0.2 2.4455 2.48 0.04 22.0 0.0271 0.16 
      0.3 2.6611 2.69 0.03 21.4 0.0254 0.16 
      0.4 2.8378 2.88 0.05 29.0 0.0271 0.16 
      0.5 3.0000 3.06 0.06 32.8 0.0330 0.17 
      0.6 3.1622 3.26 0.10 48.0 0.0523 0.21 
      0.7 3.3389 3.46 0.12 59.9 0.0566 0.20 
      0.8 3.5545 3.70 0.14 77.1 0.0556 0.19 
      0.9 3.8789 4.03 0.15 52.1 0.1028 0.28 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[06W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0,1,2,4,8,16 0.1 6.7163 6.35 -0.36 -38.0 1.0528 0.96 
      0.2 7.2955 6.84 -0.45 -52.4 0.9433 0.86 
      0.3 7.6805 7.09 -0.59 -70.2 1.0430 0.84 
      0.4 7.9961 7.38 -0.62 -72.6 1.1088 0.85 
      0.5 8.2857 7.63 -0.66 -72.8 1.2480 0.90 
      0.6 8.5753 7.93 -0.65 -66.0 1.3817 0.98 
      0.7 8.8909 8.28 -0.62 -56.8 1.5509 1.08 
      0.8 9.2759 8.71 -0.57 -48.5 1.6791 1.17 
      0.9 9.8552 9.35 -0.51 -40.0 1.8721 1.27 
 
  
  
D-10 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[06I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0,1,2,4,8,16 0.1 1.0040 1.47 0.46 72.8 0.6201 0.64 
      0.2 2.1624 2.27 0.10 19.7 0.2846 0.52 
      0.3 2.9324 2.65 -0.29 -53.7 0.3685 0.53 
      0.4 3.5636 3.00 -0.56 -91.1 0.6890 0.61 
      0.5 4.1429 3.25 -0.89 -121.0 1.3301 0.73 
      0.6 4.7221 3.40 -1.33 -167.1 2.3888 0.79 
      0.7 5.3533 3.64 -1.71 -197.6 3.6852 0.87 
      0.8 6.1233 3.91 -2.21 -232.7 5.7811 0.95 
      0.9 7.2817 4.28 -3.00 -293.6 10.0468 1.02 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[06S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma >= DOSE 0,1,2,4,8,16 0.1 2.1211 2.19 0.07 20.8 0.1120 0.33 
      0.2 2.4455 2.52 0.08 23.4 0.1162 0.33 
      0.3 2.6611 2.72 0.06 17.5 0.1014 0.31 
      0.4 2.8378 2.86 0.02 5.7 0.1006 0.32 
      0.5 3.0000 2.96 -0.04 -13.0 0.0809 0.28 
      0.6 3.1622 3.11 -0.05 -16.9 0.0963 0.31 
      0.7 3.3389 3.22 -0.12 -44.4 0.0903 0.27 
      0.8 3.5545 3.39 -0.17 -64.7 0.0949 0.26 
      0.9 3.8789 3.60 -0.28 -126.1 0.1306 0.22 
  
D-11 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[07W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 6.7163 6.08 -0.64 -98.0 0.8230 0.65 
      0.2 7.2955 6.67 -0.63 -87.4 0.9171 0.72 
      0.3 7.6805 7.37 -0.31 -40.1 0.7127 0.78 
      0.4 7.9961 7.97 -0.03 -5.0 0.2802 0.53 
      0.5 8.2857 8.35 0.06 12.7 0.2427 0.49 
      0.6 8.5753 8.70 0.13 29.9 0.1960 0.42 
      0.7 8.8909 9.11 0.22 49.5 0.2394 0.44 
      0.8 9.2759 9.62 0.35 62.7 0.4232 0.55 
      0.9 9.8552 10.57 0.72 82.6 1.2617 0.87 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[07I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 1.0040 2.22 1.22 159.0 2.0770 0.77 
      0.2 2.1624 2.80 0.63 88.6 0.9115 0.71 
      0.3 2.9324 3.23 0.30 40.4 0.6401 0.74 
      0.4 3.5636 3.72 0.15 22.1 0.5007 0.69 
      0.5 4.1429 4.06 -0.08 -14.4 0.2982 0.54 
      0.6 4.7221 4.34 -0.38 -66.4 0.4823 0.58 
      0.7 5.3533 4.56 -0.79 -126.0 1.0285 0.63 
      0.8 6.1233 4.97 -1.15 -122.3 2.2254 0.94 
      0.9 7.2817 5.85 -1.44 -106.8 3.8714 1.35 
 
 
  
D-12 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[07S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 2.1211 2.23 0.11 38.8 0.0879 0.28 
      0.2 2.4455 2.50 0.05 20.5 0.0667 0.25 
      0.3 2.6611 2.65 -0.01 -2.8 0.0637 0.25 
      0.4 2.8378 2.84 0.00 1.5 0.0859 0.29 
      0.5 3.0000 3.03 0.03 9.5 0.0899 0.30 
      0.6 3.1622 3.22 0.05 18.7 0.0888 0.29 
      0.7 3.3389 3.39 0.06 22.3 0.0641 0.25 
      0.8 3.5545 3.59 0.03 14.4 0.0538 0.23 
      0.9 3.8789 3.82 -0.06 -21.7 0.0678 0.25 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[08W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma >= DOSE 0,1,2,4,8,16 0.1 6.7163 6.54 -0.18 -17.0 1.1431 1.05 
      0.2 7.2955 7.01 -0.28 -35.5 0.7075 0.79 
      0.3 7.6805 7.29 -0.39 -52.4 0.6943 0.74 
      0.4 7.9961 7.53 -0.46 -62.7 0.7609 0.74 
      0.5 8.2857 7.84 -0.44 -50.1 0.9736 0.88 
      0.6 8.5753 8.36 -0.21 -20.2 1.1486 1.05 
      0.7 8.8909 8.83 -0.06 -4.8 1.5523 1.24 
      0.8 9.2759 9.43 0.16 11.1 2.0354 1.42 
      0.9 9.8552 10.83 0.97 64.9 3.1901 1.50 
 
  
  
D-13 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[08I] Intermediate: Beta0=-2.9, 
Beta1=0.7 
Babb 
Parameterisation 
Prior for Beta0 ~Normal(-6,var=50), Beta1 
~Gamma(shape=3/10,scale=10/3) 
Gamma >= 
DOSE 
0,1,2,4,8,16 0.1 1.0040 -2155229.16 -2155230.17 -3.2 4.6497E15 68154375.30 
      0.2 2.1624 2.34 0.18 30.2 0.3753 0.59 
      0.3 2.9324 2.84 -0.09 -16.2 0.3243 0.56 
      0.4 3.5636 3.17 -0.39 -65.4 0.5154 0.60 
      0.5 4.1429 3.44 -0.71 -109.2 0.9154 0.65 
      0.6 4.7221 3.74 -0.99 -129.5 1.5540 0.76 
      0.7 5.3533 4.07 -1.29 -150.9 2.3850 0.85 
      0.8 6.1233 4.51 -1.62 -160.4 3.6307 1.01 
      0.9 7.2817 5.23 -2.05 -194.6 5.2986 1.05 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[08S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma >= DOSE 0,1,2,4,8,16 0.1 2.1211 2.21 0.09 25.3 0.1437 0.37 
      0.2 2.4455 2.66 0.21 57.7 0.1851 0.37 
      0.3 2.6611 2.91 0.25 84.2 0.1468 0.29 
      0.4 2.8378 3.11 0.28 101.5 0.1495 0.27 
      0.5 3.0000 3.29 0.29 116.3 0.1488 0.25 
      0.6 3.1622 3.46 0.30 141.6 0.1336 0.21 
      0.7 3.3389 3.63 0.29 159.5 0.1186 0.18 
      0.8 3.5545 3.65 0.10 55.8 0.0413 0.18 
      0.9 3.8789 3.83 -0.05 -31.8 0.0221 0.14 
 
  
D-14 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[09W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 6.7163 6.00 -0.72 -171.4 0.6895 0.42 
      0.2 7.2955 6.83 -0.46 -70.8 0.6358 0.65 
      0.3 7.6805 7.52 -0.16 -25.3 0.4038 0.62 
      0.4 7.9961 8.06 0.07 12.9 0.2730 0.52 
      0.5 8.2857 8.56 0.27 52.3 0.3480 0.52 
      0.6 8.5753 9.01 0.43 78.3 0.4871 0.55 
      0.7 8.8909 9.55 0.66 115.5 0.7707 0.57 
      0.8 9.2759 10.20 0.92 147.0 1.2511 0.63 
      0.9 9.8552 11.37 1.52 214.5 2.8053 0.71 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[09I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 1.0040 1.72 0.72 100.6 1.0310 0.72 
      0.2 2.1624 2.73 0.57 92.0 0.7061 0.62 
      0.3 2.9324 3.25 0.32 48.9 0.5171 0.65 
      0.4 3.5636 3.74 0.18 26.4 0.4884 0.68 
      0.5 4.1429 4.17 0.03 4.1 0.4696 0.68 
      0.6 4.7221 4.56 -0.16 -22.2 0.5640 0.73 
      0.7 5.3533 4.90 -0.46 -53.6 0.9304 0.85 
      0.8 6.1233 5.57 -0.55 -49.8 1.5441 1.11 
      0.9 7.2817 6.48 -0.80 -63.6 2.2069 1.25 
 
 
  
D-15 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[09S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Normal(-6,var=50), Beta1 ~Gamma(shape=3/10,scale=10/3) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 2.1211 2.26 0.14 43.9 0.1255 0.32 
      0.2 2.4455 2.55 0.11 42.7 0.0717 0.25 
      0.3 2.6611 2.72 0.05 25.6 0.0487 0.21 
      0.4 2.8378 2.82 -0.02 -7.0 0.0479 0.22 
      0.5 3.0000 2.97 -0.03 -11.6 0.0592 0.24 
      0.6 3.1622 3.12 -0.04 -14.9 0.0680 0.26 
      0.7 3.3389 3.32 -0.02 -6.7 0.0722 0.27 
      0.8 3.5545 3.54 -0.01 -5.0 0.0705 0.27 
      0.9 3.8789 3.83 -0.05 -13.9 0.1313 0.36 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[10W] CentShallow: Beta0=-0.4, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE -100 to 100 by 1 0.1 -1.2837 -1.11 0.18 38.5 0.2434 0.46 
      0.2 -0.7045 -0.59 0.11 28.5 0.1719 0.40 
      0.3 -0.3195 -0.27 0.05 11.5 0.1567 0.39 
      0.4 -0.0039 0.03 0.04 9.7 0.1442 0.38 
      0.5 0.2857 0.29 0.00 0.9 0.1442 0.38 
      0.6 0.5753 0.57 -0.01 -1.7 0.1478 0.38 
      0.7 0.8909 0.85 -0.04 -11.0 0.1507 0.39 
      0.8 1.2759 1.19 -0.09 -20.7 0.1774 0.41 
      0.9 1.8552 1.72 -0.13 -28.1 0.2431 0.47 
 
  
  
D-16 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[10I] CentInterm: Beta0=-0.4, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE -100 to 100 by 1 0.1 -2.5675 -1.95 0.62 72.5 1.0997 0.85 
      0.2 -1.4090 -0.94 0.46 57.3 0.8721 0.81 
      0.3 -0.6390 -0.30 0.33 39.1 0.8403 0.85 
      0.4 -0.0078 0.16 0.17 19.1 0.7823 0.87 
      0.5 0.5714 0.59 0.02 2.6 0.6380 0.80 
      0.6 1.1507 1.04 -0.11 -12.7 0.7172 0.84 
      0.7 1.7819 1.52 -0.26 -31.3 0.7422 0.82 
      0.8 2.5518 2.11 -0.45 -55.1 0.8552 0.81 
      0.9 3.7103 3.07 -0.64 -71.9 1.2205 0.90 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[10S] CentSteep: Beta0=-0.4, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE -100 to 100 by 1 0.1 -0.7189 -0.70 0.02 8.1 0.0735 0.27 
      0.2 -0.3945 -0.38 0.01 5.5 0.0474 0.22 
      0.3 -0.1789 -0.16 0.02 9.3 0.0362 0.19 
      0.4 -0.0022 -0.00 -0.00 -0.5 0.0314 0.18 
      0.5 0.1600 0.16 -0.00 -1.7 0.0325 0.18 
      0.6 0.3222 0.32 -0.00 -1.6 0.0357 0.19 
      0.7 0.4989 0.52 0.03 12.4 0.0438 0.21 
      0.8 0.7145 0.71 -0.00 -0.7 0.0511 0.23 
      0.9 1.0389 1.02 -0.02 -6.2 0.0768 0.28 
  
D-17 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[11W] Shallow: Beta0=-11.6, Beta1=1.4 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,3,6,9,13,16 0.1 6.7163 6.84 0.12 27.0 0.2147 0.45 
      0.2 7.2955 7.23 -0.06 -19.0 0.1150 0.33 
      0.3 7.6805 7.55 -0.14 -37.3 0.1497 0.36 
      0.4 7.9961 7.88 -0.12 -31.6 0.1600 0.38 
      0.5 8.2857 8.19 -0.09 -25.8 0.1325 0.35 
      0.6 8.5753 8.52 -0.05 -14.9 0.1213 0.34 
      0.7 8.8909 8.88 -0.01 -2.6 0.1189 0.34 
      0.8 9.2759 9.30 0.02 5.9 0.1493 0.39 
      0.9 9.8552 10.03 0.17 28.4 0.3971 0.61 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[11I] Intermediate: Beta0=-2.9, Beta1=0.7 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,3,6,9,13,16 0.1 1.0040 2.53 1.53 1186.7 2.3503 0.13 
      0.2 2.1624 2.81 0.64 510.4 0.4296 0.13 
      0.3 2.9324 2.99 0.06 45.3 0.0213 0.13 
      0.4 3.5636 3.14 -0.42 -338.4 0.1954 0.13 
      0.5 4.1429 3.29 -0.86 -661.0 0.7483 0.13 
      0.6 4.7221 3.43 -1.29 -1024.3 1.6789 0.13 
      0.7 5.3533 3.58 -1.77 -1309.9 3.1502 0.14 
      0.8 6.1233 3.76 -2.36 -1640.2 5.6082 0.14 
      0.9 7.2817 4.28 -3.00 -355.5 9.7357 0.84 
 
 
  
D-18 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[11S] Steep: Beta0=-7.5, Beta1=2.5 Babb Parameterisation Prior for Beta0 ~Un(-16,16), Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0,3,6,9,13,16 0.1 2.1211 2.53 0.41 314.5 0.1875 0.13 
      0.2 2.4455 2.81 0.37 291.0 0.1503 0.13 
      0.3 2.6611 2.99 0.32 248.8 0.1224 0.13 
      0.4 2.8378 3.16 0.32 239.9 0.1186 0.13 
      0.5 3.0000 3.29 0.29 221.1 0.0996 0.13 
      0.6 3.1622 3.43 0.27 199.2 0.0931 0.14 
      0.7 3.3389 3.58 0.24 186.4 0.0743 0.13 
      0.8 3.5545 3.78 0.22 103.9 0.0970 0.22 
      0.9 3.8789 4.26 0.38 50.4 0.7120 0.75 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[12W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0 to 16 by 1 0.1 6.7163 6.65 -0.07 -9.1 0.5610 0.75 
      0.2 7.2955 7.47 0.18 29.3 0.3931 0.60 
      0.3 7.6805 7.95 0.27 54.7 0.3159 0.49 
      0.4 7.9961 8.32 0.33 73.1 0.3054 0.45 
      0.5 8.2857 8.62 0.34 78.5 0.2955 0.43 
      0.6 8.5753 8.94 0.36 90.6 0.2919 0.40 
      0.7 8.8909 9.29 0.40 96.0 0.3390 0.42 
      0.8 9.2759 9.70 0.43 92.8 0.3974 0.46 
      0.9 9.8552 10.34 0.49 86.7 0.5525 0.56 
 
  
  
D-19 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[12I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0 to 16 by 1 0.1 1.0040 1.66 0.65 129.9 0.6786 0.50 
      0.2 2.1624 2.45 0.29 55.3 0.3635 0.53 
      0.3 2.9324 3.10 0.17 30.9 0.3181 0.54 
      0.4 3.5636 3.70 0.13 23.4 0.3461 0.57 
      0.5 4.1429 4.25 0.11 18.4 0.3475 0.58 
      0.6 4.7221 4.83 0.11 18.7 0.3427 0.58 
      0.7 5.3533 5.49 0.14 21.2 0.4651 0.67 
      0.8 6.1233 6.26 0.13 18.7 0.5304 0.72 
      0.9 7.2817 7.56 0.27 27.6 1.0639 0.99 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[12S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0 to 16 by 1 0.1 2.1211 2.22 0.10 26.6 0.1478 0.37 
      0.2 2.4455 2.70 0.26 97.0 0.1356 0.26 
      0.3 2.6611 2.89 0.23 124.1 0.0858 0.18 
      0.4 2.8378 3.00 0.16 85.9 0.0590 0.18 
      0.5 3.0000 3.16 0.16 64.2 0.0927 0.26 
      0.6 3.1622 3.42 0.26 88.2 0.1571 0.30 
      0.7 3.3389 3.67 0.33 128.7 0.1780 0.26 
      0.8 3.5545 3.90 0.34 184.5 0.1501 0.18 
      0.9 3.8789 4.22 0.34 102.6 0.2244 0.33 
  
D-20 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[13W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 6.39 -0.33 -44.7 0.6381 0.73 
      0.2 7.2955 7.13 -0.16 -31.5 0.2869 0.51 
      0.3 7.6805 7.59 -0.09 -20.1 0.1918 0.43 
      0.4 7.9961 7.96 -0.04 -9.4 0.1680 0.41 
      0.5 8.2857 8.27 -0.02 -4.0 0.1527 0.39 
      0.6 8.5753 8.61 0.03 8.4 0.1388 0.37 
      0.7 8.8909 8.94 0.04 10.3 0.1865 0.43 
      0.8 9.2759 9.38 0.10 22.2 0.2264 0.46 
      0.9 9.8552 10.10 0.24 38.7 0.4566 0.63 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[13I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.58 0.58 122.6 0.5509 0.47 
      0.2 2.1624 2.43 0.27 56.4 0.2990 0.48 
      0.3 2.9324 3.11 0.17 34.3 0.2859 0.51 
      0.4 3.5636 3.67 0.11 22.0 0.2563 0.49 
      0.5 4.1429 4.28 0.13 25.6 0.2967 0.53 
      0.6 4.7221 4.88 0.16 29.2 0.3199 0.54 
      0.7 5.3533 5.47 0.12 18.8 0.3981 0.62 
      0.8 6.1233 6.26 0.14 19.0 0.5252 0.71 
      0.9 7.2817 7.61 0.33 32.0 1.1518 1.02 
 
  
  
D-21 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[13S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 2.09 -0.03 -11.3 0.0887 0.30 
      0.2 2.4455 2.40 -0.05 -28.6 0.0301 0.17 
      0.3 2.6611 2.57 -0.09 -51.0 0.0425 0.18 
      0.4 2.8378 2.77 -0.07 -26.2 0.0667 0.25 
      0.5 3.0000 3.02 0.02 6.8 0.0655 0.26 
      0.6 3.1622 3.25 0.09 42.3 0.0531 0.21 
      0.7 3.3389 3.43 0.09 51.3 0.0373 0.17 
      0.8 3.5545 3.63 0.08 34.0 0.0550 0.22 
      0.9 3.8789 4.12 0.25 55.1 0.2588 0.45 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[14W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 4.97 -1.74 -202.8 3.7826 0.86 
      0.2 7.2955 7.12 -0.18 -25.4 0.5127 0.69 
      0.3 7.6805 7.61 -0.07 -12.2 0.3156 0.56 
      0.4 7.9961 7.99 -0.01 -1.3 0.2758 0.53 
      0.5 8.2857 8.27 -0.01 -2.9 0.2331 0.48 
      0.6 8.5753 8.61 0.03 6.7 0.2040 0.45 
      0.7 8.8909 8.98 0.09 18.2 0.2371 0.48 
      0.8 9.2759 9.42 0.14 28.0 0.2784 0.51 
      0.9 9.8552 10.16 0.30 49.4 0.4659 0.61 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[14I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.26 0.26 35.0 0.6046 0.73 
      0.2 2.1624 2.39 0.23 44.2 0.3303 0.53 
      0.3 2.9324 3.09 0.16 30.3 0.2932 0.52 
      0.4 3.5636 3.70 0.13 25.0 0.2935 0.53 
      0.5 4.1429 4.33 0.19 34.7 0.3229 0.54 
      0.6 4.7221 4.92 0.20 34.9 0.3774 0.58 
      0.7 5.3533 5.64 0.28 44.8 0.4763 0.63 
      0.8 6.1233 6.46 0.34 43.4 0.7250 0.78 
      0.9 7.2817 7.89 0.60 58.4 1.4360 1.03 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[14S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 2.00 -0.12 -32.7 0.1456 0.36 
      0.2 2.4455 2.36 -0.08 -38.2 0.0548 0.22 
      0.3 2.6611 2.54 -0.12 -56.9 0.0605 0.21 
      0.4 2.8378 2.74 -0.09 -32.8 0.0887 0.28 
      0.5 3.0000 3.01 0.01 4.0 0.0982 0.31 
      0.6 3.1622 3.26 0.10 39.9 0.0759 0.26 
      0.7 3.3389 3.46 0.12 59.1 0.0561 0.20 
      0.8 3.5545 3.76 0.21 67.6 0.1404 0.31 
      0.9 3.8789 5.48 1.60 1770.5 2.5681 0.09 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[15W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0,1,2,4,8,16 0.1 6.7163 6.81 0.09 10.9 0.7093 0.84 
      0.2 7.2955 7.48 0.18 22.6 0.6695 0.80 
      0.3 7.6805 8.25 0.57 40.3 2.2984 1.41 
      0.4 7.9961 9.19 1.19 62.2 5.1051 1.92 
      0.5 8.2857 10.57 2.28 107.1 9.7465 2.13 
      0.6 8.5753 12.09 3.51 182.8 16.0183 1.92 
      0.7 8.8909 13.27 4.38 279.1 21.6336 1.57 
      0.8 9.2759 14.32 5.05 404.0 27.0447 1.25 
      0.9 9.8552 15.27 5.42 817.7 29.7688 0.66 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[15I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0,1,2,4,8,16 0.1 1.0040 1.75 0.74 130.1 0.8736 0.57 
      0.2 2.1624 2.74 0.57 87.3 0.7636 0.66 
      0.3 2.9324 3.43 0.50 86.6 0.5752 0.57 
      0.4 3.5636 3.91 0.34 52.5 0.5469 0.65 
      0.5 4.1429 4.50 0.36 39.4 0.9512 0.91 
      0.6 4.7221 5.20 0.48 48.4 1.2173 0.99 
      0.7 5.3533 5.93 0.58 60.1 1.2566 0.96 
      0.8 6.1233 6.73 0.60 77.2 0.9752 0.78 
      0.9 7.2817 7.59 0.31 39.2 0.7054 0.78 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[15S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma >= DOSE 0,1,2,4,8,16 0.1 2.1211 2.42 0.30 51.4 0.4230 0.58 
      0.2 2.4455 3.11 0.67 165.7 0.6042 0.40 
      0.3 2.6611 3.49 0.83 313.1 0.7656 0.27 
      0.4 2.8378 3.53 0.69 330.3 0.5232 0.21 
      0.5 3.0000 3.72 0.72 547.5 0.5362 0.13 
      0.6 3.1622 3.78 0.62 488.5 0.4010 0.13 
      0.7 3.3389 3.85 0.51 459.0 0.2706 0.11 
      0.8 3.5545 3.94 0.39 466.4 0.1553 0.08 
      0.9 3.8789 4.11 0.23 82.5 0.1324 0.28 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[16W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 6.7163 5.70 -1.01 -182.5 1.3385 0.56 
      0.2 7.2955 6.28 -1.02 -148.4 1.4983 0.68 
      0.3 7.6805 7.26 -0.42 -37.3 1.4224 1.12 
      0.4 7.9961 8.57 0.57 45.8 1.8841 1.25 
      0.5 8.2857 9.66 1.37 121.8 3.1489 1.13 
      0.6 8.5753 10.51 1.94 213.6 4.5786 0.91 
      0.7 8.8909 11.22 2.33 341.3 5.9148 0.68 
      0.8 9.2759 11.68 2.40 459.8 6.0433 0.52 
      0.9 9.8552 12.24 2.38 649.8 5.8099 0.37 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[16I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 1.0040 1.60 0.60 120.3 0.6065 0.50 
      0.2 2.1624 2.42 0.26 55.8 0.2827 0.46 
      0.3 2.9324 3.04 0.11 21.4 0.2852 0.52 
      0.4 3.5636 3.75 0.19 31.0 0.4173 0.62 
      0.5 4.1429 4.41 0.26 42.6 0.4513 0.62 
      0.6 4.7221 4.97 0.25 42.7 0.4059 0.59 
      0.7 5.3533 5.56 0.20 32.9 0.4199 0.62 
      0.8 6.1233 6.25 0.12 17.1 0.5348 0.72 
      0.9 7.2817 7.48 0.20 16.9 1.4554 1.19 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[16S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Un(0,Response Rate), Gamma ~Un(0,20) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 2.1211 2.28 0.15 38.5 0.1850 0.40 
      0.2 2.4455 2.68 0.23 106.0 0.1009 0.22 
      0.3 2.6611 2.84 0.18 131.6 0.0512 0.14 
      0.4 2.8378 2.93 0.09 104.8 0.0169 0.09 
      0.5 3.0000 2.99 -0.01 -12.9 0.0078 0.09 
      0.6 3.1622 3.04 -0.12 -106.0 0.0269 0.11 
      0.7 3.3389 3.18 -0.16 -83.9 0.0632 0.19 
      0.8 3.5545 3.48 -0.07 -21.9 0.1210 0.34 
      0.9 3.8789 4.29 0.41 57.7 0.6769 0.71 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[17W] Shallow: Beta0=-11.6, Beta1=1.4 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 6.7163 4.39 -2.33 -206.5 6.6890 1.13 
      0.2 7.2955 7.44 0.15 7.4 4.0717 2.01 
      0.3 7.6805 8.32 0.64 39.3 3.0509 1.63 
      0.4 7.9961 9.60 1.61 113.6 4.5934 1.42 
      0.5 8.2857 10.49 2.20 202.2 6.0199 1.09 
      0.6 8.5753 11.15 2.58 323.2 7.2914 0.80 
      0.7 8.8909 11.63 2.74 541.1 7.7458 0.51 
      0.8 9.2759 11.91 2.64 765.6 7.0746 0.34 
      0.9 9.8552 12.20 2.35 966.5 5.5704 0.24 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[17I] Intermediate: Beta0=-2.9, Beta1=0.7 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 1.0040 1.30 0.30 36.5 0.7483 0.81 
      0.2 2.1624 2.45 0.29 53.9 0.3722 0.54 
      0.3 2.9324 3.10 0.17 28.6 0.3792 0.59 
      0.4 3.5636 3.88 0.32 41.2 0.7061 0.78 
      0.5 4.1429 4.66 0.51 72.0 0.7724 0.71 
      0.6 4.7221 5.24 0.52 84.7 0.6451 0.61 
      0.7 5.3533 5.79 0.44 88.3 0.4397 0.50 
      0.8 6.1233 6.44 0.32 46.0 0.5880 0.70 
      0.9 7.2817 7.77 0.49 42.1 1.5981 1.16 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[17S] Steep: Beta0=-7.5, Beta1=2.5 Tighiouart Parameterisation Prior for Rho0 ~Beta(3.6,8.69), Gamma ~Normal(10.5,sd=3.9) Gamma Nearest DOSE 0,1,2,4,8,16 0.1 2.1211 2.18 0.06 13.4 0.2177 0.46 
      0.2 2.4455 2.70 0.26 109.4 0.1214 0.24 
      0.3 2.6611 2.85 0.19 153.7 0.0517 0.12 
      0.4 2.8378 2.92 0.09 100.4 0.0150 0.09 
      0.5 3.0000 2.98 -0.02 -32.8 0.0058 0.07 
      0.6 3.1622 3.03 -0.13 -135.1 0.0272 0.10 
      0.7 3.3389 3.16 -0.18 -81.5 0.0816 0.22 
      0.8 3.5545 3.67 0.12 24.8 0.2439 0.48 
      0.9 3.8789 5.50 1.62 412.8 2.7797 0.39 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[18W] Shallow: Beta0=-11.6, Beta1=1.4 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 6.7163 5.71 -1.01 -158.5 1.4266 0.64 
      0.2 7.2955 7.40 0.10 14.6 0.5306 0.72 
      0.3 7.6805 7.91 0.23 40.3 0.3673 0.56 
      0.4 7.9961 8.31 0.31 65.2 0.3228 0.48 
      0.5 8.2857 8.62 0.33 75.6 0.3071 0.44 
      0.6 8.5753 8.96 0.38 94.4 0.3101 0.40 
      0.7 8.8909 9.33 0.44 106.4 0.3701 0.42 
      0.8 9.2759 9.70 0.43 93.8 0.3926 0.46 
      0.9 9.8552 10.36 0.51 89.3 0.5771 0.57 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[18I] Intermediate: Beta0=-2.9, Beta1=0.7 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 1.0040 1.39 0.39 82.9 0.3645 0.46 
      0.2 2.1624 2.26 0.10 18.5 0.3140 0.55 
      0.3 2.9324 2.92 -0.01 -1.5 0.3266 0.57 
      0.4 3.5636 3.55 -0.02 -2.7 0.3638 0.60 
      0.5 4.1429 4.12 -0.02 -3.4 0.3324 0.58 
      0.6 4.7221 4.71 -0.01 -1.3 0.3909 0.63 
      0.7 5.3533 5.38 0.02 3.8 0.3502 0.59 
      0.8 6.1233 6.11 -0.01 -1.5 0.4224 0.65 
      0.9 7.2817 7.29 0.01 0.8 0.7327 0.86 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[18S] Steep: Beta0=-7.5, Beta1=2.5 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma >= DOSE 0 to 16 by 1 0.1 2.1211 2.18 0.06 12.4 0.2381 0.48 
      0.2 2.4455 2.63 0.18 52.7 0.1558 0.35 
      0.3 2.6611 2.91 0.25 109.0 0.1124 0.23 
      0.4 2.8378 3.04 0.21 103.7 0.0818 0.20 
      0.5 3.0000 3.20 0.20 77.7 0.1052 0.26 
      0.6 3.1622 3.43 0.27 93.9 0.1560 0.29 
      0.7 3.3389 3.69 0.35 139.5 0.1885 0.25 
      0.8 3.5545 3.92 0.36 188.8 0.1691 0.19 
      0.9 3.8789 4.18 0.30 122.2 0.1485 0.24 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[19W] Shallow: Beta0=-11.6, Beta1=1.4 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 6.7163 6.07 -0.65 -46.8 2.3404 1.39 
      0.2 7.2955 7.02 -0.28 -42.6 0.5056 0.65 
      0.3 7.6805 7.58 -0.10 -19.2 0.2700 0.51 
      0.4 7.9961 7.92 -0.08 -17.6 0.2093 0.45 
      0.5 8.2857 8.30 0.01 2.5 0.1648 0.41 
      0.6 8.5753 8.58 0.01 1.5 0.1558 0.39 
      0.7 8.8909 8.97 0.08 19.2 0.1950 0.43 
      0.8 9.2759 9.38 0.10 22.7 0.2185 0.46 
      0.9 9.8552 10.13 0.27 44.2 0.4497 0.61 
 
 
SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[19I] Intermediate: Beta0=-2.9, Beta1=0.7 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 1.0040 1.29 0.28 63.0 0.2844 0.45 
      0.2 2.1624 2.25 0.09 18.1 0.2430 0.49 
      0.3 2.9324 2.97 0.04 8.1 0.2339 0.48 
      0.4 3.5636 3.60 0.03 6.8 0.2361 0.48 
      0.5 4.1429 4.17 0.02 4.8 0.2550 0.50 
      0.6 4.7221 4.75 0.02 4.4 0.2922 0.54 
      0.7 5.3533 5.38 0.02 3.9 0.3545 0.59 
      0.8 6.1233 6.11 -0.01 -2.1 0.4702 0.69 
      0.9 7.2817 7.33 0.05 5.6 0.7479 0.86 
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SCENARIO SIMLABEL PARAM_TEXT PRIOR_TEXT RULE_TEXT DOSE_TEXT THETA TRUE_TARG MEAN BIAS STDZ_BIAS MSE STD 
[19S] Steep: Beta0=-7.5, Beta1=2.5 One Parameter Logistic Parameterisation Beta0=-3, Prior for Beta1 ~Un(0.01,5) Gamma Nearest DOSE 0 to 16 by 1 0.1 2.1211 1.84 -0.28 -70.4 0.2300 0.39 
      0.2 2.4455 2.36 -0.09 -42.4 0.0534 0.21 
      0.3 2.6611 2.54 -0.13 -67.1 0.0504 0.19 
      0.4 2.8378 2.74 -0.10 -39.1 0.0729 0.25 
      0.5 3.0000 2.99 -0.01 -3.0 0.0636 0.25 
      0.6 3.1622 3.25 0.09 40.1 0.0584 0.22 
      0.7 3.3389 3.43 0.09 53.7 0.0332 0.16 
      0.8 3.5545 3.59 0.04 20.5 0.0314 0.17 
      0.9 3.8789 3.98 0.10 27.1 0.1451 0.37 
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Appendix D (Continued) Accuracy of the EWOC Estimator 
Mean Square Error (MSE) in Graphical Form 
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NOTE: See Table 9 for explanation of scenarios 
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Appendix E Simulation Programs 
Main SAS macro for EWOC analysis 
/******************************************************************************* 
* EWOC_BABB.SAS - implements EWOC using Babb et al (1998) parameterisation 
******************************************************************************** 
* Project : PhD 
* Study :   Used for simulating EWOC 
* Author :  N.Kinnersley 
* SAS version : 9.2 
* $Id$ 
* $Source$ 
******************************************************************************** 
* Macro to implement EWOC and output mcmc results and optionally plots.  
*                                                                               
******************************************************************************** 
* Inputs : None 
* 
* Outputs : Output dataset containing Posterior estimates of model parameters 
*           Optional printing of Proc MCMC results to an RTF file             
* 
* Called macros : None 
* 
*******************************************************************************/ 
 
%macro ewoc_babb(INDATA=,GROUP=,SUBJECTS=,RESPONSES=, 
                 MCMCSEED=,THETA=,XMIN=,XMAX=, 
                 BETA0_PRIOR=,BETA1_PRIOR=,BETA0_INIT=,BETA1_INIT=, 
                 NBI=,NMC=,NTHIN=,AVDOSES=,TITNUM=1,FOOTNUM=1,EST=, 
                 PLOT=,OUTFILE=,OUTDATA=); 
 
  %* INDATA=input dataset (requires variables &GROUP &SUBJECTS &RESPONSES); 
  %* GROUP=variable containing group identifier e.g. DOSE or STD_DOSE; 
  %* SUBJECTS=variable containing number of subjects/patients in the GROUP; 
  %* RESPONSES=variable containing number of responses in respective group; 
  %* MCMCSEED=random number seed (used for reproducibility); 
  %* THETA=target response rate; 
  %* XMIN=lowest dose to consider for estimating next dose; 
  %* XMAX=highest dose to consider for estimating next dose; 
  %* BETA0_PRIOR=prior distribution for BETA0 (if necessary, use %str when 
specifying); 
  %* BETA1_PRIOR=prior distribution for BETA1 (if necessary, use %str when 
specifying) 
  %* BETA0_INIT=initial estimate of probability of response at XMIN; 
  %* BETA1_INIT=initial estimate of dose achieving required response rate; 
  %* NBI=Number of burn-ins for MCMC; 
  %* NMC=Number of MC runs after burn-in for MCMC; 
  %* NTHIN=Value of Thinning option for MCMC; 
  %* AVDOSES=list of available doses that can potentially be simulated; 
  %* TITNUM=which title number to use for MCMC option  
             printing (default=1, 0 for no title printing); 
  %* FOOTNUM=which footnote number to use for MCMC option  
             printing (default=1, 0 for no footnote printing); 
  
E-2 
  %* EST=Estimate of choice from Posterior. Allowable values are MEAN or Pnn where 
         nn is replaced by number to represent percentile of Posterior. If Pnn  
         used then it corresponds to the Bayesian-feasible level denoted by alpha; 
  %* PLOT=Y for plot of estimated dose-response curve. Default is blank (only the 
          output dataset POSTPLOT_&OUTDATA that could be used to plot later is  
          created); 
  %* OUTFILE=if specified, creates an RTF file with name OUTFILE_OUTDATA.rtf  
             in current directory; 
  %* OUTDATA=output dataset name for patient-level data; 
 
 
  %* If EST=Pnn format used then create STATS variable to hold requested percentile 
        e.g. EST=P75 leads to 75. Otherwise STATS defaults to all; 
  %if %upcase(%substr(%cmpres(&EST),1,1)) = P %then %do; 
      %let STATS=statistics(percentage=(%substr(&EST,2))); 
  %end; 
  %else %let STATS=%nrstr(statistics=all); 
 
  %if %length(&OUTFILE) %then %do; 
    ods rtf file="./reports/&OUTFILE._&OUTDATA..rtf" style=styles.listing 
bodytitle_aux; 
  %end; 
 
  %if %upcase(%substr(%cmpres(&PLOT),1,1)) = Y %then %do; 
     ods graphics on; 
  %end; 
 
  %if %eval(&TITNUM > 0) %then %do; 
      %* Calculate how many Subjects used in analysis and create Macro var for 
Simulation number; 
      proc sql noprint; 
        select sum(&SUBJECTS),max(SIM) into :N_SUBJ,:TSIM 
          from &INDATA; 
      quit; 
  
      title&TITNUM "&EST Posterior Estimates of Target Dose for Response 
Rate=&THETA"; 
      title%eval(&TITNUM+1) "Available doses {&AVDOSES} Sim=%cmpres(&TSIM), 
N=%cmpres(&N_SUBJ)"; 
  %end; 
 
  %if %eval(&FOOTNUM > 0) %then %do; 
    footnote&footnum j=l h=8pt "MCMCSEED=&MCMCSEED, NBI=&NBI, NMC=&NMC, 
NTHIN=&NTHIN"; 
  %end; 
 
  proc mcmc data=&INDATA nbi=&NBI nmc=&NMC nthin=&NTHIN outpost=&OUTDATA  
            seed=&MCMCSEED monitor=(_PARMS_ RHO0 GAMMA) &STATS; 
   
 
    * Pass SIM variable to output dataset using BY statement containing only 1 
value; 
    by SIM; 
 
    * For efficiency, use code block option for transformations of  
    constants that stay the same across the dataset; 
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    begincnst; 
      LTHETA=log(&THETA/(1-&THETA)); 
    endcnst; 
  
    parms BETA0 &BETA0_INIT BETA1 &BETA1_INIT ; 
 
    prior BETA0 ~ &BETA0_PRIOR; 
    prior BETA1 ~ &BETA1_PRIOR; 
 
    * Derive quantities that are functions of parameters i.e. NOT at the 
observation level 
      (see SAS 9.2 Help Example 52.3 on Generalized LM for similar example); 
    beginnodata; 
      * Rho0 is probability at dose=0; 
      RHO0=exp(BETA0) / (1 + exp(BETA0)); 
      LRHO0=log(RHO0/(1-RHO0)); 
 
      * GAMMA is estimated dose at THETA (per Chu et al (2009) parameterisation); 
      GAMMA = ( LTHETA - BETA0 ) / BETA1 ; 
    endnodata; 
 
    * Calculate probability of response using BETA0 BETA1 parameterisation; 
    P=logistic(BETA0 + ( BETA1*&GROUP )); 
 
    * If P is exactly 0 or 1 Binomial sampling fails so round-off to just above 0 
(below 1); 
    if abs(P) le 1e-8 then        P=0.000001; 
    else if abs(1-P) le 1e-8 then P=0.999999; 
    model &RESPONSES ~ binomial(&SUBJECTS, P); 
 
    ods select Parameters PostSummaries PostIntervals mcse ess TADpanel; 
 
    ods output postsummaries=POSTSUMM_&OUTDATA; 
  run; 
 
  * Store total sample size in macro var for merging onto results; 
  proc sql noprint; 
    select sum(&SUBJECTS) into :N_SUBJ 
      from &INDATA; 
  quit; 
 
  %* Collapse summary dataset into single obs for storing chosen estimate and 
     multiple obs dataset for plotting, where ESTIMATE of choice is used; 
  data POSTSUMM_&OUTDATA(keep=SIM EST_B0--EST_LABEL) 
       POSTPLOT_&OUTDATA(keep=SIM EST_B0--EST_LOGISTICP); 
    do until (EOF); 
       set POSTSUMM_&OUTDATA end=EOF; 
       if PARAMETER eq 'BETA0' then EST_B0=&EST; 
       else if PARAMETER eq 'BETA1' then EST_B1=&EST; 
       else if PARAMETER eq 'GAMMA' then EST_GAM=&EST; 
       else if PARAMETER eq 'RHO0' then EST_RHO0=&EST; 
       * Logit values needed for plotting; 
       LEST_RHO0=log(EST_RHO0/(1-EST_RHO0)); 
    end; 
    * Create values common to all MCMC simulations for plotting; 
    N_MCSIM=N; 
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    * XMIN to XMAX is range of available doses; 
    XMIN=&XMIN; 
    XMAX=&XMAX; 
    * Current total number of patients; 
    N_SUBJ=&N_SUBJ; 
    * Create variable used for drawing vertical reference line at GAMMA; 
    YREF=0; 
    * Create macro variable used in subsequent plot; 
    call symput('EST_GAM', trim(left(put(EST_GAM,11.4)))); 
 
    THETA=&THETA; 
    LTHETA=log(THETA/(1-THETA)); 
 
    EST_LABEL="&EST"; 
    output POSTSUMM_&OUTDATA; 
 
    do DOSE=XMIN to XMAX by 0.05; 
       EST_LOGITP = (1/(EST_GAM - XMIN)) * ( (EST_GAM*LEST_RHO0) - ( XMIN*LTHETA) + 
(LTHETA - LEST_RHO0)*DOSE ) ; 
       EST_LOGISTICP= exp(EST_LOGITP) / (1 + exp(EST_LOGITP)); 
       output POSTPLOT_&OUTDATA; 
    end; 
  run; 
 
  %if %upcase(%substr(%cmpres(&PLOT),1,1)) = Y %then %do; 
    /**************************************************************************/ 
    /* Present results graphically                                            */ 
    /**************************************************************************/ 
      %if %eval(&TITNUM > 0) %then %do; 
          title%eval(&TITNUM+2) "Estimated Dose Response Curve"; 
          title%eval(&TITNUM+3) "Prior for Beta0~&BETA0_PRIOR, Beta1~&BETA1_PRIOR";  
      %end; 
 
      proc sgplot data=POSTPLOT_&OUTDATA noautolegend; 
        series x=DOSE y=EST_LOGISTICP / group=THETA; 
        XAXIS values=(&XMIN to &XMAX); 
        YAXIS values=(0 to 1 by 0.1); 
        label THETA='Target Response Rate' 
              EST_LOGISTICP='Prob(Response)' 
              DOSE='Dose'; 
        vector x=EST_GAM y=THETA / xorigin=0 yorigin=THETA 
                                  lineattrs=(pattern=shortdash); 
        vector x=EST_GAM y=YREF / xorigin=EST_GAM yorigin=THETA  
                                  lineattrs=(pattern=shortdash); 
        inset "Posterior Estimate &EST" 
              "for Target Dose (Gamma)" 
              "= &EST_GAM" / position=right; 
      run; 
  %end; 
 
  %* Reset titles and footnotes; 
  %if %eval(&TITNUM > 0) %then %do; 
      title&TITNUM;  
  %end; 
  %if %eval(&FOOTNUM > 0) %then %do; 
    footnote&footnum; 
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  %end; 
 
  %if %length(&OUTFILE) %then %do; 
    ods rtf close; 
  %end; 
 
  %if %upcase(%substr(%cmpres(&PLOT),1,1)) = Y %then %do; 
    ods graphics off; 
  %end; 
 
%mend ewoc_babb; 
 
<Other SAS programs available upon request > 
Macros 
ewoc_babb.sas
 
ewoc_tig.sas  ewoc_oparm.sas
 
ewoc_mvn_babb
 
sim_1pat.sas  sim_data.sas  
next_dose.sas  avdoseresp.sas  run_sim.sas  profiles.sas  summ_data.sas
 
doseresp.sas  
 
Calling programs 
av0_16by1_w_le.sa
 
av0_16by1_w_nr.s
 
av0_16by1_i_le.sa
 
av0_16by1_i_nr.sa
 
av0_16by1_s_le.
 
av0_16by1_s_nr.
 
av0_16d_w_le.sas
 
av0_16d_w_nr.sas
 
av0_16d_i_le.sas
 
av0_16d_i_nr.sas
 
av0_16d_s_le.sas
 
av0_16d_s_nr.sa
 
av6_esd_w_nr.sas
 
av6_esd_i_nr.sas
 
av6_esd_s_nr.sas
 
conv_c_nr.sas  conv_e_nr.sas
 
conv_p_nr.sas
 
 
Summarising simulation results 
    
